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Background –  
An increase in opioid prescribing has led to an increase in opioid overdoses.
1,2
 No study has 
estimated the incremental costs subsequent to an opioid overdose event in prescription opioid 
  
 
xiv 
users, or the prevalence and costs of overdose events in family members of prescription opioid 
users and in overdose victims with no identifiable source of prescription opioid. The latter group 
will be referred to as “others”.   
Objectives –  
The first objective of this study was to estimate the prevalence of opioid overdoses in 
aforementioned groups. The second objective was to estimate the incremental costs and resource 
utilization associated with opioid overdoses in these groups.  
Methods –  
This study is a retrospective analysis using claims data from SelectHealth, a not-for-profit health 
insurance organization in Utah and southern Idaho. We estimated the prevalence of opioid 
overdoses in the sample population, as well as in each group, by year. For the cost estimation we 
collapsed family members and others into one category – “non-medical users”. To estimate costs 
we used an incremental cost approach whereby we used propensity scores to match cases 
(patients who suffered from an opioid overdose) to appropriate controls (patients who did not 
suffer from an opioid overdose) and estimated the direct medical costs incurred in each group in 
the year following an overdose. Generalized Linear Models were used to estimate incremental 
costs and resource utilization. Sensitivity analyses were conducted to measure the robustness of 
the estimates. 
Results –  
The prevalence of opioid overdoses increased by 84.8% in prescription opioid users (from 55.6 
per 100,000 in 2011 to 102.8 per 100,000 in 2014), increased by 37.9% in family members of 
  
 
xv 
prescription opioid users (from 5.9 per 100,000 in 2011 to 8.2 per 100,000 in 2014) and 
increased by 179.9% in others (from 8.2 per 100,000 in 2011 to 23.1 per 100,000 in 2014).  
The prevalence of opioid overdoses in acute users increased by 14.7% (from 43.8 per 100,000 in 
2011 to 50.3 per 100,000 in 2014) as compared to 165.9% in chronic users (from 187.0 per 
100,000 in 2011 to 497.3 per 100,000 in 2014). 
The incremental direct medical costs per patient per year were estimated to be $65,277 (p-
value<0.05) in prescription opioid users who suffered from an overdose and $41,102 (p-
value<0.05) in non-medical users who suffered from an overdose. Overdose-specific costs were 
estimated to be $12,111 for prescription opioid users and $11,070 in non-users.  
Conclusions –  
Our study found that the prevalence of opioid overdoses increased steadily from 2011 to 2014 in 
the sample population. The prevalence of overdoses was much higher in chronic opioid users as 
compared to acute users. Differences between overdose-specific costs and total incremental costs 
may suggest that overdoses are associated with substantial costs in addition to costs for the initial 
treatment of the overdose. While the cost to payers due to overdoses in prescription opioid users 
is substantial, payers also incur costs from diversion of opioids. 
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CHAPTER I: 
 
Introduction 
 
Since 2000, the United States has witnessed a 200% increase in the rate of overdose deaths 
involving opioids.
2
 The rise in the number of deaths has been synchronous with the increase in 
the number of opioid prescriptions– health care providers wrote 259 million prescriptions for 
opioid analgesics in 2012, enough for every American adult to have a bottle of pills.
3
 Increases 
in opioid prescribing have been accompanied by increases in opioid-related emergency room 
(ER) visits, inpatient visits, mortality and costs.  
 
Previous studies have estimated costs associated with ER visits and inpatient visits in patients 
suffering from an overdose event. A study has also quantified the economic burden of opioid 
overdoses in the United States and estimated costs associated with each episode of poisoning.
4
 
With this study, in addition to estimating the prevalence of opioid overdose we have addressed 
several gaps in literature. These include estimating the prevalence of opioid overdoses by acute 
and chronic opioid use, estimating the prevalence by medical and non-medical opioid use and 
estimating the downstream costs for patients who suffer from an opioid poisoning event.  We 
used a matched control methodology to compare the healthcare expenditures between the cases 
(individuals who suffer from an overdose) and controls (individuals who do not suffer from an 
overdose) after adjusting for comorbidities and other risk factors.  
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The specific aims, introduction, and background are provided in this chapter. 
Chapter 2 provides a literature review regarding previous studies that have estimated the 
prevalence, source of opioid and costs of opioid overdoses. Chapter 2 also provides the rationale 
for the study. Chapters 3 explains the methods and results for Specific Aim I and Chapter IV 
explains the methods and results for Specific Aim II. Finally, Chapter 5 contains the discussion 
of the results of this study.  
 
 
Specific Aims 
 
Specific Aim 1 –  
A: Estimate the prevalence of opioid overdoses in the sample population 
B: Estimate the prevalence of opioid overdoses in prescription opioid users, family members of 
prescription opioid users and others 
B: Estimate the prevalence of opioid overdoses for acute and chronic opioid users 
 
Specific Aim II –  
A: Estimate the incremental downstream costs and resource utilization in prescription opioid 
users who suffered from an overdose 
B: Estimate the incremental downstream cost and resource utilization in family members of 
prescription opioid users and others (non-users) who suffered from an overdose 
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Background 
 
Poisoning is the leading cause of injury death in the United States. A majority of poisoning 
deaths are cause by drug overdoses. 
5
 Each day 46 people in the United States die from an 
overdose of prescription opioid analgesics. 
3
 Opioid analgesics are a class of drugs used in the 
treatment of pain, but they have a high potential for addiction, abuse and misuse. 
 
Opioids  
 
Opioids exert their pain alleviating action by binding at receptors on cell membranes in the 
central nervous system, intestines and musculoskeletal tissues. The primary receptors identified 
in humans are mu, delta and kappa. 
6
 Based on the efficacy and potency at these receptors, 
opioids are classified as full agonists, partial agonists or agonist-antagonists. Examples of pure 
agonists are morphine, codeine, hydrocodone, fentanyl and oxycodone. Buprenorphine is a 
partial agonist; butorphanol and dezocine are examples of mixed agonist-antagonists. Naloxone 
and naltrexone are pure antagonists and are administered for prevention or reversal of opioid 
effects. 
7
 
 
Opioids are used to treat both acute and chronic pain. Acute pain is believed to be a result of 
disease, inflammation or injury to the tissue. This pain is usually limited to a shorter time period. 
An example of acute pain is pain resulting from trauma or surgery. Chronic pain persists over a 
longer period of time as compared to acute pain and is resistant to most medical treatments. 
Examples of chronic pain patients are those suffering from cancer or chronic conditions like 
arthritis. 
8
 The pain that cancer patients suffer is very different when compared to other chronic 
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pain and therefore, chronic pain is often further classified as chronic cancer pain and chronic 
non-cancer pain.  
Chronic pain affects an estimated 100 million Americans, or one third of the U.S. population. 
9
 
In spite of lacking evidence for maintenance of pain relief for chronic pain, prescriptions of 
opioid medications for chronic pain have increased dramatically since the 1990s. 
10–13
 Among 
patients starting long-term opioid therapy for chronic non-cancer pain, back pain and extremity 
pain are the most common pain diagnoses (38% and 30%, respectively).
14
 
Nearly 14.5 million Americans with a history of cancer are alive and the number is expected to 
rise to 19 million by 2024. 
15
 Approximately one-third of cancer patients report their pain to be 
moderate to severe. 
16
 Opioids analgesics are considered to be first line treatment for moderate to 
severe cancer pain. 
17,18
  
 
Opioid epidemic 
 
There were many factors in the 1990s that lead to what is called the ‘opioid epidemic’ in the 
United States. The undertreatment of pain was an important issue that was gaining momentum. 
In the 1980s, pain specialists unequivocally supported the use of prescription opioid analgesics 
for the management of chronic nonmalignant pain. 
19–21
 In 1998, the Federation of State Medical 
Boards in the United States laid out guidelines for use of controlled substances for treatment of 
pain. These guidelines stated that no disciplinary action would be taken against practitioners 
based solely on the frequency and/or quantity of opioids prescribed. 
22
 In 2000, The Joint 
Commission (TJC) (formerly known as The Joint Commission on Accreditation of Healthcare 
Organizations) advocated for pain to be recognized as the fifth vital sign in addition to blood 
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pressure, temperature, respiratory and heart rate. 
23
 While all these events were in motion, new 
formulations of opioids were released and there was an explosion of opioids in the market.  
As a result of these events, prescriptions for opioid analgesics in the United States increased by 
700% between 1997 and 2007. 
1
 This trend of increased prescribing of opioids has been 
accompanied by increased levels of prescription opioid overdose. Between 1999 and 2008, the 
number of drug overdose deaths involving opioid analgesics in the United States saw a three-fold 
increase. 
5
 Between 1999 and 2002, deaths attributable to opioid analgesics increased by 91.2%, 
while those attributable to heroin and cocaine increased by 12.4% and 22.8% respectively. 
24
 
 
Clinical manifestations of opioid overdose 
 
Opioid overdose (or opioid poisoning) is characterized by symptoms such as respiratory 
depression, decreased mental status, miotic pupils and absent bowel sounds. 
25
 The presentation 
of overdose can range from euphoria to coma. A complete list of symptoms is given in Table 1. 
However, the best predictor of opioid overdose is respiratory depression and it can be fatal if left 
untreated. 
26,27
  
Table 1 – Clinical manifestations of opioid overdose 28 
1. Respiratory depression  
2. Miosis 
3. Stupor 
4. Hepatic injury from acetaminophen or hypoxemia 
5. Myoglobulinuric renal failure 
  
 
5 
6. Rhabdomyolysis  
7. Absent or hypoactive bowel sounds 
8. Compartment syndrome 
9. Hypothermia 
 
In cases of respiratory depression that lead to fatal overdose, the victim’s breathing slows to the 
point where oxygen levels in the blood fall below the level needed to transfer oxygen to the vital 
organs. The individual becomes unresponsive, blood pressure progressively decreases and the 
heart rate slows, ultimately resulting in a cardiac arrest. Death can occur within minutes of 
opioid ingestion. Often, there is a longer period of unresponsiveness that can last for several 
hours before the patient dies. This period is sometimes associated with loud snoring, leading to 
the term “unrousable snorers”.29 
Most cases of opioid overdoses can be managed in the emergency department, with more severe 
or complicated cases requiring inpatient admission. Pharmacologic treatment for overdoses 
consists of naloxone, a competitive mu receptor opioid antagonist that reverses the CNS 
depressant effects of the opioid.
28
 It is usually administered in the hospital setting, but can be 
administered by emergency medical service personnel and now, family members. By June 2016, 
all but 3 states (Kansas, Minnesota and Wyoming) had passed legislation to improve access to 
naloxone. These laws are structured into three broad domains which intend to increase naloxone 
prescribing and distribution, increase pharmacy naloxone access and encourage overdose 
witnesses to call on emergency responders. However, these laws exhibit heterogeneity across 
states and differ based on who can receive prescriptions for naloxone, whether laypeople are 
  
 
6 
allowed to adminsiter the medication and whether the prescribers, dispenser or individuals who 
administer naloxone are subject to immunity. 
30
  
 
Risk factors 
Opioid overdose can occur for a variety of reasons. For one, new users of opioid therapy might 
not be aware of the side effects of their medication and may miss the warning signs of an 
impending overdose. Patients might experience an overdose event when they switch from one 
opioid to another as well. 
25
  
Various studies have examined risk factors for opioid overdose. Patients at an increased risk of 
opioid overdose are those using higher doses of prescribed opioids, 
14,31
 long-acting opioids 
versus short-acting opioids, 
32
 opioids in combination with other sedating substances, such as 
alcohol and benzodiazepines, the household members of people in possession of opioids, 
33
 
Medicaid and low-income patients, 
34
 patients living in rural communities versus urban areas 
35
, 
patients with a mental illness, patients with a history of alcohol and substance abuse, 
36
 patients 
with a history of opioid dependence and patients with a hospitalization during 6 months before 
the serious toxicity or overdose event. 
37
 
Despite the fact that patients who have suffered from an opioid overdose are at a higher risk of 
suffering from a subsequent overdose, the vast majority of these patients continue to receive 
opioids. 
38
 
 
Two special populations, children and older adults, are at increased risk of overdose.   
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Overdose in children is characterized by a delayed onset of toxicity, unexpectedly severe 
overdose and prolonged toxic effects. 
39,40
 These effects are due to differences in rates of 
absorption, distribution and metabolism in children as compared to adults. 
41
 Older adults also 
have increased susceptibility to opioids and should be monitored closely. This population has 
various other co-existing conditions and age related changes in physiology and body composition 
that may increase the risk of an overdose event. 
42,43
 
 
Misuse and Abuse 
 
Various terms are used to describe the context under which opioid overdoses may occur. 
Misuse and abuse are terms often used to describe behaviors related to opioid use disorders. 
There are different sets of definitions used for these terms.  These are summarized in Figure 1.  
The National Institute of Drug Abuse (NIDA) definitions of misuse and abuse define misuse as 
an umbrella term for abuse. The differentiation of misuse or abuse is based on whether it is 
acceptable to use that medication the way it is being used.
44
 
NIDA also had a definition specifically for prescription drug abuse – “the use of a medication 
without a prescription, in a way other than as prescribed, or for the experience or feelings 
elicited.”45 This definition includes the reason for the abuse. 
Katz et al. attribute misuse to medications and abuse to illicit drugs only. This is a more 
restrictive definition and may not be applicable in the area of opioid analgesics. 
46
 
In Diagnostic and Statistical Manual of Mental Disorders, 5
th
 Edition (DSM-V), abuse and 
dependence were collapsed and are now defined as a broad term – substance use disorder.  
We will use the NIDA definition of prescription drug abuse in this study. 
 
  
 
8 
 
Definition Source Definition 
NIDA 
 
 
 
 
 
 
 
 
 
 
Misuse – “Taking a medication in a manner other 
than that prescribed or for a different condition than 
that for which the medication is prescribed.” 
 
 
Abuse – “The intentional misuse of a medication 
outside of the normally accepted standards of 
use.”44  
Katz et al. 
 
 
 
 
 
 
Misuse – “Use of a medication (for a medical 
purpose) other than as directed or as indicated, 
whether willful or unintentional, and whether harm 
results or not.” 
 
Abuse - “Any use of an illegal drug” or “the 
intentional self-administration of a medication for a 
nonmedical purpose such as altering one’s state of 
consciousness.” 
DSM-V 
 
 
 
 
 
 
 
 
 
Substance Use Disorder – “the recurrent use of 
alcohol and/or drugs causes clinically and 
functionally significant impairment, such as health 
problems, disability, and failure to meet major 
responsibilities at work, school, or home.”48 
NIDA – National Institute of Drug Abuse; DSM – Diagnostic Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV) 
Figure 1 – Misuse, abuse and dependence definitions (adapted)47 
 
Drug Diversion 
Diversion of prescription opioids is a widespread problem and can lead to prescription opioid 
abuse. Diversion has taken many forms: doctor shopping, pill brokering, and, most commonly, 
taking medications from the family medicine chest. Doctor shopping involves obtaining 
medications from multiple providers. Pill brokers are agents who partner with Medicare patients 
to gain access to their pills. There is growing evidence of these practices and alliances between 
Misuse Abuse 
Misuse Abuse 
Substance Use 
Disorder 
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healthcare providers and patients for diverting and selling prescription opioids. 
49–51
 A study 
among Medicare patients revealed that 12% of Medicare patients filled prescriptions from 4 or 
more opioid providers. 
52
 
 
The 2013 National Survey on Drug Use and Health (NSDUH) reports sources of non-medical 
use of painkillers (Figure 2). More than half (53%) of respondents said that they procured the 
medication for free from a relative or friend and nearly 15% said that they either bought it from a 
friend or took the medication without their consent. The primary source of the drug was a 
medical provider. 
53
 
 
Figure 2 –Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among 
Past Year Users Aged 12 or Older: 2012-2013
53
 
 
Literature suggests that prescription opioid use by a family member could result in unintentional 
overdose episodes in their dependents. In children, 12% of all drug exposures are attributable to 
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prescription opioid analgesics. 
54
 Opioid overdose events in children are often a result of children 
finding and ingesting medications that were intended for adults. 
55
 
Opioid analgesics are one of the classes of drugs most commonly abused by Americans 14 years 
and older. 
56
 Of those who abuse prescription analgesics, 55% reported getting it from a relative 
or a friend and approximately 5% reported taking them from a friend or relative without their 
consent. 
57
 Increased prescribing of opioids in patients with pain leads to the greater access to 
these drugs for their dependents. This increases the chances of overdoses in users as well as their 
dependents.  
 
Resource utilization  
The National Poison Data System (NPDS) records “exposures”, which are calls to a poison 
center when an individual has been exposed to an opioid. A report released by NPDS in 2010 
indicates that nearly one in every four opioid exposures results in an admission to a health care 
facility. 
58
 According to a Center for Disease Control and Prevention (CDC) report, for each 
unintentional poisoning death due to an opioid analgesic, nine people are admitted for substance 
abuse treatment, 35 people visit the emergency department, 161 people report drug abuse or 
dependence and 461 report non-medical uses of opioids. 
34
 
 
Long-term effects of opioid overdose 
 
Episodes that do not result in death may contribute significantly to the morbidity of the patients. 
While administering naloxone may reverse most symptoms related to the overdose, little is 
known about the long-term impact of overdoses on an individual’s organ systems. Non-fatal 
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episodes can lead to cerebral hypoxia, pulmonary edema, pneumonia and cardiac arrhythmia that 
may result in prolonged hospitalizations. Overdoses may also lead to muscular impairment and 
neurological damage and the number of overdoses experienced is a significant predictor of 
poorer cognitive performance. Surviving an overdose greatly increases the risk of dying from a 
later overdose. Overall, morbidity is likely to be greater among older, more experienced and 
dependent users 
59,60
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Summary 
 
In conclusion, the increased rate of opioid prescribing has led to an opioid epidemic in the 
United States. Increased prescribing has led to an increase in opioid diversion as well. The 
number of fatal and non-fatal overdoses have increased significantly, not only in prescription 
opioid users but in abusers as well.  The overall trend of increasing deaths from prescription 
opioid use and decreasing deaths from illicit drug use in the past several years has been noted 
across most literature – this is indicative of the magnitude of the opioid epidemic.24,61–63  
The high prevalence of opioid overdoses has led to increased resource utilization and healthcare 
costs. While other studies have examined costs associated with opioid overdoses, no study has 
examined the cost associated with the downstream costs of opioid overdoses.
4,64–66
 This will be 
discussed in greater detail in Chapter 2.  
The goal of this study was to estimate the prevalence, the costs associated with opioid overdose 
events and the downstream costs associated with an opioid overdose in three distinct populations 
based on the source of opioid – patients who had their own opioid prescription (prescription 
opioid users), patients who had a family member with an opioid prescription and patients who 
did not have an identifiable source of their prescription (non-users). 
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CHAPTER II: 
 
Literature Review 
Literature review summarizing the prevalence of opioid overdoses, source of drugs in opioid 
overdoses and cost associated with opioid overdoses 
 
A literature review for this study was completed in June 2016.  
 
The objective of this study was to estimate the prevalence and incremental cost and resource 
utilization for two groups of patients – prescription opioid users who suffer from a prescription 
opioid overdose and non-users who suffer from a prescription opioid overdose (family members 
and others).  
Since the first aim of this study dealt with prevalence, we conducted a literature review to 
summarize the prevalence of opioid overdoses in the United States.  
Further, we made an assumption that patients who do not have their own prescription but suffer 
from an overdose use diversion as a means to obtain the prescription opioid. To better understand 
this area, we conducted a literature review to identify the sources of medications in patients who 
suffer from an opioid overdose.  
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Finally, to assess gaps in literature and subsequently compare our findings to other estimates, we 
conducted a literature review to summarize the studies that have estimated costs associated with 
opioid overdoses in the United States.  
Two databases were used for the literature review – MEDLINE and CINAHL. First, MEDLINE 
was searched via PubMed for relevant studies from a combination search of search strings that 
comprised MeSH terms and keywords. CINAHL database via EBSCO host was searched using a 
combination search of similar keywords to identify additional articles.  
After we obtained articles using the appropriate search terms (described below for each section 
respectively), titles and abstracts were first screened for inclusion criteria and exclusion criteria 
for each section respectively. After applying the exclusion criteria, article reference lists from 
included studies and review articles were evaluated for eligibility for inclusion in the literature 
review. 
Section 2.1 – Prevalence of opioid overdoses 
The search terms used to identify literature for this literature review are presented in Table 2.  
Table 2 – Search terms used to identify literature for the prevalence of opioid overdoses 
Search terms Articles 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/poisoning*) AND 
(Prevalence)) 
902 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/poisoning*) AND 
(Hospitalization)) 
90 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/poisoning*) AND 
(Emergency Service, Hospital/utilization*)) 
9 
 1003 
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The inclusion and exclusion criteria applied were as follows –  
Inclusion criteria:  
Studies evaluating the prevalence of opioid overdoses. 
Exclusion criteria: 
1. Evaluated prevalence of overdoses for other illicit drugs and opioids 
2. Included codes for adverse effect of opioids along with overdose codes or evaluated 
prevalence of ER visits and inpatient visits in general 
3. Only evaluated overdose death rates 
4. Only evaluated trends or changes in opioid overdose patterns and did not report the prevalence 
5. Studies not conducted in the United States 
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This search yielded a total of 1003 articles of which 6 studies fit the eligibility criteria. These studies are summarized in Table 3. In addition, a 
review article was also assessed for other relevant articles that might have been missed in the search.
67
 
Table 3 – Summary of findings for prevalence of opioid overdoses 
Author Database Patient Group (if any) Setting Results 
Fulton-Kehoe et al.
68
  WA Medicaid 2006-2010 Medicaid ER visits 
and/or 
inpatient visits 
2006 – 416 per 100,000 opioid users 
2010 – 492 per 100,000 opioid users 
Hasegawa et al. 
64
  SEDD 2010-2011 
SID 2010-2011 
18 years and older ER visits 50.5 per 100,000 population 
(includes Heroin) 
Inocencio et al. 
4
  DAWN 2009 - ER visits 130.5 per 100,000 population 
Fulton-Kehoe et al. 
69
 
 
WA worker’s compensation system 
2004-2010 
 
 
NIS  
2004-2010 
 
Non-federal workers in 
WA who were prescribed 
an opioid 
 
National sample 
 
ER visits 
and/or 
inpatient visits 
 
 
Inpatient visits 
WA workers –  
2004 – 3.6 per 10,000 opioid users 
2010 – 3.4 per 10,000 opioid users 
 
National Sample –  
2004 – 2.7 per 100,000 persons 
2010 – 12.6 per 100,000 persons  
White et al.
70
  NIS 1998-2008 18-24 years Inpatient visits 1999 – 21.4 per 100,000 population 
2008 – 47.68 per 100,000 population 
Braden at al. 
71
  HealthCore 
Arkansas Medicaid 
2000-2005 
Chronic opioid therapy 
18 years and older 
 
ER visits HealthCore* –  
241.6 per 100,000 chronic opioid users 
 
Medicaid* –  
354.3 per 100,000 chronic opioid users 
WA = Washington State; SEDD = State Emergency Department Database; SID = State Inpatient Database; DAWN = Drug Abuse Warning 
Network; ER = Emergency Room; NIS = National Inpatient Sample; NHAMCS = National Hospital Ambulatory Medical Care Survey; NAMCS = 
National Ambulatory Medical Care Survey; NSDUH = National Survey on Drug Use and Health; *These rates were not presented in the paper, but 
were estimated based on the information in Table 2 of their study.  
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Summary of Literature 
 
Fulton Kehoe et al. 
68
  
The objective of this study was to assess the impact of the implementation of the WA State 
Opioid Guidelines of 2007 on opioid poisoning rates using Medicaid data. They also examined 
prescription history before the poisoning events.  
The study sample consisted of individuals who had at least 1 claim for an opioid prescription in 
the Medicaid fee-for-service system during the study period (April 2006 and December 2010). 
Opioid poisoning events were identified using ICD-9-CM codes for poisonings (965.00, 965.09 
and 965.02) from ER and inpatient hospital claims. 
Methadone poisonings rates were 10 times higher than those of other prescription opioid 
poisonings and increased between 2006 and 2010. The prevalence of poisonings leveled off after 
implementation of the WA opioid guideline in 2007. The rates of opioid poisonings from 2006-
2010 were 416, 485, 491, 492 and 492 per 100,000 users respectively.  
 
Hasegawa et al. 
64
  
The goal of the study by Hasegawa et al. was to quantify the rate of ER visits for opioid 
overdoses and understand the association between frequent ER visits for overdose and inpatient 
visits, near-fatal events, and in-hospital mortality.  
The databases used for this analysis were the Healthcare Cost and Utilization Project (HCUP) 
State Emergency Department Databases (SEDD) and State Inpatient Databases (SID) for 
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California and Florida (2010-2011). The SEDD contains data for all treat-and-release and 
transfer ER visits from short-term, acute care, nonfederal, community hospitals in participating 
states. The SID contains information about all inpatient discharges from short-term, acute care, 
nonfederal, general, and other specialty hospitals in participating states, including those 
discharges admitted from the ER.  
Opioid poisoning events were identified using ICD-9-CM codes for poisoning by opiate drugs 
and related narcotic drugs (code 965.0x) in the primary or secondary diagnosis fields.  
The rate of ER visits for opioid overdose was 50.5 per 100,000 population (including heroin). 
While nearly half of ER visits for opioid overdose resulted in an inpatient visits, a prevalence 
rate for inpatient visits was not reported.  
 
Inocencio et al. 
4
 
Inocencio et al. estimated weighted prevalence estimates for prescription opioid-related 
poisoning using Drug Abuse Warning Network (DAWN) data from 2009. Poisoning cases were 
identified from cases classified as suicide attempt, overmedication, malicious poisoning, or a 
category labeled “other.” Cases who were referred to detoxification, admitted to a chemical 
dependency or detoxification setting, or psychiatric unit were excluded. 
The prevalence of all opioid poisoning visits to the ER was estimated to be 534,490 or 174 per 
100,000 population. Approximately 75% (130.5 per 100,000) of all opioid poisoning visits 
involved non-heroin opioids, while the rest involved heroin and combinations.  
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Fulton-Kehoe et al., 2013
69
 
In this study, prevalence was analyzed using two databases – the WA workers’ compensation 
system and the Nationwide Inpatient Sample (NIS) data. The WA workers’ compensation 
database insures approximately two-thirds of non-federal workers in Washington and includes all 
medical, hospital, and pharmacy bills for State Fund workers’ compensation claims.  
Poisonings (overdoses) were identified using ICD-9-CM codes for opioid poisonings (965.00, 
965.02, 965.09, E850.1 and E850.2) from the WA worker’s database. It is not clear as to whether 
the same codes were used to identify events in the NIS data as well.  
The rate of opioid poisonings among prescription opioid users in WA remained relatively steady 
from 2004 (3.6/10,000) through 2010 (3.4/10,000). 
There was a significant increase in the prevalence of opioid poisonings from 1993 (2.7 per 
100,000 persons) to 2010 (12.6 per 100,000 persons) nationally. From 2004-2010, the national 
rate of opioid poisonings increased by 72%.  
 
White et al., 2011
70
 
This study estimated the numbers, rates, and costs of inpatient hospital stays due to alcohol 
overdoses, drug overdoses and their co-occurrence in 18- to 24-year-olds using the NIS data.  
The definition of drug overdoses (identified by ICD-9-CM codes) included poisoning by drugs, 
medicinals, and biological substances; accidental poisoning by drugs, medicinals, and biological 
substances; suicide and self-inflicted poisoning by drugs and medicinals; homicidal poisoning by 
drugs and medicinal substances; and/or poisoning by drugs and medicinals, undetermined 
  
20 
whether accidentally or purposely inflicted. They found that the rates of hospitalization as a 
result of drug overdoses on prescription opioid pain medications (for example,  
Oxycodone/acetaminophen, hydrocodone/acetaminophen, oxycodone, codeine, meperidine and 
morphine) increased 122% between 1999 (rate = 21.44 per 100,000 population) and 2008 (rate = 
47.68 per 100,000 population) 
The authors did not estimate the costs specifically due to prescription opioid overdoses.  
 
Braden et al., 2010
71
 
The aim of the study was to estimate the association between chronic opioid therapy and adverse 
outcomes. This study used administrative claim records from Arkansas Medicaid and HealthCore 
commercially insured enrollees, 18 years and older, who used prescription opioids for at least 90 
continuous days within a 6-month period between 2000 and 2005 and had no cancer diagnoses.  
While the prevalence of overdoses was not reported, it was calculated using data from Table 2 
(Twelve-Month Health Service Utilization by Adult Enrollees Who Used Opioids Continuously 
for 90 Days or Longer During a 6-Month Period From 2000 to 2005) in the study.  
The prevalence of ER visits due to opioid overdose among chronic opioid users in the 
HealthCore database was estimated to be 241.6 per 100,000 while that in the Medicaid database 
was 354.3 per 100,000 over the five-year period from 2000 to 2005.   
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Conclusions 
Fulton Kehoe et al., 2015 and Braden et al., 2010 estimated the prevalence of overdoses in the 
Medicaid population.  Fulton Kehoe et al. reported prevalence for ER visits and/or inpatient 
visits while Braden et al. reported prevalence for ER visits. Fulton Kehoe et al. estimated the 
prevalence in all WA Medicaid patients to be 492 per 100,000 opioid users in 2010. 
68
 Braden et 
al. found the prevalence of ER visits to be 354.3 per 100,000 in chronic opioid therapy patients 
over a 5 year period (200-2005) in the Arkansas Medicaid population. Additionally, in the only 
study so far to report the prevalence of ER visits due to opioid overdoses in commercially 
insured enrollees, Braden et al. reported the prevalence to be 241.6 per 100,000 in patients on 
chronic opioid therapy. 
71
 
Two studies used the NIS to estimate the prevalence of hospitalizations due to opioid overdose. 
Fulton Kehoe et al., 2013 estimated the national prevalence of hospitalizations due to opioid 
overdoses to be 12.6 per 100,000 persons in 2010 while White et al. estimated the prevalence of 
hospitalizations due to opioid overdose to be 47.68 per 100,000 population in 18-24 year olds. 
Part of the discrepancy is due to use of different ICD codes used to identify overdoses in each of 
the studies. Neither of the studies clearly specified which ICD codes were used to identify 
overdose events. Additionally, prevalence for different age groups was estimated in each of the 
studies respectively 
69,70
 Fulton-Kehoe et al. also estimated the prevalence of ER visits and/or 
inpatient visits for opioid overdoses and report a prevalence of 3.4 per 10,000 opioid users in 
2010. The codes used for this analysis were clearly stated. 
69
 
Hasegawa et al., 2014 estimated the prevalence of ER visits for all opioid overdoses in California 
and Florida and report it to be 50.5 per 100,000 population. This rate also includes overdoses due 
to heroin.
64
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Finally, Inocencio et al., 2013 report the prevalence of prescription opioid overdoses in a 
national sample to be 130.5 per 100,000 population using DAWN 2009 data. These results might 
not match other studies that use administrative data to estimate overdoses because DAWN has a 
different system of identifying and classifying overdoses. Cases in DAWN were categorized into 
8 types of cases – these include suicide attempt, seeking detoxification, alcohol only, adverse 
reaction, overmedication, malicious poisoning, accidental ingestion and other. Inocencio et al. 
defined opioid-related poisoning cases that were classified in DAWN as suicide attempt, 
overmedication, malicious poisoning or a category labelled “other”. 4   
Due to differences in the methodology used to identify opioid overdoses using claims data and 
different populations studied, we cannot make direct comparisons between prevalence estimates 
obtained from these studies.  
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Section 2.2 - Source of prescription opioid in prescription opioid overdoses 
The search terms used for this literature review are presented in Table 4. 
Table 4 - Search terms used to identify literature for the source of prescription opioid in opioid 
overdoses 
Search terms Articles 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/poisoning*) AND  
(source of drug OR source of medication)) 
55 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/ poisoning*) AND          
(source of prescription drug OR source of prescription medication)) 
21 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/ poisoning*) AND  
(access to medication OR access to drug)) 
72 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/ poisoning*) AND  
(obtain medication OR obtain drug)) 
22 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/ poisoning*) AND 
(Prescription Drug Misuse*/statistics & numerical data)) 
36 
 206 
 
The inclusion and exclusion criteria applied were as follows –  
Inclusion criteria:  
1. Studies that reported the source of prescription opioid in case of an opioid overdose 
2. Studies that reported source of opioid for abuse or non-medical use 
Exclusion criteria:  
2. Studies not conducted in the United States 
This search yielded a total of 206 articles of which twelve studies fit the eligibility criteria.  
These studies are summarized in Table 5.
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Table 5 – Summary of findings for source of opioid in prescription opioid overdoses 
Author Data Source Results* 
Baumblatt et al.
72
  Tennessee Controlled Substances 
Monitoring Program (TNCSMP) data  
2007-2011 
Increased risk of opioid-related overdose death was associated 
with 4 or more prescribers, 4 or more pharmacies, and more than 
100 MMEs (Morphine Milligram Equivalents).  
People with 1 or more risk factor accounted for 55% of all 
overdose deaths. 
Frank et al.
73
  Interviews with young adults (18-32 years) 
who reported nonmedical prescription 
opioid use in the past month  
(New York City) 
Study participants stated that their initial prescription opioid use 
was due to the widespread availability in a household setting and 
the perception of being relatively harmless and less addictive as 
compared to heroin since they were given the status of a 
“medication”.  
National Survey on Drug 
Use and Health
53
  
Survey of a representative sample of U.S. 
civilian, noninstitutionalized population   
(12 years or older) 
More than half of non-medical users (53%) obtained the opioid 
prescription free from a friend or family, 21% obtained the 
prescription from a doctor and nearly 15% bought it or took it 
from a friend or relative.  
Johnson et al.
74
  Interviews with family or close friends of 
the deceased 
2008-2009 
The source of prescription opioids for people who suffered from 
opioid-related deaths was a healthcare provider in majority of 
cases (91.8 %).  
Other sources (not mutually exclusive) included: for free from a 
friend or relative (24%), from someone without their knowledge 
(18.2%), purchase from a friend, relative, or acquaintance (16.4 %) 
and purchase from a dealer (not a pharmacy) (11.6 %)  
Lanier et al.
75
  Interviews with family or close friends of 
the deceased 
2008-2009 
Obtaining prescription pain medication from a non-prescription 
source was 4.3 times more common among decedents as compared 
to respondents who reported prescription opioid use during the 
previous year (35.8% vs. 8.3%). 
CDC. Morbidity and 
Mortality Weekly Report. 
76
  
Utah Controlled Substance Database (CSD)  
Utah Poison Control Center (PCC)  
2002-2011 
There were 462 exposures attributable to buprenorphine, of which 
3 led to death.  
Ogle et al.
77
  Medical Examiner files (Florida) 
Toxicology reports 
A total of 155 accidental deaths listed oxycodone as a cause of 
death, of which more than half (52.9%) did not have prescriptions 
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2009 for oxycodone.  
Lankenau et al.
78
  Interviews with young IDUs (16-25 years) 
(Los Angeles and New York) 
Initiation into opioid misuse was facilitated by easy access to one’s own 
prescription (16%), family member’s prescription (22%) and friends’ and 
acquaintances’ prescription (62%).   
Weimer  et al.
79
  Office of The Chief Medical Examiner files 
Virginia Prescription Monitoring Program 
2004 
A total of 61 methadone-related overdose deaths were identified.  
The majority of methadone overdose deaths in this study were related to 
illicit methadone use (67%); 28% of the decedents were prescribed 
opioids.  
Cicero et al.
80
  Survey of prescription opioid dependent 
patients entering drug treatment programs 
The study population was divided into groups – Health Care 
professionals (HC) and Non-Health Care professionals (NHC). The HC 
group was more likely to use doctors’ prescriptions and forged 
prescriptions. The NHC group was more likely to use dealers or a friend 
or relative to obtain the prescription opioid.  
Bailey et al.
81
  Poison centers participating in the 
RADARS System 
2003-2006 
A total of 9,179 exposures in children under 6 years were identified; 92% 
occurred in the home. Exposures were associated with 8 deaths, 43 major 
effects, and 214 moderate effects.  
Green et al.
82
  Abusers identified from the ASI-MV® 
Connect database  
Women abusers were more likely to obtain their prescription opioids 
from family, friends, acquaintances or their own prescriptions whereas 
men abusers were more likely to obtain them from dealers.  
Shah et al.
83
  Medical Examiner files (New Mexico) 
1998-2002 
Of 143 methadone-related deaths, 22.4% were attributable to methadone 
alone, 23.8% were due to methadone/prescription drugs (no illicit drugs), 
50.3% were due to methadone/illicit drugs and 3.5% were due to 
methadone/alcohol.  
Of 79 decedents (55.2%) with a known source of methadone, 86% 
obtained methadone through a physician prescription.  
CDC = Center for Disease Control and Prevention; RADARS = Researched Abuse, Diversion and Addiction-Related Surveillance; IDU = Injection 
Drug User; ASI-MV Connect = Addiction Severity Index Multimedia Version Connect 
*Results pertinent to source of opioid in opioid overdoses are reported 
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Summary of Literature 
 
Baumblatt et al.
72
 
The objective of this matched case-control study was to identify risk factors associated with 
opioid-related overdose deaths. 
72
 The Tennessee Controlled Substances Monitoring Program 
collects patient information for all prescriptions of controlled substances (Schedules II to IV). 
Cases were identified as patients who had suffered from an opioid-related death during the study 
period (January 1, 2009 – December 31, 2010) who had one or more opioid prescription in the 
12 months before their death. For each case patient, 20 live controls were selected by random-
number generation. Controls were patients with 1 or more opioid prescriptions during the 12 
months before the date of death of the matched case patient. The authors found that of all people 
in Tennessee prescribed opioids during 2011, 7.6% used more than 4 prescribers, 2.5% used 
more than 4 pharmacies, and 2.8% had a mean daily dosage greater than 100 morphine milligram 
equivalents (MME).  
Increased risk of opioid-related overdose death was associated with 4 or more prescribers, 4 or 
more pharmacies, and more than 100 MME. People with 1 or more risk factor accounted for 55% 
of all overdose deaths. 
 
Frank et al. 
73
 
This was a qualitative study in which 46 young adults (ages 18-32) from New York City who 
had engaged in non-medical prescription opioid use in the past 30 days were interviewed. The 
interviews were in-depth, semi-structured and audio recorded. While the goal of the study was to 
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understand the overdose knowledge and experience of non-medical prescription opioid users, the 
results briefly discussed opioid initiation and source of opioid at the time of initiation.  
The authors reported that the study participants’ early impressions of prescription opioids were 
that they were relatively harmless and as compared to heroin, less likely to result in an overdose. 
Since these opioids were accessible in a household setting and they had “medication” status, the 
participants viewed these as less addictive and began using them.  
 
Results from the 2013 National Survey on Drug Use and Health (NSDUH): Summary of 
National Findings
53
 
NSDUH is the primary source of statistical information on the use of illegal drugs, alcohol, and 
tobacco in the United States civilian, noninstitutionalized population aged 12 or older. This 
survey has been conducted by the Federal Government since 1971. The surveys were conducted 
through face-to-face interviews with a representative sample of the United States population. The 
data was collected from residents of households, non-institutional group quarters (for example – 
shelters, dormitories and rooming houses) and from civilians living on military bases. 
Among the study participants who used prescription opioids non-medically in the past year, 53% 
reported that they obtained the medication for free from a friend or relative, 21% obtained the 
medication from one doctor and 15% bought or took it from a friend or relative without their 
knowledge (Figure 2). For the 53% who obtained the opioid from a friend or relative, 84% were 
prescribed the opioid by one doctor.  
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Johnson et al.
74
 
The objective of the study by Johnson et al. was to identify characteristics related to 
unintentional prescription opioid overdose deaths in Utah.  
Decedents were identified from records of the Utah Office of the Medical Examiner (OME) in 
Utah from October 2008 to October 2009. Manner and causes of death were determined by OME 
on the basis of scene-of-death investigation, autopsy, and toxicology findings. Decedents were 
included in the study if they were Utah residents aged 18 years or older, had a manner of death 
characterized by the OME as either unintentional or undetermined, had a prescription opioid 
listed as a cause of death and did not have a violent event (e.g., fall or drowning) as a cause of 
death. 
Interviews were conducted by trained interviewers by telephone, with persons who were 
identified by OME death-scene investigators as either next of kin or best person to contact. The 
questions were based on the deceased’s chronic conditions, chronic pain, prescription medication 
use, healthcare providers and mental health amongst others.  
The source of prescription opioids was from a healthcare provider in most of the cases (91.8 %).  
Other sources (not mutually exclusive) included: for free from a friend or relative (24%), from 
someone without their knowledge (18.2%), purchase from a friend, relative, or acquaintance 
(16.4 %) and purchase from a dealer (not a pharmacy) (11.6 %).   
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Lanier et al.
75
 
The goal of this study by Lanier et al. was to identify the risk factors for prescription opioid 
deaths in Utah. The study design is similar to the study carried out by Johnson et al.
74
, with the 
inclusion of a control group.  
Controls were identified from the Utah 2008 Behavioral Risk Factor Surveillance System 
(BRFSS), a survey database maintained by the Utah Department of Health (UDOH) in 
partnership with the Center of Disease Control and Prevention (CDC).  Respondents who 
reported prescription opioid use during the previous year were selected as controls for this study.  
BRFSS 2008 contained information regarding the use of prescription pain medications during the 
past year, their pattern of use (as prescribed or other) when last prescribed, their source (by 
prescription from a health care provider, a nonprescription source, or both), names of 
medications, and the presence of chronic pain.  
Approximately 90% of both groups had obtained their prescription pain medication by 
prescription from a health care provider. Of those decedents who obtained their prescription 
medication through a prescription, 52.9% used their medications more often or in higher 
quantities than prescribed whereas only 3.2% of their comparison group misused their 
medication.  
Obtaining prescription pain medication from a non-prescription source was 4.3 times more 
common among decedents as compared to the control group (35.8% vs. 8.3%). 
 
 
  
30 
Center for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 2012 
76
 
This report by the CDC estimates the prevalence of exposures attributable to buprenorphine in 
Utah from 2002 to 2011. The Utah Controlled Substance Database (CSD) and the Utah Poison 
Control (PCC) data were used for this study. The CSD tracks all outpatient prescriptions for 
Schedule II–V drugs dispensed in Utah. The PCC maintains data on reported human exposures 
to buprenorphine and other drugs (including intentional and unintentional, therapeutic and 
nontherapeutic exposures). Standardized information collected for each exposure includes age, 
sex, substance, route of exposure, reason for exposure, location of exposure, location of caller, 
therapy provided, clinical effects, management location, and medical outcome. Exposures can be 
any kind of exposure to an opioid, from holding the medication to ingestion.  
A total of 462 exposures to buprenorphine were recorded in the PCC database from 2002-2011. 
Of all the exposures, 54% were in adults 20 years and older, 39% were in children less than 5 
years and 7% were among the 6-19 year age group.  
Of all the exposures, 3 (less than 1%) resulted in respiratory arrest in children.  
 
Ogle et al., 2012
77
 
Ogle et al. analyzed toxicological findings of accidental deaths involving oxycodone in an effort 
to identify the source of medication that resulted in these deaths.  
Medical Examiner files and toxicology reports from 2009 were used to assess demographic and 
clinical characteristics of the decedents as well as the presence and concentration of oxycodone 
and other drugs.  
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All oxycodone-related deaths were included in this study. These were cases when (1) oxycodone 
was the primary or contributory cause of death (n = 117), as well as those where (2) oxycodone 
was the incidental cause of death (n = 38).  
A total of 155 deaths were identified. More than half of the population (52.9%) did not have 
prescriptions for oxycodone. 
 
Lankenau et al., 2012 
The goal of this exploratory qualitative study was to describe patterns of initiation into 
prescription opioid misuse. The study participants were 50 young injection drug users (IDUs) 
aged 16-25 years from Los Angeles and New York who had misused a prescription opioid at 
least three times in the past three months.  
They found that Vicodin (hydrocodone and acetaminophen) was the drug most commonly used 
at initiation, followed by OxyContin (oxycodone) and Percocet (oxycodone and acetaminophen). 
Three sources of the prescription opioid at the time of initiation were reported – misusing a 
family member’s prescription, misusing one’s own prescription and misusing a prescription 
obtained from a friend or an acquaintance.  
While 60% of study participants grew up in households or visited extended families where 
opioids were prescribed, one-third reported initiating opioid use with an opioid taken from a 
family member. Also, nine participants reported that they misused a family member’s 
prescription after initiating misuse via other sources.  
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Nearly 75% of study participants were prescribed opioids for pain conditions such as dental 
procedures and sports injuries of which 22% reported using their own prescription as the source 
of the first opioid misuse.  
A majority of the participants (62%) reported acquiring the drug of initiation from a friend or 
acquaintance. The friends or acquaintances often obtained the drugs from their family members 
or used their own.  
 
Weimer et al., 2011 
79
 
Weimer et al. describe case series of patients who died from methadone poisoning or overdose in 
rural western Virginia during 2004. They also compare cases according to the source of 
methadone.  
Three data sources were used for this study – medical examiner records, Opiate Treatment 
Programs (OTP) medical records, and Virginia Prescription Monitoring Program (PMP) database 
records.  
For this analysis, all cases occurring during the study period, where the cause of death was 
poisoning, were identified for possible inclusion in the study. Methadone-related cases were 
defined as those deaths where the manner of death was intentional and unintentional, methadone 
was present in the toxicological analyses, and methadone was found to be a direct or contributing 
cause of death by the medical examiner. For each decedent, the possible sources of methadone 
were prescribed by a non-OTP physician, prescribed by an OTP-physician, or illicit. 
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A total of 61 methadone-related overdose deaths were identified. The majority of methadone 
overdose deaths in this study were related to illicit methadone use (67%); 28% of the decedents 
were prescribed opioids and 5% of the decedents obtained it from an OTP.  
 
Cicero et al., 2010 
80
 
Cicero et al. examined whether the frequency of misuse of fentanyl and other opioids in the real 
world matched their predicted potential abuse from abuse liability assessments. A total of 1,818 
prescription opioid dependent patients entering drug treatment programs were recruited in this 
study. Participants were included in the study if they had a diagnosis for prescription opioid 
analgesic abuse or dependence using the DSM – IV criteria and if they used prescription opioids 
once in the past 30 days to get high. The participants were asked to complete an anonymous 
survey that covered their drug use and health-related issues. 
The study participants were divided into two groups – 196 Health Care professionals (HC) and 
1,622 Non Health Care professionals (NHC). The authors reported that the HC group was more 
likely to use doctors’ prescriptions and forged prescriptions when they abused prescription 
opioids. In comparison the NHC group was more likely to use a dealer or prescriptions obtained 
from friends or families. Other sources that were not significantly different between the two 
groups were stolen prescriptions, prescriptions obtained from the ER and opioids bought on the 
internet.  
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Bailey et al., 2009 
81
 
The goal of this study was to estimate the impact of opioid abuse on overdoses in children. 
Data from poison centers participating in the Researched Abuse, Diversion and Addiction- 
Related Surveillance (RADARS) System was analyzed for children under 6 years for 7 opioids 
from January 2003-June 2006. 
Exposures represent a range of behaviors, from holding the medication to ingestion. Exposures 
and associated medical outcomes were characterized with an opioid ‘mention’ as the unit of 
analysis. Each mention represents a prescription opioid to which a child was exposed and for 
which information was gathered through a call to a participating poison center. Moderate effects 
were those where the symptoms were not life threatening; major effects were instances where the 
patient exhibited symptoms that were life threatening or resulted in disability or disfigurement.  
A total of 9,179 exposures were identified; 99% of the exposures involved ingestion and 92% 
occurred in the home. Exposures were associated with 8 deaths, 43 major effects, and 214 
moderate effects. 
 
Green et al., 2009 
82
 
The goal of this study was to describe characteristics of women who abuse prescription opioids 
and to contrast gender differences among prescription opioid abusers. Addiction Severity Index 
Multimedia Version® (ASI-MV®) Connect is a continuous real-time data stream that collects 
data on substances used and abused by adult clients (18 years or older) entering substance abuse 
treatment across various centers in the United States. Data for patients that completed the ASI-
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MV® was used to identify the study sample. The study sample consisted of 3,821 assessments of 
people entering substance abuse treatment from November 2005 to March 2008 who reported 
abuse of prescription opioids in the past month.  
Women reported that their prescription opioids were more likely obtained from family, friends or 
acquaintances or from their own prescriptions, whereas men reported obtaining prescription 
opioids from dealers.  
A high percentage of both men and women reported obtaining prescription opioids from a dealer. 
Other sources of prescription opioids that were mentioned were multiple doctors, stealing and 
internet. The other sources represented less than 15% of responses.  
 
Shah et al., 2005 
83
 
One of the objectives of the study was to characterize methadone-related deaths.  
Overdose deaths from the Medical Examiner file in New Mexico were examined from 1998-
2002. All unintentional drug overdose decedents who were residents of and died in New Mexico 
from 1998 to 2002 and for whom methadone was cited as a cause of death, alone or in 
combination with another drug (illicit and/or prescription), were classified as methadone-related 
deaths.  The circumstances of death and the decedent’s medical and drug use history (if present) 
were collected by abstractors using a standard data collection form. Data for circumstances of 
death included location of overdose, day of the week death was pronounced, evidence of 
injection drug use (IDU) at the scene (defined by presence of track marks or syringe at the 
scene), source of methadone and reason for ingestion (pill bottle with decedent’s name, medical 
records), and methadone blood concentration. Data for history of drug use were collected when 
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available from medical records and family history. History of drug use included illicit drug use, 
non-medicinal use of prescription drugs, IDU and previous overdose. 
Of 143 methadone-related deaths, 22.4% were attributable to methadone alone, 23.8% were due 
to methadone/prescription drugs (no illicit drugs), 50.3% were due to methadone/illicit drugs and 
3.5% were due to methadone/alcohol.  
The source of methadone was available for 79 decedents; 68 decedents (86%) had a physician 
prescription for methadone and 11 decedents (7.7%) obtained diverted methadone (either 
purchased ‘off the street’ or obtained from a prescription for someone else). The source of 
methadone for 44.8% of the sample was not indicated. 
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Conclusions 
The above studies suggest that this is an extremely complex area. Patients who misuse or abuse 
opioids and/or suffer from an overdose obtain their medications from a wide variety of sources – 
from friends and relatives to multiple pharmacies and prescribers to illicit drugs. The 
geographical variation in the studies also suggests that this problem affects many regions of the 
United States.  
A majority of the studies that identified a source of the overdose, identified them for deceased 
patients. The other two studies identified exposures in children. Ours is the first study that 
identifies a potential source of opioid for overdoses based on family-level data.  
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Section 2.3 – Costs associated with prescription opioid overdoses 
  
The search terms used for this literature review are presented in Table 6. 
Table 6 - Search terms used to identify literature for the costs associated with prescription opioid 
overdoses 
Search terms Articles 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/poisoning*) AND (Cost)) 68 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/ poisoning *) AND          
(Healthcare costs)) 
17 
((Analgesics, Opioid/overdose* OR Analgesics, Opioid/ poisoning *) AND  
(Costs and Cost Analysis)) 
21 
 106 
 
The inclusion and exclusion criteria applied were as follows –  
Inclusion criteria:  
Evaluated costs attributed to opioid overdose 
 Exclusion criteria:  
1. Evaluated costs due to opioid abuse, misuse or dependence 
2. Evaluated cost-effectiveness of opioid analgesics 
3. Studies not conducted in the United States 
This search yielded a total of 106 articles of which the 1 study fit the eligibility criteria 
(Inocencio et al., 2015.) The other three studies were obtained during the search in section 1 
because they were not pulled up by the section 3 search terms.  These studies are summarized in 
Table 7. 
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Table 7 – Summary of findings for costs associated with prescription opioid overdoses  
Author Opioid Use Data Sources Costs  Results 
Hasegawa et al.
64
 (2014) “Opioid overdoses” SEDD 2010-2011 
SID 2010-2011 
ER and Inpatient 
charges 
Median ER charges per patient –  
$4,521 
 
Median inpatient charges per 
patient –  
$22,460  
 
$208 million for total ER and 
inpatient charges annually 
Yokell et al.
65
 (2014) “Prescription 
Opioid Overdoses” 
NEDS 2010 ER and Inpatient 
charges 
Average ER charges –  
(prescription opioids*) 
$3,640 
 
Average inpatient charges –  
(prescription opioids*) 
$29,497 
 
Inocencio et al.
4
 (2013) “Opioid-related 
poisoning” 
DAWN 2009 
NEDS 2009 
NIS 2009 
GAO Report 2006 
Red Book 2012 
NVSS 2009 
Direct and indirect costs Direct costs –  
Average cost per poisoning event 
(prescription opioids*) – 
$4,255 
 
Indirect costs –  
Average costs per poisoning event  
(prescription opioids*) – 
$34,825 
 
$20.4 billion total costs annually 
SEDD = State Emergency Department Database; SID = State Inpatient Database; DAWN = Drug Abuse and Warning Network; 
NEDS = Nationwide Emergency Department Sample; ER = Emergency Room; NIS = National Inpatient Sample; GAO = Government 
Accountability Office Report; NVSS = National Vital Statistics System; *Since these studies report costs incurred due to heroin 
overdoses as well, the costs listed in the above table are specifically incurred due to an overdose from a prescription opioid.  
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Summary of literature 
 
Hasegawa et al., 2014 
64
 
The goal of the study by Hasegawa et al. was to quantify the rate of ER visits for opioid 
overdoses (including heroin) and understand the association between frequent ER visits for 
overdose and hospitalizations, near-fatal events, and in-hospital mortality.  
This was a retrospective population-based cohort study that utilizes encounter data abstracted 
from the Healthcare Cost and Utilization Project (HCUP) State Emergency Department 
Databases (SEDD) and State Inpatient Databases (SID) for the states of California and Florida 
for 2010 and 2011. These databases capture all ER visits regardless of disposition and with 
information on short-term outcomes for patients admitted through the ER. The study sample 
included all patients who suffered from an overdose during the study period.  Patients who did 
not have an ER visit in 2010 were excluded since they would not have a 365 day follow-up 
period. Also, patients who had a gap of more than a year for another ER visit from the index date 
(first ER visit) were excluded since they wanted to examine the association of frequency of ER 
visits with other factors.  
The cost analysis was carried out for the state of Florida. The total charges for ER and inpatient 
services for opioid overdoses were estimated to be $208 million annually. When broken down by 
visits with hospitalization and without, median charges per patient were $4521 in patients 
without hospitalization and $22,460 in patients with hospitalization. Patients who had 1 or more 
hospitalizations during the study period were responsible for 93.2% of total charges.  
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Yokell et al., 2014 
65
 
Yokell et al. also used the NEDS sample to describe prescription and non-prescription opioid 
overdoses, but used 2010 data to obtain weighted prevalence estimates and charges related to 
overdose events.
65
 ER characteristics, demographic and clinical characteristics of the patients 
and outcomes for prescription and non-prescription opioid overdose events were reported. 
ICD-9-CM diagnostic codes and injury codes for prescription opioid (965.02, 965.09, E850.1, 
E850.2), heroin overdoses (965.01, E850.0) and unspecified opioid (965.00 with no E-code for 
heroin or prescription opioid overdose) were used to identify opioid overdose events.  
ER visits due to prescription opioids constituted 67.8% of all overdoses; 16.1% were due to 
heroin, 13.4% were a result of unspecified opioids and 2.7% were due to multiple opioid types. 
Of all patients admitted to the ER for an overdose, 45.3% were treated and released from the ER 
and 50.6% were admitted to the hospital.  
The average charges for an ER visit for an opioid overdose due to prescription opioids was 
$3,640, for heroin was $3,692 and for unspecified or multiple types of opioid was $4,121.  
The total ER and inpatient charges for patients in this sample were estimated to be $2.3 billion 
annually. 
 
Inocencio et al., 2013 
4
 
Inocencio et al. evaluated the economic burden of opioid poisonings using a societal 
perspective.
4
 The method of economic evaluation used was the bottom-up approach in which 
mean estimates of each cost component are multiplied by national estimates of prevalence. 
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Weighted prevalence estimates for prescription opioid poisonings were obtained from 2009 Drug 
Abuse Warning Network (DAWN). Direct costs included emergency room (ER) costs, inpatient 
costs, ambulance costs, drug costs and device costs. ER and inpatient costs were obtained from 
the Healthcare Cost and Utilization Project (HCUP) 2009 Nationwide Emergency Department 
Sample (NEDS) and the 2009 National Inpatient Sample (NIS). Ambulance costs were obtained 
from a 2006 Government Accountability Office (GAO) report.
84
 Drug costs were obtained from 
the 2012 Red Book and costs for syringes and intranasal devices were based on market prices 
obtained from a medical services supply company.
85,86
 A Monte Carlo simulation was used to 
impute missing costs.  
Prevalence of opioid poisoning visits to the ER were estimated to be 174 per 100,000 people; 
approximately 75% involved non-heroin opioids and 25% involved heroin and combinations. 
The average direct cost per poisoning event for prescription opioids was estimated to be $4,255 
and the indirect costs per poisoning event for prescription opioids were $34,825.  The cost per 
case for prescription opioids was greater than that heroin ($38,541 vs $33,793). Total costs were 
estimated to be $20.4 billion for that year, with indirect costs constituting 89% of the total costs.  
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Conclusions 
 
Studies by Hasegawa et al. report median ER and inpatient charges associated with an overdose 
to be $4,521 and $22,460 respectively.
64
 Yokell et al. estimated the mean ER and inpatient 
charges associated with an overdose to be $3,640 and $29,497 respectively.
65
 However, the 
estimates by Hasegawa et al. also include heroin overdoses. Also, since mean and median values 
are reported these estimates are not directly comparable, though they are in the same range. 
Inocencio et al. report the average cost associated with a prescription opioid overdose to be 
$4,225. 
4
 
The studies presented above have limitations. An opioid overdose was treated as an acute event 
and downstream costs subsequent to an opioid overdose were not evaluated.  Additionally, while 
the studies focused on ER and inpatient charges, there are instances when overdose events are 
resolved outside the hospital setting – these costs were not captured.  
As with all the studies using NEDS data, charges for opioid overdoses are reported. These do not 
reflect the true cost of opioid overdoses and are typically overestimates.   
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Rationale 
 
To our knowledge, ours is the first study that will estimate and compare the prevalence of opioid 
overdoses for acute and chronic opioid use. Additionally, we also identified patients who had an 
opioid overdose and classified them by source of opioid. A majority of the studies that identified 
a source of overdose, identified them for deceased patients. Ours is the first study that identifies a 
potential source of opioid for overdoses based on family-level data.  
While most studies have identified prevalence based on data for ER visits and/or inpatient visits, 
we have built on this literature and captured the prevalence of opioid overdoses that were 
resolved at other places of service – for example, in ambulances or the outpatient setting.  
We have captured the downstream costs over a year for patients who suffer from an opioid 
poisoning event. Since we had all medical claims data, we are also able to capture costs apart 
from ER and inpatient costs – for example, outpatient costs, laboratory costs and ambulance 
services, among other healthcare facility costs. Additionally, we have reimbursement costs and 
not charges, so our estimates will be more accurate. 
Prescription data allowed us to identify a control group, i.e., patients with an opioid prescription 
who did not suffer from a poisoning event. This allowed us to compare the healthcare 
expenditures between the two groups after adjusting for comorbidities and other risk factors. 
We also estimated the cost of opioid poisonings in family members of patients with an opioid 
prescription as well as the cost of opioid poisoning in patients who do not have an opioid 
prescription as compared to patients who did not suffer from an overdose. These estimates will 
add to the literature on opioid diversion.  
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CHAPTER III 
 
Methods and results for specific aim 1: 
Prevalence of opioid overdoses in prescription opioid users, family members of prescription 
opioid user and others 
 
Section 3.1 – Methods 
 
This section describes the study methodology used to estimate the prevalence of prescription 
opioid overdoses in prescription opioid users, family members of prescription opioid users and 
individuals who did not have an opioid prescription themselves and neither did any family 
member (categorized as “others”) between July 2010 and June 2015. 
 
Database  
Data for the study consisted of medical and pharmacy claims from SelectHealth. SelectHealth is 
a not-for-profit health insurance organization serving members in Utah and southern Idaho. 
SelectHealth is committed to helping people live the healthiest lives possible. SelectHealth offers 
medical, dental, vision, pharmacy benefit management, and life and disability coverage to its 
members. We were provided with claims for a subset of patients for this study. The data included 
medical and pharmacy claims for patients who had at least one opioid analgesic prescription and 
their families and patients who had an opioid overdose event between July 2010 and June 2015. 
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In 2015, SelectHealth insured approximately 650,000 patients of the commercial population, 
80,000 patients through managed Medicaid and 30,000 through their Medicare Advantage plan. 
The medical claims file contained all medical claims for a patient, including a claim ID, the date 
the claim was filed, the diagnosis code and description (in International Classification of 
Diseases, 9
th
 Revision, Clinical Modification (ICD-9-CM) format), the place the service was 
provided and the allowed cost for each claim. Examples of places of service in the dataset 
include Emergency Room - hospital (ER), inpatient hospital, outpatient hospital, ambulance – 
land, hospice and nursing facility. Allowed cost is the reimbursement that the payer paid the 
provider for the service.
87
 
Database elements in the pharmacy claims file included a claim ID, date the claim was filed, 
medication name, National Drug Code (NDC), Generic Product Identifier (GPI), days’ supply, 
quantity supplied and allowed cost for each claim. 
The member data file contained a unique encrypted member ID for each patient that was used to 
link the patient across the medical and the pharmacy files, their date of birth, sex, and their 
relationship to the primary cardholder.  
 
Sample selection  
The following patients were included in this study –  
-  All patients who received an opioid in the period from July 2010 to June 2015 
- All patients who suffered from at least one opioid overdose event (non-heroin) in the period 
from July 2010 to June 2015 
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While cancer patients were not excluded from this analysis, we will report the estimates for 
number of cancer patients who had an opioid overdose.  
 
Identification of overdose events (ICD codes)  
Opioid overdoses were identified using International Classification of Diseases, 9
th
 Revision, 
Clinical Modification (ICD-9-CM) codes (Table 8). 
Table 8 – ICD-9 CM codes for overdose events 
Code Description 
E850.1 Accidental poisoning by methadone 
E850.2 Accidental poisoning by other opiates and related narcotics 
 
965.0 Poisoning by opium (alkaloids), unspecified 
965.02 Poisoning by methadone 
965.09 Poisoning by other opiates  
 
We used the following conditions to identify a unique opioid overdose event –  
If the same patient had two different claims for an overdose on the same day, we considered the 
two claims to be one event.  
When opioid overdose cases had claims that spanned more than 1 day, claim fill dates that were 
less than 7 days from the first event were considered one event. Subsequent claims that were 7 or 
more days after the index event were considered a new event. 
69
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Identification of prescription opioid users  
The pharmacy claims data included a Generic Product Identifier (GPI) and National Drug Code 
(NDC) for all the drugs. However, since we did not have a key or legend to identify a drug using 
GPI or NDC, prescription opioids were identified manually. We identified a list of 7,087 unique 
drugs from which opioids and benzodiazepines were identified manually. Mixed formulations 
containing an opioid were included in the study as well.  
All patients who had a prescription for an opioid during the study period were classified as a 
prescription opioid user.   
 
Identification of prescription opioid users who suffered from an overdose  
To be able to link a prescription to an overdose, we assessed for temporality. In the context of 
this study, we define an overdose case to be temporal if the patient was prescribed an opioid 
before the overdose. This could be an active prescription or medication from a prescription 
within the previous year. A patient who had a prescription for an opioid before they had the 
overdose were classified as a prescription opioid user who suffered from an overdose.  
We chose to use this definition of temporality because there is increasing evidence that leftover 
opioid pills are not disposed appropriately and are often saved for later and even shared with 
others. Nearly 62% of people who have leftover opioid pills keep them for later use rather than 
disposing them. 
88
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To create a stronger link between the prescribed opioid and the overdose, we further restricted 
the definition of temporal overdoses to patients who had an overdose within one year of their 
most recent prescription opioid fill date.  
All patients who had an overdose within 1 year of their most recent prescription opioid fill date 
were classified as recent prescription opioid users. If patients did not meet this criteria, they were 
then categorized as family members of prescription opioid users or others as applicable and as 
explained below. 
 
Identification of Family Members of Prescription Opioid Users who suffered from an 
overdose  
To identify family members of prescription opioid users who suffered from an overdose we 
created a “family ID” variable based on the encrypted member ID we were given in the data by 
removing the last digit of the encrypted member ID. For example, patients 101 and 102 belong to 
the same family with the family ID ’10’.  
We checked for temporality in this group as well by checking if the family member received 
their opioid prescription before the patient had an overdose. If yes, then the patient was 
considered to be a family member of a prescription opioid user who suffered from an overdose 
from their family member’s prescription. If temporality was not established, the patient was 
considered to be an “other” opioid overdose patients who obtained their prescription opioid from 
elsewhere. We did not check if the prescription was dispensed within a year before the overdose 
in this case because we made the assumption that individuals who obtain the medication from 
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family members can get them at any time and it does not necessarily have to be an active 
prescription. 
Patients who did not have an opioid prescription themselves, but had an overdose and shared the 
same family ID with a patient who had an opioid prescription fill before the date of the overdose, 
were classified as family members or dependents of prescription opioid users who suffered from 
an overdose. 
In addition to patients who were categorized as described above, patients who were not 
categorized as recent prescription opioid users were then assessed to identify if they were family 
members of patients who had an opioid prescription using the same process described above. 
 
Identification of “Other Overdosers” group – Patients who do not have an identifiable 
source for their prescription opioid but suffered from an overdose  
Patients who did not have a temporal opioid prescription within a year from the date of the 
overdose, did not have a family member who had an opioid prescription before the date of their 
overdose but suffered from an overdose were classified as “Other” overdosers. These patients did 
not have a known and identifiable source for their prescription opioid.  
The classification of patients into these three groups is explained in Figure 3. 
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Morphine Equivalent Daily Dose  
For opioids, it is important to convert the strength of all the medications to the standard 
Morphine Equivalent Daily Dose (MEDD) format so as to be able to compare each medication’s 
potency against a standard – Morphine.  
The following method was used to calculate the MEDD –  
Step 1 – Quantity/day: For each medication, the quantity was divided by the days’ supply to get 
the quantity per day of the drug consumed.  
In case of solid oral dosage forms like tablets or capsules, we rounded down unless the 
quantity/day was less than 1. If the quantity/day was less than 1, we left the estimate as is.   
Step 2 – Amount/day: This was followed by calculating the amount per day, where the strength 
was multiplied by the quantity/day obtained in step 1. 
Step 3 – Morphine equivalents/day: The product of step 2 was then multiplied by the appropriate 
morphine equivalent conversion factors. A list of these factors are presented in  
 
 
 
 
 
 
 
Table 9.   
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We modified this formula to calculate the MEDD for patches. Since the strength is in mcg/hour, 
we converted the strength to mg/hour and then to mg/day by multiplying it by 24. 
 
 
 
 
 
 
 
Table 9 - Opioid Morphine Equivalent Conversion Factors
89,90
 
Major Group Type of Opioid  Morphine 
equivalent 
conversion factor 
per mg of opioid 
Short-acting, less potent 
(Schedule III/IV) 
Propoxyphene (with or without aspirin, 
acetaminophen or ibuprofen) 
0.23 
 Codeine + (acetaminophen, ibuprofen or 
aspirin) 
0.15 
 Hydrocodone + (acetaminophen, ibuprofen 
or aspirin)  
Hydrocodone and homatropine 
1.0 
 Tramadol with or without aspirin 0.10 
 Butalbital and codeine (with or without 
aspirin, acetaminophen or ibuprofen) 
0.15 
 Dihydrocodeine (with or without aspirin, 
acetaminophen or ibuprofen) 
0.25 
 Pentazocine (with or without aspirin, 
acetaminophen or ibuprofen) 
0.37 
Short-acting, more potent 
(Schedule II) 
Morphine sulfate 1.0 
 Codeine sulfate 0.15 
 Oxycodone (with or without aspirin, 
acetaminophen or ibuprofen) 
1.5 
 Hydromorphone 4.0 
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 Meperidine hydrochloride 0.1 
 Fentanyl citrate transmucosal 0.125 
 Oxymorphone 3.0 
 Tapentadol 0.4 
 Opium 1.0 
Long-acting  
(Schedule II) 
Morphine sulfate sustained release 1.0 
 Fentanyl transdermal 2.4 
 Levorphanol tartrate 11.0 
 Oxycodone HCL controlled release 1.5 
 Methadone 3.0 
Schedule III Buprenorphine patch 12.6 
 Buprenorphine tablet or film 10 
 
Benzodiazepine poisoning 
Benzodiazepine poisoning was identified using ICD-9CM codes. We identified patients with 
concurrent use of opioids and benzodiazepine if they had a diagnosis for both opioid overdose 
and benzodiazepine poisoning on the same day.  
Table 10  - ICD-9 CM codes for benzodiazepine poisoning 
Code Description 
E853.2 Accidental poisoning by benzodiazepine-based tranquilizers 
969.4 Poisoning by benzodiazepine-based tranquilizers 
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Excluded patients –  
1. Not temporal –  
i.e. prescription does not precede overdose 
(N = 50) 
 
2. The time between the most recent fill and overdose 
exceeds 1 year*  
(N = 34) 
 
Prescription opioid users who suffered from an 
overdose 
(N = 527) 
Group 1 –  
Recent prescription opioid users who suffered 
from an overdose 
(N = 444) 
Excluded patients –  
1. Not dependents –  
(N = 47) 
 
2. Not temporal–  
i.e. prescription in family member does not precede 
overdose 
(N =23) 
Group 3 –  
Others – Neither did the patient nor did any family 
member have a prescription before the overdose 
(Original N =123, 70 patients added) 
(N = 193) 
Group 2 –  
Dependents of prescription opioid users who 
suffered from an overdose 
(N = 65) 
Excluded patients moved to Group 2 –  
Dependents of prescription opioid users who 
suffered from an overdose 
(Original N = 51, 84 patients added) 
(N = 135) 
* 1 patient is in 2 groups, a prescription opioid user and the other group. The first overdose was on 07/09/2010 and did not have a prescription associated with it. The 
next overdose was on 09/29/2011 and had a prescription associated with it.  
  Figure 3 – Categorizing patients into groups based on source of opioid 
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Identification of Acute and Chronic Opioid Users 
After prescription opioid users were identified, we further classified these patients as acute and 
chronic users.  
Acute and chronic opioid user identification was done by year for patients who had a 
prescription opioid in the same year they had the overdose.  
Patients can be chronic users in one year and acute users in another year. For example, if patients 
had surgery and were prescribed opioids for four months, they would be classified as chronic 
users in the year of the surgery. If the same patient was then prescribed an opioid for an acute 
condition two years later, the patient would be classified as an acute opioid user in that year.  
We identified chronic users based on a modification of the ‘episode’ approach used in previous 
studies that have focused on long-term opioid therapy.
12,89
 Since we were identifying and 
subsequently classifying patients by year, we modified the definition to suit our study design and 
data.  
We identified patients as chronic opioid users if the total days’ supply for all the opioids that a 
patient was prescribed was greater than 120 days in that year. We assessed days’ supply for all 
opioids so as to account for opioid switching. Based on the variability in literature that has 
looked at long-term opioid therapy, we decided to identify all patients with 120+ days’ supply as 
chronic opioid users, irrespective of whether the use was continuous or not. 
14,69,91–93
  
Due to the cross-sectional nature of the data, we could not look back a few months to check if 
these patients had a prescription in November or December of the previous year since a many 
patients were not enrolled in the previous year. Therefore, we may have misclassified some 
chronic users as acute.  
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Prevalence 
Prevalence is defined as the ratio of the number of existing events (old and new) to the total 
population at risk.  
We report the following prevalence estimates –  
i. Prevalence of opioid overdose events in the sample population by year  
Prevalence of opioid overdoses in the sample population  
                                                               = Number of overdoses in the sample population in a year 
                                                                   Number of people enrolled in the plan in that year 
 
 
ii. Prevalence of opioid overdose events by patient group (based on source of opioid) 
Prevalence of opioid overdose events in recent prescription opioid users  
                                                = Number of overdoses in recent prescription opioid users in a year 
                                                            Number of patients prescribed an opioid in that year      
We also report the following rate for prescription opioid users –  
Opioid overdoses per 100,000 opioid prescriptions  
                                                = Number of overdoses in recent prescription opioid users in a year 
                                                           Number of opioid prescriptions dispensed that year 
 
Prevalence of opioid overdose events in family members of prescription opioid users  
                     = Number of overdoses in family members of prescription opioid users in a year 
                              Number of family members of prescription opioid users in that year 
Prevalence of opioid overdose events in patients with no source of opioid (others)  
                                                                        = Number of overdoses in these patients in a year 
                                                                                Number of “others” enrolled in that year 
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The number of others was estimated by subtracting the number of prescription opioid users and 
family members of prescription opioid users from the number of people enrolled in the plan that 
year.  
 
iii. Prevalence of opioid overdose events for acute and chronic opioid users 
 Prevalence of opioid overdose events for acute users  
                                                            = Number of overdoses in acute opioid users in a year  
                                                                      Number of acute opioid users in that year  
Prevalence of opioid overdose events for chronic users  
                                                           = Number of overdoses in chronic opioid users in a year  
                                                                   Number of chronic opioid users in that year  
 
Sensitivity Analysis 
We used sensitivity analysis to determine the extent to which the assumption that individuals 
who obtain the medication from family members can obtain an old prescription and not 
necessarily an active one influence the prevalence estimates. We restricted the time from the 
family member’s most recent opioid prescription fill date to the overdose to one year. 
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Section 3.2 – Results 
The results for Specific Aim 1 are presented in this section.  
We first describe the prescription opioid users in our sample. This is followed by the prevalence 
of opioid overdoses in the sample population and the prevalence of opioid overdoses in each of 
the three groups – recent prescription opioid users, family members of recent prescription opioid 
users and others.  
We then report the prevalence of acute and chronic opioid use and overdoses in acute and 
chronic opioid users.  
 
Prescription opioid users in the sample population –  
There were a total of 398,069 prescription opioid users in the study sample. Majority of the 
patients prescribed a prescription opioid were in the 18-64 age group. More women were 
prescribed opioids as compared to men. The average Morphine Equivalent Daily Dose (MEDD) 
for all prescription opioid users was 81.95 mg/day. 
Prescription opioid users in the sample population are described in Table 11.  
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Table 11 – Demographics for all medication users in the study population 
Characteristic All medication users 
(N = 667,718) 
Prescription opioid users 
(N = 398,069 ) 
Non-users 
(N = 269,649 ) 
Age, n (%) 
     0-17 
     18-44 
     45-65 
     65 and above 
 
172,840 (25.83) 
295,226 (44.21) 
160,665 (24.06) 
39,347 (5.89) 
 
45,681 (11.48) 
206,830 (51.96) 
115,995 (29.14) 
29,563 (7.43) 
 
126,799 (47.02) 
88,396 (32.78) 
44,670 (16.57) 
9,784 (3.63) 
Gender, n (%) 
     Female 
     Male 
 
353,909 (53.00) 
313,809 (47.00) 
 
223,803 (56.22) 
174,266 (43.78) 
 
130,106 (48.25) 
139,543 (51.75) 
MEDD, mean (SD) N/A 81.21 (137.70) N/A 
* Reported only for patients who had complete information 
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Opioid overdoses in the sample population –  
There were a total of 770 opioid overdose events in the period from June 2010 – July 2015 in this population. The prevalence of opioid overdose 
events by year is reported in Table 12. There was a 119% increase in the prevalence of patients who suffered from an opioid overdose in prescription 
opioid users from 2011-2014.  A graph demonstrating the rise in the rate of opioid overdose events is shown in Table 12.  
Table 12 – Prevalence of opioid overdoses in the sample population  
Year 2010 
(half year) 
2011 2012 2013 2014 2015 
(half year) 
%∆ (2011-2014)* 
Number of overdoses 49 91 98 174 224 134  
Number of enrollees 517,351 540,846 530,877 550,170 607,060 664,558  
Prevalence*  
(per 100,00 enrollees) 
- 
 
16.83 18.46 31.63 36.9 - 119.2 
Prevalence of opioid overdoses in the sample population = Number of overdoses in the sample population in a year 
                                                                                                  Number of people enrolled in the plan in that year 
*Only computed for complete years 
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Figure 4– Opioid Overdoses per 100,000 enrollees 
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Patients who suffered from an overdose by Group –  
The three groups into which patients who suffered from an overdose were categorized – recent 
prescription opioid users who suffered from an overdose, family members of prescription opioid 
users who suffered from an overdose and others – are described in Table 13.  
We also described medication use for the most recent opioid fill before the overdose event for 
recent prescription opioid users. While women suffered from more overdoses compared to men 
among the recent prescription opioid users and others, more men suffered from opioid overdoses 
among family members of recent prescription opioid users. Nearly 19% of non-users (family 
members and others) who suffered from an overdose were in the 0-17 year age category. 
Formulations containing hydrocodone and oxycodone were the most recent fills before an opioid 
overdose in 68% of prescription opioid users and the mean (SD) MEDD amongst those 
prescribed an opioid was 127 mg/day (162.94 mg/day). 
  
 
63 
Table 13 – Characteristics of patients who have suffered from an overdose  
Characteristic Recent Prescription 
Opioid Users 
(N = 444) 
Family Members 
 
(N = 65) 
Others 
 
(N = 193) 
Age, n (%) 
0-17 
18-44 
45-64 
65 and older 
 
14 (3.15) 
204 (45.95) 
190 (42.79) 
36 (8.11) 
 
18 (27.69) 
41 (63.08) 
6 (9.23) 
0 (0) 
 
30 (15.54) 
82 (42.49) 
54 (27.98) 
27 (13.99) 
Gender, n (%) 
Male 
Female 
 
175 (39.41) 
269 (60.59) 
 
35 (53.85) 
30 (46.15) 
 
73 (37.82) 
120 (62.18) 
Cancer patients, n (%) 28 (6.32) 0 (0.00) 4 (2.07) 
Concurrent benzodiazepine poisoning, n (%) 8 (1.8) 1 (1.5) 4 (2.07) 
Opioid/Formulation containing opioid*, n (%) 
Buprenorphine 
Codeine 
Fentanyl 
Hydrocodone 
Hydromorphone 
Methadone 
Morphine 
Oxycodone 
Oxymorphone 
Tapentadol 
Tramadol 
 
1 (0.23) 
18 (4.08) 
19 (4.31) 
124 (28.12) 
13 (2.95) 
12 (2.72) 
38 (8.62) 
177 (40.14) 
5 (1.13) 
5 (1.13) 
29 (6.58) 
N/A N/A 
Type of opioid prescription (ER/LA/CR)*, n (%) 47 (10.66) N/A N/A 
Average MEDD*, mean (SD) 126.94 (162.94) N/A N/A 
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MEDD = Morphine Equivalent Daily Dose; ER = Extended Release; LA = Long Acting; CR = Controlled Release; SD = Standard 
Deviation 
*3 patients did not have complete information about days’ supply and quantity dispensed. We have reported these estimates only for 
patients who had complete information (N=440) 
 
 
Recent CDC guidelines have stated that physicians should carefully assess benefit and risks when increasing dosage to ≥50 MEDD 
and should avoid increasing doses to ≥90 MEDD.94 Therefore, we looked at the number of prescriptions that were in these buckets in 
our sample. The results are reported in Table 14.  
Table 14 – Morphine Equivalent Daily Dose (as categorized by CDC guidelines)95 
MEDD Number of prescriptions (%) Mean Median Standard deviation 
50 
50-89 
90 
1,168,751 (62.66) 
212,553 (11.40) 
484,014 (25.95) 
25.31 
63.62 
226.76 
27 
60 
180 
12.59 
9.8 
208.71 
MEDD = Morphine Equivalent Daily Dose;  
*These values were estimated for those prescriptions which had complete information only 
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The mean and median MEDD for acute and chronic users by year is presented in Table 15.  
Table 15 – Morphine Equivalent Daily Dose (MEDD) for acute and chronic users 
Year Acute Users Chronic Users 
2011 
       Mean (SD) 
       Median 
 
63.68 (79.99) 
35 
 
95.09 (165.90) 
40 
2012 
       Mean (SD) 
       Median 
 
64.80 (80.12) 
35 
 
98.65 (178.43) 
40 
2013 
       Mean (SD) 
       Median 
 
65.60 (84.19) 
35 
 
103.91 (191.38) 
40 
2014 
       Mean (SD) 
       Median 
 
67.30 (83.94) 
35 
 
106.56 (187.61) 
40 
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Some patients in all three groups suffered from more than one overdose during the study period. We report the frequencies and the 
percentage of people who suffered from more than one overdose by group in Table 16. 
Table 16 - Repeated overdoses 
 Recent Prescription 
Opioid Users 
Family Members Others 
 
Number of Patients 444 65 193 
Number of Overdoses 493 67 210 
Repeated Overdoses 49 2 17 
Percentage of people who had a repeat overdose event (%) 11.04 2.94 8.81 
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Opioid overdoses by group by year – 
 
i. Recent prescription opioid users 
The frequencies and prevalence of opioid overdoses in the recent prescription opioid user group is reported in Table 17.  
 
Table 17 – Prevalence of overdoses in recent prescription opioid users 
Year 2010 
(half year) 
2011 2012 2013 2014 2015 
(half year) 
%∆ (2011-2014)* 
Number of overdoses 30 59 68 103 143 90  
Number of patients with an opioid Rx 57,344 106,108 106,942 122,369 139,149 95,442  
Prevalence* 
(per 100,000 users) 
- 55.60 63.59 84.17 102.77 - 84.83 
Prevalence  = Number of overdoses in recent prescription opioid users in a year 
                                     Number of patients prescribed an opioid that year 
*Only computed for complete years; Rx = prescription 
 
A graph showing the rising prevalence of opioid overdoses in recent prescription opioid user group is shown in Figure 5. We also 
report a graph demonstrating the rate of opioid overdoses per 100,000 opioid prescriptions by year in Figure 6. 
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Figure 5 – Opioid overdoses (Prescription Opioid Users) per 100,000 opioid prescription users  
 
Figure 6 – Opioid Overdoses (Prescription Opioid Users) per 100,000 opioid prescriptions  
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ii. Family Members of recent prescription opioid users 
The frequencies and prevalence of opioid overdoses in the family members of prescription opioid users group is reported in Table 18. 
After 2012, the prevalence of overdoses in this group has remained steady.  
Table 18 – Prevalence of overdoses in Family Members of Recent Prescription Opioid Users 
Year 2010 
(half year) 
2011 2012 2013 2014 2015 
(half year) 
%∆ (2011-2014)* 
Number of overdoses 3 10 14 12 15 13  
Number of patients with a family 
member with an opioid Rx 
105,011 167,625 166,209 170,314 181,834 133,390  
Prevalence* 
(per 100,000 users) 
- 5.97 8.42 7.05 8.23 - 37.86 
Prevalence  = Number of overdoses in family members of opioid users in a year 
                       Number of family members of prescription opioid users that year 
*Only computed for complete years; Rx = prescription 
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iii. Others 
The frequencies and prevalence of opioid overdoses in the patients who do not have an identifiable source of opioid (others) is 
reported in Table 19. 
 
Table 19 – Prevalence of overdoses in others 
Year 2010 
(half year) 
2011 2012 2013 2014 2015 
(half year) 
%∆ (2011-2014)* 
Number of overdoses 16 22 16 59 66 31  
Number of other enrollees - 267,113 257,726 257,487 286,070 -  
Prevalence* 
(per 100,000 users) 
- 8.24 6.21 22.91 23.07 - 179.98 
Prevalence  = Number of overdoses in others in a year 
                       Number of other enrollees that year 
*Only computed for complete years 
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Acute and Chronic Opioid Use –  
 
The proportions of acute and chronic opioid users for each year are reported in Table 20. 
Table 20 – Acute and Chronic Users by Year 
Year 2011  2012 2013 2014 
Acute Users, n (%) 98,088 (92.44) 94,912 (91.94) 111,508 (91.12) 125,286 (90.04) 
Chronic Users, n (%) 8,020 (7.56) 8,323 (8.06) 10,861 (8.88) 13,863 (9.96) 
*Only included complete years 
 
Frequencies and prevalence of overdoses in acute and chronic users by year is reported in Table 21. 
Table 21 – Number of overdoses in acute and chronic patients by year 
i. Acute users 
Year 2011 2012 2013 2014 %∆ (2011-2014)* 
Number of overdoses 43 35 43 63  
Prevalence 
(per 100,000 acute users) 
43.84 36.88 38.56 50.28 14.72 
Prevalence of opioid overdoses in acute users = Number of overdoses in acute opioid users in a year 
                                                                                    Number of acute opioid users in that year 
*Only included complete years 
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ii. Chronic users 
Year 2011 2012 2013 2014 %∆ (2011-2014)* 
Number of overdoses 15 26 54 69  
Prevalence 
(per 100,000 chronic users) 
187.03 312.39 497.19 497.3 165.89% 
Prevalence of opioid overdoses in chronic users = Number of overdoses in chronic opioid users in a year 
                                                                                            Number of chronic opioid users in that year 
*Only included complete years 
  
In 25 cases, the prescription opioid user received the prescription opioid in a year before the overdose. Since they did not receive a 
prescription in the year they suffered from an opioid overdose, the user could not be classified as an acute or chronic user in that year 
and therefore, was not included in the prevalence analysis.  
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A graph comparing the prevalence of overdoses in acute and chronic users is shown in Figure 7. This graph demonstrates the 165% 
rise in the prevalence of overdoses in chronic users in the past few years.  
While there has not been a steep rise in overdoses in acute opioid users, we can see a slight increase in 2014 as compared to 2012 and 
2013. 
 
Figure 7  - Overdoses per 100,000 prescription opioid users (acute and chronic respectively) by year 
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Sensitivity Analysis 
 
The results of a sensitivity analysis restricting the time between the family members’ most recent 
prescription fill date and the overdose to one year are reported in Table 22. From the original 
estimates, 12 patients who had an overdose from a family member’s prescription were moved to 
the others group because the most recent prescription for the family member was filled more 
than a year before the overdose.  
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Table 22 – Characteristics of patients who have suffered from an overdose (revised definition of family members who suffered from 
an opioid overdose) 
Characteristic Recent Prescription 
Opioid Users 
(N = 444) 
Family Members 
 
(N = 53) 
Others 
 
(N = 205) 
Age, n (%) 
0-17 
18-44 
45-64 
65 and older 
 
14 (3.15) 
204 (45.95) 
190 (42.79) 
36 (8.11) 
 
15 (28.30) 
33 (62.26) 
5 (9.43) 
0 (0.00) 
 
33 (16.10) 
90 (43.90) 
55 (26.83) 
27 (13.17) 
Gender, n (%) 
Male 
Female 
 
175 (39.41) 
269 (60.59) 
 
30 (56.60) 
23 (43.40) 
 
78 (38.05) 
127 (61.95) 
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CHAPTER IV 
 
Methods and Results for Specific Aim 2: 
Specific Aim 2A: Estimate the incremental cost and resource utilization in prescription opioid 
users who suffered from an overdose 
 
Specific Aim 2B: Estimate the incremental cost and resource utilization in family members of 
prescription opioid user and others who suffered from an overdose 
 
Methods 
Specific Aim 2A: Estimate the incremental cost and resource utilization in prescription opioid 
users who suffered from an overdose 
 
This section describes the study methodology used to estimate the cost and resource utilization 
associated with prescription opioid overdose in prescription opioid users between July 2010 and 
June 2015. 
 
Study design 
The study design was a retrospective data analysis using claims data. For this aim, we used a 
matched control methodology (propensity score matching) to match cases with controls. We then 
used an incremental (or econometric approach) to estimate the economic cost of opioid overdose 
by calculating the difference in mean costs for the two groups. 
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The index date was defined as the most recent opioid fill before the overdose for cases and the 
first opioid fill for controls. This date was used to evaluate baseline characteristics for study 
participants. 
The follow-up date was defined as the first opioid overdose for cases. The database was the same 
as that used for Specific Aim 1, i.e. medical and pharmacy claims data from SelectHealth. 
The duration between the most recent opioid prescription and the overdose was calculated for 
cases and the same duration was then applied to their respective controls from the first fill date to 
obtain the assigned follow-up date. The study design is explained in  and  for cases and controls 
respectively. 
Once matched, the participants were followed for one year from the date of the overdose and 
costs and resource utilization were estimated for this duration. 
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Figure 8 – Study timeline for cases 
 
  
 
 
 
Database 
Figure 9 – Study timeline for control 
 
Perspective  
The cost estimation and resource utilization were carried out using a payer perspective. Most 
costs incurred by payers are direct costs and include the cost of medical care provided (for 
example – ER costs, inpatient costs, drug costs, laboratory costs, medical devices, and 
professional fees). Payers also have indirect cost in administering their programs for staff, space, 
utilities, etc.
96
 We were only provided with the data to be able to assess the direct cost 
component for this study. We have captured allowed costs (or reimbursements) for cost 
estimation in this study.  
Most recent opioid fill date 
(Index date) 
Overdose date 
(Follow-up date) 
End of follow-up period  
Follow-up period – 1 year  Maximum duration of 1 year  Baseline period – 3 months  
First opioid fill date 
(Index date) 
Assigned “Overdose” date 
(Follow-up date) End of follow-up period  
Follow-up period – 1 year  Baseline period – 3 months  Maximum duration of 1 year  
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Sample Selection  
The inclusion and exclusion criteria for incremental cost estimation and resource utilization for 
prescription opioid users is similar to that of the prevalence aim, with four additional exclusion 
criteria. One, we excluded cancer patients. Since cancer patients are very different from any 
other population with regards to the severity of sickness and healthcare utilization, we decided to 
exclude these patients. The ICD-9-CM codes and method used for identification of cancer 
patients have been included in the appendix (Table A1).  
Two, we restricted the sample to patients for whom we had at least 3 months of baseline data 
because needed baseline resource utilization and comorbidity information for propensity score 
matching. It is important to note that while we would have preferred a longer baseline period, we 
had to make a compromise due a greater influx and outflux of patients from year to year than we 
had anticipated. A baseline period of 3 months was a middle ground to be able to capture 
baseline characteristics without losing a large portion of our sample. 
We also excluded all patients for whom we did not have one year of follow-up to estimate costs. 
This includes patients who were not enrolled for one year after the follow-up date and patients 
who had an overdose after July 01, 2014.   
Finally, we excluded patients for whom we did not have complete information to calculate the 
MEDD (Morphine Equivalent Daily Dose). Any patient who did not have complete information 
on the medication, strength, dosage form, days’ supply and quantity dispensed were excluded.  
A flowchart explaining the exclusion of patients is shown in Figure 10.  
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Figure 10 – Sample selection for recent prescription opioid users 
 
 
  
Exclude cancer patients = 28 
Exclude cancer patients = 13,189 
Cases = 416 
Controls = 376,554 
Exclude patients with incomplete medication information = 3 
Exclude patients with incomplete medication information = 3,009 
 
Cases = 413 
Controls = 373,545 
Exclude patients without 90 day baseline period = 27 
Exclude patients without 90 day baseline period = 57,614 
 
Cases = 386 
Controls = 315,931 
 
Exclude patients with overdoses after July 1st, 2014 = 138 
Exclude patients if “overdose date” falls after July 1st, 2014 = 133,506 
Cases = 248 
Controls = 182,425 
 
Cases = 444 
Controls = 389,743 
Exclude patients without 1 year follow-up period = 49 
Exclude patients without 1 year follow-up period = 60,605 
Cases = 199 
Controls = 121,820 
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Propensity score matching 
We performed propensity score matching using the greedy algorithm (also known as nearest 
neighbor matching).  This method allows each case to be matched with the most suitable control 
available for matching at that point in the matching process and then the case and control are 
removed from the matching process. We performed a 1:1 match where each case was matched 
with one control. 
One of the key issues in propensity score matching is model specification, i.e. identification of 
the variables that are included in the model to evaluate a propensity score. We included all the 
variables that were available to us that have been shown to increase the risk of an overdose in a 
patient. 
 
Variables used in Propensity Score Matching  
Dependent –  
Overdose –  
An overdose event was identified using the ICD-9-CM codes described in Chapter 3. Overdose 
is defined as a categorical variable indicating whether or not a patient suffered from an overdose 
event during the study period.  
  
  
  
 
82 
Independent –  
Age –  
The age variable was categorized in the following manner – 0-17 years, 18-44 years, 45-64 years 
and 65 and older.  
 
Sex –  
The sex was categorized as male and female.  
 
Comorbidities –   
Comorbidity scores are frequently used to reduce potential confounding and account for disease 
severity in epidemiological research. The Charlson Comorbidity Index (CCI) and the Elixhauser 
method are commonly used methods in administrative data studies.
97
 We used the CCI along 
with some important variables from the Elixhauser method.  
Each condition is assigned a score of 1, 2, 3 or 6 depending on the risk of dying associated with 
the disease. The scores are then summed and the total score predicts mortality. 
A more detailed description of the comorbidities included in the CCI, weights and the ICD-9-
CM codes is given in Table 23.  
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Table 23 – Comorbidities included in CCI, assigned scores and corresponding enhanced  
ICD-9-CM codes 
98,99
 
 
Comorbidity Score Enhanced ICD-9-CM 
Myocardial infarction 1 410.x, 412.x 
Congestive heart failure 1 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 
404.11, 404.13, 404.91, 404.93, 425.4-425.9, 428.x  
Peripheral vascular disease 1 093.0, 437.3, 440.x, 441.x, 443.1, 443.2, 443.8, 
443.9, 447.1, 557.1, 557.9, V43.4 
Cerebrovascular disease 1 362.34, 430.x-438.x  
Dementia 1 290.x, 294.1, 331.2 
Chronic Pulmonary disease 1 416.8, 416.9, 490.x-505.x, 506.4, 508.1, 508.8 
Rheumatic disease 1 446.5, 710.0-710.4, 714.0-714.2, 714.8, 725.x  
Peptic ulcer disease 1 531.x-534.x 
Mild liver disease 1 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 
070.6, 070.9, 570.x, 571.x, 573.3, 573.4, 573.8, 
573.9, V42.7 
Diabetes without chronic 
complication 
2 250.0-250.3 
Diabetes with chronic 
complication  
2 250.4, 250.5, 250.6, 250.7 
Hemiplegia or paraplegia 2 334.1, 342.x, 343.x, 344.0-3446, 344.9 
Renal disease 2 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 
404.13, 404.92, 404.93, 582.x, 5830.0-583.7, 
585.x, 586.x, 588.0, V42.0, V45.1, V56.x 
Any malignancy, including 
lymphoma and leukemia, except 
malignant neoplasm of the skin 
2 140.x-172.x, 174.x-195.8, 200.x-208.x, 238.6 
Moderate or severe liver disease 3 456.0-456.2, 572.2-572.8 
Metastatic solid tumor 6 196.x-199.x 
AIDS/HIV 6 042.x-044.x 
 
We chose to include four variables from the Elixhauser comorbidity index – alcohol abuse, drug 
abuse, psychoses and depression – in the propensity score model as independent variables since 
these patients are at a higher risk for an overdose.
36
 These variables were defined as categorical 
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variables indicating whether or not a patient was diagnosed with these conditions during the 
baseline period. 
The codes used for these comorbidities are listed in Table 24.  
Table 24 – Additional comorbidities included in the propensity score model98  
Comorbidity ICD-9-CM codes 
Alcohol abuse 265.2, 291.1-291.3, 291.5, 291.8, 291.9, 
303.0, 303.9, 305.0, 357.5, 425.5, 535.3, 
571.0, 57.1-571.3, 980.x, V11.3 
Drug abuse 292.x, 304.x, 305.2-305.9, V65.42 
Psychoses 293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 
297.x, 298.x 
Depression  296.2, 296.3, 296.5, 300.4, 309.x, 311 
 
Health Care Utilization in the baseline period –  
All direct medical care costs were computed for the 3-month baseline period for the cases and 
controls. These included all medical and pharmacy reimbursements for that period. 
 
Dose – 
The MEDD was calculated as described in Chapter III, Section 3.1 (page 53). 
 
Extended Release/Long-Acting Opioid – 
If any of the opioid formulations were marked “ER”, “XR” or “CR”, they were identified as 
extended release or long-acting formulations. In addition to these formulations, “Exalgo tab 
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12mg” and “Hydrocodone Polistirex and Chlorpheniramine Polistirex LIQ 10-8/5ML” were 
identified as extended release formulations.  
 
Benzodiazepine Use – 
While there is evidence that the concurrent use of opioids and benzodiazepines increases the risk 
of opioid overdose
100,101
, in this study we are not necessarily looking at the active concurrent use 
of both medications. Benzodiazepines, like opioids, can be leftover and used at a later date.  
Based on this assumption, we identified prescription opioid users who had a prescription for a 
benzodiazepine before the index date.  
 
Logistic Regression Model –  
Logit (Overdose=1) = βo + β1 (sex) + β2 (age) + β3 (CCI Score) + β4 (alcohol abuse) + β5 (drug 
abuse) + β6 (psychosis) + β7 (depression) + β8 (healthcare cost in the baseline period) + β9 (MED) 
+ β10 (ER/LA/CR formulation) + β11 (benzodiazepine use)  
 
Propensity Score Matching diagnostics –  
After cases and controls were matched using propensity score matching, we assessed for balance 
using standardized difference.  
Standardized difference for continuous variables was computed using the following formula –  
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Where x ̅1 and x ̅2 denote the sample mean of a baseline variable and s1
2
 and s2
2
 denote the sample 
variances in the case and control, respectively.  
Standardized difference for categorical variables was computed using the following formula – 
 
Where p̂1 and p̂2 denote the proportion of a binary baseline variable in the case and control group, 
respectively. 
 
A standardized difference that is less than absolute value 0.1 has been taken to indicate a 
negligible difference in the mean or proportions of a covariate between the case and control 
groups. 
102
 
We plotted the distributions of propensity scores for the cases and controls to visually assess if 
matching made the distributions alike. 
103
 We also used the two sample Kolmogorov-Smirnov 
(K-S) test to assess if the 2 groups were sampled from populations with similar distributions. 
104
 
 
Outcome measures 
The primary study outcome is the incremental cost over a year between prescription opioid users 
who have suffered from at least one overdose event and prescription opioid users who have not 
suffered from an overdose event. 
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The study outcomes also include all-cause and overdose-specific costs and all-cause and 
overdose-specific healthcare resource utilization. 
Overdose-specific outcomes were identified by claims that had ICD-9-CM codes for opioid 
overdoses. 
The costs were broken down into the following categories based on the place of service variable 
provided in the dataset ( 
Table 25).  
 
Table 25 – Categorization of place of service 
Category Variable 
1. Emergency Room (ER) "EMERGENCY ROOM- HOSPITA" 
2. Inpatient "INPATIENT HOSPITAL", "INPATIENT 
PSYCHIATRIC F", and "COMPREHENSIVE 
INPATIENT" 
3. Outpatient "AMBULATORY SURGICAL CEN", "COMMUNITY 
MENTAL HEALTH", "COMPREHENSIVE 
OUTPATIEN", "OFFICE", "ON CAMPUS 
OUTPATIENT HO", "OUTPATIENT HOSPITAL", and 
"RURAL HEALTH CLINIC" 
4. Others “AMBULANCE-AIR OR WATER", "AMBULANCE-
LAND", "END STAGE RENAL DISEASE", 
"FEDERALLY QUALIFIED HEA", "GROUP HOME", 
"HOSPICE", "INDEPENDENT LABORATORY", 
"MOBILE UNIT", "NURSING FACILITY","OTHER 
UNLISTED FACILITY", "PATIENT'S 
HOME","PSYCHIATRIC FACILITY PA", "SKILLED 
NURSING FACILIT", "STATE OR LOCAL PUBLIC H", 
and "URGENT CARE FACILITY" and "WALK-IN 
RETAIL HEALTH C" 
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Statistical Analyses  
Baseline covariates were summarized descriptively. Means and standard deviations were 
reported for continuous variables and frequencies and percentages were reported for categorical 
variables. Balance was assessed using standardized differences as described above.  
Regression was used to model the resource utilization and costs to control for the variables for 
which propensity score matching process did not achieve adequate balance.  
We used a Generalized Linear Model (GLM) with Poisson distribution and a log link function to 
obtain adjusted incremental resource utilization estimates. For count variables, such as healthcare 
resource utilization, the Poisson distribution is commonly adopted to represent the distribution. 
The Poisson distribution is used to represent variables for which the variance is proportional to 
the mean. 
105
 If the number of patients with zero resource utilization was greater than 10%, a 
two-part model was used to obtain the incremental resource utilization. In the first step, a logistic 
regression model predicted the probability of having healthcare resource use for each patient. 
106
 
The second step used a GLM regression analysis to estimate the adjusted resource utilization for 
patients who suffered from an overdose and for patients who did not. The adjusted resource 
utilization was then multiplied by the patient’s probability of having healthcare resource 
utilization. This step adjusted the mean resource utilization estimate downward to account for 
patients who did not have any healthcare utilization for a specific place of service – for example, 
ER visits. 
We used a Generalized Linear Model (GLM) with gamma distribution and a log link function to 
obtain adjusted incremental cost estimates. For cost data, such as healthcare costs, the gamma 
distribution is commonly adopted to represent the distribution due to the skewed nature of costs. 
The gamma distribution is used to represent variables for which the variance is proportional to 
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the square of the mean. 
105
 If the number of patients with zero costs was greater than 10%, a two-
part model was used to obtain the incremental cost. In the first step, a logistic regression model 
predicted the probability of having positive cost for each patient. 
107
 The second step used a 
GLM regression analysis to estimate the adjusted cost for patients who suffered from an 
overdose and for patients who did not. The adjusted cost was then multiplied by the patient’s 
probability of having a positive cost. This step adjusts the mean cost estimate downward to 
account for patients who had zero costs. 
Adjusted healthcare resource utilization and costs during the follow-up period were summarized 
descriptively. Means and 95% confidence intervals (CIs) were reported for resource utilization 
estimates and cost estimates.  
We also reported the effect sizes for the incremental cost estimates. The effect size was estimated 
using the following formula
108
 –  
Effect size = Mean cost of cases – Mean cost of controls 
                         Standard deviation of the controls 
An effect size is a quantitative measure of the difference between two groups and takes into 
account the sample size of the study.  
The standard deviation (SD) of the controls was estimated from the standard error (SE) (refer to 
the outputs in Appendix) using the formula –  
SD = SE * √n 
A p-value of <0.05 was considered statistically significant.  
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All costs were adjusted to 2015 U.S. dollars using the medical and prescription component of the 
CPI. 
109
 
All analyses were conducted using SAS version 9.4 and Stata IC 14. 
110,111
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Sensitivity Analyses  
We used sensitivity analyses to determine the extent to which some of our assumptions 
influenced our estimates. We conducted three sets of sensitivity analyses –  
1. Excluded patients who had costs in the follow-up period greater than $1 million  
2. Excluding patients with End Stage Renal Disease (ESRD) – Patients with ESRD need 
continued treatment and have higher resource utilization.  
3. Adopted a 6-month baseline and six-month follow-up period – In order to gauge if a longer 
baseline period might better control for comorbidities, we conducted a sensitivity analysis with a 
6-month baseline period. To account for a reduction in sample size due to a longer baseline 
period, we decreased the follow-up period to six months instead of one year.  
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Methods 
Specific Aim 2B: Incremental Cost and Resource Utilization in Family Members of Prescription 
Opioid User and Others who suffered from an overdose 
 
This section describes the study methodology used to estimate the cost and resource utilization 
associated with prescription opioid overdose in family members of prescription opioid users and 
individuals who did not have an opioid prescription themselves and neither did any family 
member (“others”) between July 2010 and June 2015. 
We combined the family members of prescription opioid user group and the others group into 
one category for this aim. Since none of the individuals in either group received their own opioid 
prescription, these individuals were most likely diverters and/or abusers of the drug. Therefore, 
these two groups were assumed to have similar type of drug taking behaviors and were collapsed 
into one category. We will refer to this group as “non-medical users”. 
The methods in this section are very similar to the methods for Specific Aim 2A with some 
differences –  
1. Identification of the index date for the cases and controls  
2. The variables used in the propensity score matching procedure  
Only sections that highlight the differences in the methods of the analysis for the non-user group 
will be presented.  
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Study design 
The study design was a retrospective data analysis using claims data. For this aim, we used a 
matched control methodology (propensity score matching) to match cases with controls. We then 
used an incremental (or econometric approach) to estimate the difference in costs for the two 
groups. 
The index date was defined as the date of the overdose for cases and 3 months after the first 
medical encounter for controls.  
Once matched, the participants were followed for one year from the index date and costs and 
resource utilization were estimated for this duration. The study design is explained in Figure 11 
and Figure 12 for cases and controls respectively. 
 
 
 
 
Figure 11 – Study timeline for cases  
 
 
 
 
 
Figure 12 – Study timeline for controls 
Overdose date 
(Index date) 
End of follow-up period  
Baseline period – 3 months  Follow-up period – 1 year  
First medical encounter 
 
Assigned “Overdose” date 
(Index date) 
Baseline period – 3 months  Follow-up period – 1 year  
End of follow-up period  
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Sample Selection  
The inclusion and exclusion criteria for resource utilization and incremental cost estimation is 
the same as that of Specific Aim 2A.  
A flowchart explaining the exclusion of patients is shown in Figure 13. 
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Figure 13 – Sample selection for non-medical users  
Cases = 258 
Controls = 262,895 
Exclude cancer patients = 4 
Exclude cancer patients = 2,326 
Cases = 254 
Controls = 260,569 
Exclude patients without 90 day baseline period = 26 
Exclude patients without 90 day baseline period = 0 
 
Cases = 228 
Controls = 260,569 
 
Cases = 157 
Controls = 222,004 
 
Cases = 123 
Controls = 201,354 
 
Exclude patients with overdoses after July 1st, 2014 = 71 
Exclude patients with index date after July 1st, 2014 = 38,565 
 
 Exclude patients without 1 year follow-up period = 34 
Exclude patients without 1 year follow-up period = 20,650 
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Propensity score matching 
Variables used in Propensity Score Matching – 
The variables used in this propensity score match are demographics (age, sex), comorbidities at 
baseline, and healthcare resource utilization in the baseline period. 
The variables have been categorized or computed using the same method used for the 
prescription opioid users.  
One important difference between the propensity score matching between the prescription opioid 
users and non-users is that we could not account for the opioid-specific variables (MED and 
whether the opioid was an extended release formulation) since we do not have information about 
the opioid that caused the overdose in these patients.  
 
Logistic Regression Model –  
Logit (Overdose=1) = βo + β1 (sex) + β2 (age) + β3 (CCI Score) + β4 (alcohol abuse) + β5 (drug 
abuse) + β6 (psychosis) + β7 (depression) + β8 (healthcare cost in the baseline period)  
The methods used for propensity score matching diagnostics in Specific Aim 2A are applied here 
as well.  
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Sensitivity Analyses  
We conducted the same set of sensitivity analyses as listed for Specific Aim 2A –  
1. Excluded patients who had costs in the follow-up period greater than $1 million  
2. Excluded patients with End Stage Renal Disease (ESRD)  
3. Adopted a 6-month baseline and 6-month follow-up period  
 
Human Subjects Protection and Data Privacy 
SelectHealth data was de-identified and used encrypted member IDs. Access to the dataset was 
restricted to individuals listed on the protocol. The data were maintained in a password-protected 
environment on the VCU server. The study proposal was submitted to the Institutional Review 
Board (IRB) at Virginia Commonwealth University for an exemption 45 CFR 46.404. The 
approval number was HM20004383.   
  
  
 
98 
Results 
Specific Aim 2A: Incremental Cost and Resource Utilization for Prescription Opioid Users who 
suffered from an overdose 
 
The results of the propensity score matching are reported followed by the incremental resource 
utilization and cost estimates between prescription opioid users who suffered from an overdose 
event and prescription opioid users who did not.  
 
Propensity score matching diagnostics –  
The distribution of the computed propensity scores before and after matching are shown in  and 
15 respectively.   
The K-S statistic before matching was 7.88, p-value<0.0001 and after matching was 0.201, p-
value = 1.000. This indicates that the propensity scores have similar distributions for those who 
suffered from an overdose and those who did not after matching.  
The baseline characteristics before and after propensity score are presented in Table 26 and 
Table 27 respectively. The mean propensity scores before and after matching are also presented.  
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Figure 14 – Propensity score distribution before matching                        Figure 15 – Propensity Score distribution after matching 
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Table 26  - Baseline characteristics for recent prescription opioid users before matching 
Characteristics Overdose cohort 
(N = 199)                       
Control cohort 
(N = 121,820) 
 
ASD 
 
Age group (years), n (%) 
0-17 
18-44 
45-64 
65 and above 
 
4 (2.01) 
104 (52.26) 
79 (39.70) 
12 (6.03) 
 
13,984 (11.48) 
64,659 (53.08) 
37,246 (30.57) 
5,931 (4.87) 
 
0.385 
0.016 
0.192 
0.051 
 
Sex, n (%) 
Female 
Male 
 
123 (61.81) 
76 (38.19) 
 
67,525 (55.43) 
54,295 (44.57) 
 
0.13 
0.13 
 
CCI Score, mean (SD) 0.34 (0.81) 0.07 (0.34) 0.435 
Other comorbidities, n (%) 
Alcohol abuse 
Drug abuse 
Psychoses 
Depression 
 
3 (1.51) 
9 (4.52) 
8 (4.02) 
39 (19.60) 
 
121 (0.10) 
316 (0.26) 
130 (0.11) 
3,362 (2.76) 
 
0.158 
0.282 
0.278 
0.555 
MEDD, mean (SD) 110.1 (140.8) 54.5 (69.81) 0.5 
ER/XR/CR, n (%) 23 (11.62) 857 (0.70) 0.466 
Benzodiazepine use, n (%) 100 (50.25) 24,249 (19.91) 0.671 
Baseline healthcare costs, mean (SD) 16,576 (42,925) 2,931 (15,540) 0.423 
Propensity score, mean (SD)* 0.02 (0.06) 0.002 (0.007)  
ASD = Absolute Standardized Differences; CCI = Charlson Comorbidity Score; CR = Controlled Release; ER = Extended Release; 
MEDD = Morphine Equivalent Daily Dose XR = Extended Release; *This variable was not included in the model 
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Table 27 – Baseline characteristics for recent prescription opioid users after matching 
Characteristics Overdose cohort 
(N = 198)                        
Control cohort 
(N = 198) 
ASD 
 
Age group (years), n (%) 
0-17 
18-44 
45-64 
65 and above 
 
4 (2.02) 
104 (52.53) 
78 (39.39) 
12 (6.06) 
 
11 (5.56) 
78 (39.39) 
87 (43.94) 
22 (11.11) 
 
0.186 
0.266 
0.092 
0.181 
Sex, n (%) 
Female 
Male 
 
122 (61.62) 
76 (38.38) 
 
129 (65.15) 
69 (34.85) 
 
0.073 
0.073 
CCI Score, mean (SD) 0.33 (0.81) 0.39 (0.96) 0.068 
Other comorbidities, n (%) 
Alcohol abuse 
Drug abuse 
Psychoses 
Depression 
 
3 (1.52) 
9 (4.55) 
7 (3.54) 
39 (19.70) 
 
4 (2.02) 
13 (6.57) 
6 (3.03) 
38 (19.19) 
 
0.038 
0.089 
0.029 
0.013 
MEDD, mean (SD) 110.55 (141.09) 105.82 (152.03) 0.032 
ER/XR/CR, n (%) 22 (8.59) 17 (11.59) 0.099 
Benzodiazepine use, n (%) 99 (50.00) 99 (50.00) 0 
Baseline healthcare costs, mean (SD) 16,634 (43,027) 14,867 (74,261) 0.029 
Propensity score, mean (SD)* 0.02 (0.04) 0.02 (0.04)  
ASD = Absolute Standardized Differences; CCI = Charlson Comorbidity Score; CR = Controlled Release; ER = Extended Release; 
MEDD = Morphine Equivalent Daily Dose XR = Extended Release; *This variable was not included in the model 
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The baseline characteristics before matching were significantly different for all variables.  
After propensity score matching, the two groups matched on all variables except age (Table 27).  
To account for this imbalance between the two groups, a regression analysis was performed and age was 
included in the model to obtain adjusted incremental costs and resource utilization. 
 
 
Extreme values 
As part of the cost analysis, allowed costs with a value of ‘0’ were observed in the dataset. A claim 
could have been paid for by another payer, bundled with another claim or payment for that claim could 
have been denied. Therefore, we used all values as they were and did not impute costs for claims with a 
value of ‘0’. 
Additionally, there were patients with costs in the follow-up period greater than $1,000,000. When the 
healthcare costs of these patients were examined closely, we did not find any duplicate claims on the 
same day for the same diagnosis. The allowed costs were per claim and per diagnoses. However, we saw 
examples of recurring costs for a month in the outpatient setting, high charges for claims for seemingly 
benign conditions like nausea and claims that were identical except that some had a cost value and some 
had a zero value. We tried to get more information about these claims, but were unable to and used them 
as they were for our analysis. However, we excluded patients with costs in the follow-up period greater 
than $1,000,000 in a sensitivity analysis. 
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The proportion of patients who had a medical encounter is categorized by place of service and presented in Table 28. Unadjusted estimates 
for healthcare utilization by place of service for prescription opioid users is presented in Table 29.  
Table 28 – Healthcare resource utilization by prescription opioid users with and without at least one overdose event in the follow-up period in 
a matched population (Number of patients) 
Variable 
 
Cases Controls p-value 
Patients, n 198 198  
Resource utilization, n (%)    
All-cause inpatient visits 135 (68.18) 32 (16.16) <0.0001 
All-cause ER visits  183 (92.42) 62 (31.31) <0.0001 
All-cause outpatient visits 194 (97.98) 190 (95.96) 0.2410 
All-cause other visits 177 (89.40) 126 (63.64) <0.0001 
Overdose-specific inpatient visits * 79 (39.90) N/A N/A 
Overdose-specific ER visits* 138 (69.70) N/A N/A 
Overdose-specific outpatient visits* 26 (13.13) N/A N/A 
Overdose-specific other visits* 8 (4.04) N/A N/A 
*Are not mutually exclusive 
 
Table 29 – Unadjusted healthcare resource utilization for prescription opioid users with and without at least one overdose event in the follow-
up period in a matched population (Number of visits) 
Resource utilization, mean (SD) Cases Controls Difference  p-value 
Patients, n 198 198   
All-cause inpatient visits 1.60 (2.57) 0.27 (0.39) 1.33 (2.71) <0.0001 
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All-cause ER visits  3.52 (4.46) 0.85 (3.38) 2.67 (5.69) <0.0001 
All-cause outpatient visits 19.55 (17.90) 13.11 (14.36) 6.44 (21.95) <0.0001 
All-cause other visits 9.39 (19.28) 3.88 (9.31) 5.51 (20.55) 0.0002 
Overdose-specific inpatient visits 0.43 (0.57) N/A N/A N/A 
Overdose-specific ER visits 0.87 (0.71) N/A N/A N/A 
Overdose-specific outpatient visits 0.16 (0.44) N/A N/A N/A 
Overdose-specific other visits 0.07 (0.53)   N/A N/A N/A 
 
Unadjusted healthcare costs for prescription opioid users by place of service are presented in Table 30.  
Table 30 – Unadjusted healthcare costs for prescription opioid users with and without at least one overdose event in the follow-up period in a 
matched population  
Mean health care cost, US$ (95% CI)     Cases Controls Cost difference  
 
p-value 
All-cause health care costs 76,811 (50,637, 102,984) 16,545 (11,991, 21,098) 60,266 (33,646, 86,886 ) <0.0001 
All-cause inpatient 33,460 (18,392, 48,528) 4,188 (1,820, 6,557) 29,272 (14,118, 44,426 ) 0.0002 
All-cause ER  5,846 (4,774, 6,917) 1,695 (786, 2,604) 4,151 (2,706, 5,595) <0.0001 
All-cause outpatient  24,398 (7,051, 41,745) 6,233 (4,530, 7,937) 18,165 (628, 35,702 ) 0.0424 
All-cause others  9,635 (4,397, 14,872) 2,022 (794, 3,250) 7,613 (2,216, 13,010) 0.0059 
Pharmacy costs  3,473 (2,859, 4,086) 2,407 (1,854, 2,960) 1,066 (280, 1,858) 0.0086 
Overdose-specific inpatient  10,491 (1,450, 19,532) N/A N/A N/A 
Overdose-specific ER  1,498 (1,117, 1,879) N/A N/A N/A 
Overdose-specific outpatient  58 (-35, 151) N/A N/A N/A 
Overdose-specific others  64 (15, 112) N/A N/A N/A 
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Incremental resource utilization 
Adjusted healthcare resource utilization for recent prescription opioid users is given in Table 31. Healthcare resource utilization was different 
for every category of place of service between cases and controls groups during the follow-up period. This indicates that including the 
overdose event, the cases had greater healthcare resource utilization as compared to the controls. (All p-values <0.05). 
Table 31 – Adjusted healthcare resource utilization for recent prescription opioid users with and without at least one overdose event in the 
follow-up period in a matched population  
Resource utilization, Mean (95% CI) Cases Controls Adjusted difference in  
resource utilization (95% CI) 
 p-value 
Patients, n 198 198   
All-cause inpatient visits 1.62 (1.39, 1.86) 0.27 (0.16, 0.38) 1.36 (1.10, 1.62) <0.0001 
All-cause ER visits  3.43 (3.14, 3.72) 0.89 (0.66, 1.12) 2.54 (2.17, 2.91) <0.0001 
All-cause outpatient visits 19.67 (19.04, 20.29) 13.02 (12.52, 13.53) 6.64 (5.84, 7.45) <0.0001 
All-cause other visits 9.89 (9.28, 10.51) 3.67 (3.23, 4.10) 6.23 (5.48, 6.98) <0.0001 
Overdose-specific inpatient visits 0.43 (0.35, 0.51) N/A N/A N/A 
Overdose-specific ER visits 0.87 (0.77, 0.97) N/A N/A N/A 
Overdose-specific outpatient visits 0.16 (0.1. 0.22) N/A N/A N/A 
Overdose-specific other visits 0.07 (-0.003, 0.14) N/A N/A N/A 
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Incremental cost 
The incremental difference between all cause healthcare costs for recent prescription opioid users who suffered from an overdose and those 
who did not was estimated to be $65,277 (P-value <0.05) (Table 32). The cost difference for all places of service except for others were 
significantly different between the two groups. Overdose-specific healthcare costs were estimated to be $12,111. The Stata outputs for 
incremental cost and resource utilization estimation are presented in Appendix B. The effect size of the incremental all-cause healthcare costs 
was estimated to be 1.37. According to Cohen’s interpretation of effect size, an effect size greater than 0.8 represents a large effect size.  
 
Table 32 – Adjusted healthcare costs for recent prescription opioid users with and without at least one overdose event in the follow-up period 
in a matched population  
Mean health care cost, US$ (SD)     Cases Controls Cost difference (95% CI) 
 
p-value 
All-cause health care costs 81,007 (55,539, 106,475) 15,730 (11,031, 20,429) 65,277 (39,440, 91,114) <0.0001 
All-cause inpatient 34,336 (19,003, 49,669) 3,925 (347, 7503) 30,411 (14,583, 46,240) <0.0001 
All-cause ER  5,726 (4,515, 6,938) 1,731 (1,012, 2,450) 3,996 (2,587, 5,404) <0.0001 
All-cause outpatient  22,234 (11,955, 32,513) 6,905 (3,379, 10,431) 15,329 (4,402, 26,257) 0.006 
All-cause others  11,166 (3,491, 18,842) 1,736 (501, 2,971) 9,431 (1,992, 16,869) 0.013 
Pharmacy costs  3,494 (2,702, 4,286) 2,393 (1,853, 2,932) 1,101 (160, 2,042) 0.022 
Overdose-specific inpatient  10,491 (1,450, 19,532) N/A 10,491 (1,450, 19,532)  
Overdose-specific ER  1,498 (1,117, 1,879) N/A 1,498 (1,117, 1,879)  
Overdose-specific outpatient  58 (-35, 151) N/A 58 (-35, 151)  
Overdose-specific others  64 (15, 112) N/A 64 (15, 112)  
 
  
 
107 
 
Table 33 and Table 34 list the five diagnoses with the highest per patient cost for those who suffered from an overdose and those who did not. 
The overdose group has two diagnoses of drug dependence which are associated with drug abuse and one diagnosis for amphetamine abuse, 
unlike the patients who did not suffer from an overdose.  
 
Table 33 – Diagnoses with the highest cost in the follow-up year for prescription opioid users who suffered from an overdose 
Diagnosis description  ICD-9-CM code Cost per patient ($) 
1. Combinations of drug dependence excluding opioid type drug, unspecified 304.80 416,927 
2. Amphetamine or related acting sympathomimetic abuse, continuous 305.71 268,587 
3. Autoimmune disease, not elsewhere classified 279.49 228,975 
4. Diabetes with peripheral circulatory disorders, type II or unspecified type, not 
stated as uncontrolled 
250.70 
 
227,916 
 
5. Opioid type dependence, unspecified use 304.00 122,174 
 
Table 34 – Diagnoses with the highest cost in the follow-up year for prescription opioid users who did not suffer from an overdose.  
Diagnosis description ICD-9-CM code Cost per patient ($) 
1. Bulimia 307.51 95,123 
2. Other pneumothorax and air leak 512.8 86,474 
3. Mechanical complication of other vascular device, implant, and graft 996.1 73,625 
4. Coronary atherosclerosis of native coronary artery 414.01 62,685 
5. Dissecting aortic aneurysm of unspecified site 441.00 62,416 
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Table 35 and Table 36 list the most commonly occurring diagnoses for patients who suffered from an overdose (excluding overdoses) and 
patients who did not. In patients who suffered from an overdose, two codes are for pain and the other three codes represent overdoses due to 
other substances, depression and alteration of consciousness. The patients who did not have an overdose suffer from depression, but no other 
diagnoses indicate risk factors for an overdose. 
Table 35 - Most frequent diagnoses in the follow-up year for prescription opioid users who suffered from an overdose, excluding overdose 
diagnoses 
Diagnosis description  ICD-9-CM code Number of patients 
1. Major depressive affective disorder, recurrent episode, moderate 296.32 88 
2. Poisoning by unspecified drug or medicinal substances 977.9 80 
3. Alteration of consciousness, other 780.09 50 
4. Pain in limb 729.5 47 
5. Abdominal pain, unspecified site 789.00 46 
 
Table 36 – Most frequent diagnoses in the follow-up year for prescription opioid users who did not suffer from an overdose 
Diagnosis description  ICD-9-CM code Number of patients 
1. Need for other prophylactic vaccination and inoculation against single diseases V05.8 44 
2. Examination of eyes and vision V72.0 34 
3. Diabetes mellitus without mention of complication, type II or unspecified type, not 
stated as uncontrolled 
250.00 33 
4. Major depressive affective disorder, recurrent episode, mild 296.31 29 
5. Other malaise and fatigue 780.79 27 
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Cost Curve 
The costs on the day of the overdose (time point 0) and subsequently after the overdose in prescription opioid users are shown in Figure 16. 
 
Figure 16 – Costs since overdose event for prescription opioid users (unadjusted) 
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Sensitivity Analyses 
1. Exclude costs greater than $1 million  
In the prescription opioid user group, three patients (all cases) had costs greater than $1 million. We assessed for balance after excluding the 
three patients and balance was achieved for all variables except for age. GLM was used to obtain adjusted estimates. The results are presented 
in Table 37.  
Table 37 – Sensitivity Analysis – Adjusted healthcare costs for recent prescription opioid users with and without at least one overdose event 
in the follow-up period in a matched population after excluding patients with costs greater than $1 million during the follow-up period 
Mean health care cost, US$  
(95% CI)      
Cases 
(N= 195) 
Controls 
(N= 198) 
Cost difference (95% CI) 
 
p-value 
All-cause health care costs 63,412 (44,646, 82,178) 15,693 (11,322, 20,064) 47,720 (28,573, 66,866) <0.0001 
All-cause inpatient 30,152 (17,061, 43,242) 3,924 (438, 7,409) 26,288 (12,576, 39,881) <0.0001 
All-cause ER  5,758 (4,527, 6,989) 1,731 (1,011, 2,450) 4,027 (2,602, 5,453) <0.0001 
All-cause outpatient  12,817 (7,905, 17,730) 6,189 (3,852, 8,526) 6,628 (1,173, 12,084) 0.017 
All-cause others  9,486 (2,991, 15,981) 1,755 (504, 3,007) 7,731 (1,483, 13,979) 0.015 
Pharmacy costs  3,502 (2,735, 4,270) 2,400 (1,863, 2,937) 1,103 (178, 2,027) 0.019 
Overdose-specific inpatient  10,221 (1,190, 19,253) N/A N/A  N/A 
Overdose-specific ER  1,467 (1,087, 1,848) N/A N/A N/A 
Overdose-specific outpatient  58 (-35, 151) N/A N/A N/A 
Overdose-specific others  64 (15, 112) N/A N/A N/A 
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2. Exclude patients with End Stage Renal Disease (ESRD) 
In the prescription opioid user group, two patients (1 case, 1 control) had claims for ESRD in the follow-up period. We assessed for balance 
after excluding the two patients and balance was achieved for all variables except for age. GLM was used to obtain adjusted estimates. The 
results are presented in Table 38.  
Table 38 – Sensitivity Analysis – Adjusted healthcare costs for recent prescription opioid users with and without at least one overdose event 
in the follow-up period in a matched population after excluding patients with ESRD 
Mean health care cost, US$  
(95% CI)     
Cases 
(N=197) 
Controls 
(N=197) 
Cost difference (95% CI) 
 
p-value 
All-cause health care costs 74,415 (51,372, 97,457) 15,823 (11,125, 20,521) 58,592 (35,108, 82,076) <0.0001 
All-cause inpatient 29,970 (17,007, 42,930) 3,939 (439, 7,438) 26,030 (12,501, 39,560) <0.0001 
All-cause ER  5,731 (4,505, 6,957) 1,691 (979, 2,405) 4,040 (2,623, 5,457) <0.0001 
All-cause outpatient  22,162 (11,846, 32,477) 6,939 (3,360, 10,517) 15,223 (4,240, 26,206) 0.007 
All-cause others  9,280 (2934, 15,625) 1,721 (479, 2,963) 7,559 (1,451, 13,667) 0.015 
Pharmacy costs  3,495 (2,733, 4,257) 2,407 (1,869, 2,945) 1,088 (168, 2,008) 0.020 
Overdose-specific inpatient  10,273 (1,196, 19,350) N/A N/A N/A 
Overdose-specific ER  1,505 (1,123, 1,888) N/A N/A N/A 
Overdose-specific outpatient  58 (-35, 152) N/A N/A N/A 
Overdose-specific others  64 (15, 113) N/A N/A N/A 
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3. Adopted 6-month baseline and 6-month follow-up periods 
We obtained a sample of 259 cases and 109,988 controls after assessing for eligibility and obtained 257 matched pairs after propensity score 
matching. This cohort of prescription opioid users achieved balance for all variables. We used a paired t-test to obtain incremental cost 
estimates. The results of this analysis are presented in Table 39.  
Table 39 – Sensitivity Analysis – Adjusted healthcare costs for recent prescription opioid users with and without at least one overdose event 
in a 6-month follow-up period in a matched population 
Mean health care cost, US$  
(95% CI)     
Cases 
(N=257) 
Controls 
(N=257) 
Cost difference (95% CI) 
 
p-value 
All-cause health care costs 55,629 (36,901, 74,356) 14,181 (1,021, 27,341) 41,448 (18,355, 64,541) 0.0005 
All-cause inpatient 25,856 (14,735, 36,977) 2,110 (877, 3,343) 23,746 (12,523, 34,968) <0.0001 
All-cause ER  5,035 (3,692, 6,378) 529 (262, 797) 4,503 (3,129, 5,882) <0.0001 
All-cause outpatient  15,994 (2,870, 29,118) 3,020 (2,093, 3,946) 12,975 (-204, 26,153) 0.0536 
All-cause others  6,926 (3,577, 10,274) 7,211 (-5,825, 20,247) -286 (-13,779, 13,208) 0.9668 
Pharmacy costs  1,819 (1,490, 2,148) 1,311 (934, 1,687) 508 (6, 1,010) 0.0474 
Overdose-specific inpatient  9,596 (2,586, 16,606) N/A N/A N/A 
Overdose-specific ER  1,395 (1,069, 1,722) N/A N/A N/A 
Overdose-specific outpatient  82 (-1, 165) N/A N/A N/A 
Overdose-specific others  32 (0, 64) N/A N/A N/A 
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Results 
Specific Aim 2B: Incremental Cost and Resource Utilization in Family Members of Prescription 
Opioid User and Others 
 
The results of the propensity score matching are reported followed by the incremental resource 
utilization and cost estimates between non-users who suffered from an overdose event and those 
who did not.  
 
Propensity score matching diagnostics – 
The distribution of the computed propensity scores before and after matching are shown in 
Figure 17 and 18 respectively.   
The K-S statistic before matching was 4.08, p-value<0.0001 and after matching was 1.22,  p-
value = 0.1037.  This indicates that the propensity scores have similar distributions across the 
patients who suffered from and overdose and those who did not after matching.  
The baseline characteristics before and after matching for non-medical users are presented in 
Table 40 and Table 41 respectively.  The mean propensity scores before and after matching are 
also presented.
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Figure 17 – Propensity score distributions before matching                    Figure 18 – Propensity score distributions after matching 
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Table 40 – Baseline characteristics for non-medical users before matching 
Characteristics Overdose cohort 
 (N = 123)          
Control cohort 
 (N = 201,354)                                      
ASD                                              
Age group (years) 
0-17 
18-44 
45-64 
65 and above 
 
19 (15.45) 
60 (48.78) 
33 (26.83) 
11 (8.94) 
 
99,376 (49.35) 
63,699 (31.64) 
31,863 (15.82) 
6,416 (3.19) 
 
0.777 
0.355 
0.271 
0.243 
Sex, n (%) 
Female 
Male 
 
70 (56.91) 
53 (43.09) 
 
97,553 (48.45) 
103,801 (51.55) 
 
0.17 
0.17 
CCI Score, mean (SD) 0.23 (0.86) 0.07 (0.33) 0.246 
Other comorbidities, n (%) 
Alcohol abuse 
Drug abuse 
Psychoses 
Depression 
 
1 (0.81) 
10 (8.13) 
3 (2.44) 
18 (14.63) 
 
211 (0.10) 
588 (0.29) 
314 (0.16) 
4,985 (2.48) 
 
0.106 
0.398 
0.202 
0.445 
Baseline healthcare costs, mean (SD) 13,101 (62,071) 2,128 (19,014) 0.239 
Propensity score, mean (SD)* 0.006 (0.03) 0.0006 (0.002)  
ASD = Absolute Standardized Differences; CCI = Charlson Comorbidity Index; SD = Standard Deviation 
 *This variable was not included in the model 
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Table 41 – Baseline characteristics for non-medical users after matching 
Characteristics Overdose cohort 
 (N = 122)                   
Control cohort 
(N = 122)                                      
ASD                                              
 
Age group (years) 
0-17 
18-44 
45-64 
65 and above 
 
19 (15.57) 
59 (48.36) 
33 (27.05) 
11 (9.02) 
 
30 (24.59) 
54 (44.26) 
29 (23.77) 
9 (7.38) 
 
0.227 
0.082 
0.075 
0.06 
Sex, n (%) 
Female 
Male 
 
69 (56.56) 
53 (43.44) 
 
58 (47.54) 
64 (52.46) 
 
0.181 
0.181 
CCI Score, mean (SD) 0.23 (0.86) 0.35 (0.64) 0.158 
Other comorbidities, n (%) 
Alcohol abuse 
Drug abuse 
Psychoses 
Depression 
 
1 (0.82) 
9 (7.38) 
2 (1.64) 
17 (18.03) 
 
8 (6.56) 
8 (6.56) 
5 (4.10) 
22 (13.93) 
 
0.308 
0.032 
0.148 
0.112 
Baseline healthcare costs, mean (SD) 7,946 (24,280) 29,561 (74,021) 0.392 
Propensity score, mean (SD)* 0.003 (0.008) 0.003 (0.008)  
ASD = Absolute Standardized Difference; CCI = Charlson Comorbidity Index; SD = Standard Deviation 
*This variable was not included in the model 
 
The propensity score matching process was not able to balance the variables to the requirement in this study (ASD <0.1) (Table 41). 
To account for this imbalance between the two groups regression analysis was performed and age, sex, CCI score, alcohol abuse, 
psychoses, depression and log of baseline healthcare costs were included in the model to obtain adjusted incremental costs and 
resource utilization. We transformed the baseline healthcare cost variable to its logarithmic form so as to meet the assumptions of 
linear regression.   
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The proportion of patients who had a medical encounter is categorized by place of service and presented in Table 42. Unadjusted estimates 
for healthcare utilization by place of service for non-medical users are presented in Table 43.  
Table 42 – Unadjusted healthcare resource utilization for non-medical users with and without at least one overdose event in the follow-up 
period in a matched population (Number of patients) 
Variable Cases Control p-value 
Patients, n 122 122  
Resource utilization, n (%)    
All-cause inpatient visits 78 (63.93) 14 (11.48) <0.0001 
All-cause ER visits  107 (87.70) 24 (19.67) <0.0001 
All-cause outpatient visits 115 (94.26) 106 (86.89) 0.0486 
All-cause other visits 92 (75.41) 64 (52.46) 0.0002 
Overdose-specific inpatient * 55 (45.08) N/A N/A 
Overdose-specific ER visits* 82 (67.21) N/A N/A 
Overdose-specific outpatient visits* 10 (8.20) N/A N/A 
Overdose-specific other visits* 2 (1.64) N/A N/A 
*Are not mutually exclusive    
 
Table 43 – Unadjusted healthcare resource utilization for non-medical users with and without at least one overdose event in the follow-up 
period in a matched population (Number of visits) 
Resource utilization, Mean (SD) Cases Controls Difference p-value 
Patients, n 122 122   
All-cause inpatient visits 1.58 (3.34) 0.29 (1.42) 1.30 (3.62) <0.0001 
All-cause ER visits  2.97 (5.17) 0.60 (1.93) 2.37 (5.48) <0.0001 
All-cause outpatient visits 15.22 (17.71) 8.76 (11.92) 6.50 (20.70) 0.0008 
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All-cause other visits 6.19 (12.26) 6.01 (12.26) 0.18 (32.05) 0.9506 
Overdose-specific inpatient 0.47 (0.53) N/A N/A N/A 
Overdose-specific ER visits 0.85 (0.84) N/A N/A N/A 
Overdose-specific outpatient visits 0.23 (1.07) N/A N/A N/A 
Overdose-specific other visits 0.02 (0.13) N/A N/A N/A 
 
Unadjusted healthcare costs for non-users by place of service are presented in Table 44.  
Table 44 – Unadjusted healthcare costs for non-medical users with and without at least one overdose event in the follow-up period in a 
matched population 
Mean health care cost, US$ (95% CI)     
 
Cases 
(N=122) 
Controls 
(N=122) 
Cost difference  p-value 
All-cause health care costs  40,104 (25,296, 54,911) 17,387 (2,182, 32,591) 22,717 (1,920, 43,514) 0.0325 
All-cause inpatient 22,256 (11,400, 33,112) 3,728 (-892, 33,112) 18,528 (6,599, 30,458) 0.0026 
All-cause ER  4,049 (1,566, 6,532) 448 (225, 670) 3,601 (1,104, 6,099) 0.0051 
All-cause outpatient  5,885 (2,410, 9,360) 3,682 (1,877, 5,487) 2,203 (-1,390, 5,796) 0.2272 
All-cause others  7,059 (1,806, 12,312) 6,590 (-3,186, 16,365) 469 (-10,685, 11,623) 0.9338 
Pharmacy costs  855 (496, 1,213) 2,940 (496, 5,384) -2085 (-4,572, 402) 0.0996 
Overdose-specific inpatient  9,963 (45,577) N/A N/A N/A 
Overdose-specific ER  923 (1,824) N/A N/A N/A 
Overdose-specific outpatient  163 (1,725) N/A N/A N/A 
Overdose-specific others  24 (199) N/A N/A N/A 
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Incremental resource utilization  
Healthcare resource utilization was different for every category of place of service between the cases and the control groups during the 
follow-up period (Table 45). This indicates that including the overdose event, the cases had greater healthcare resource utilization as 
compared to the controls. (All p-values <0.05).  
Table 45 – Adjusted healthcare resource utilization for non-medical users with and without at least one overdose event in the follow-up period 
in a matched population  
Resource utilization, Mean (95% CI) Cases Controls Adjusted difference in  
resource utilization (95% CI) 
p-value 
Patients, n 122 122   
All-cause inpatient visits 1.57 (1.26, 1.88) 0.38 (0.14, 0.62) 1.19 (0.79, 1.59) <0.0001 
All-cause ER visits  3.20 (2.75, 3.64) 0.52 (0.29, 0.75) 2.68 (2.18, 3.18) <0.0001 
All-cause outpatient visits 15.11 (14.40, 15.82) 8.83 (8.29, 9.37) 6.28 (5.37, 7.20) <0.0001 
All-cause other visits 10.05 (8.40, 11.71) 4.10 (3.18, 5.03) 5.95 (4.23, 7.60) <0.0001 
Overdose-specific inpatient visits 0.47 (0.37, 0.56) N/A N/A N/A 
Overdose-specific ER visits 0.85 (0.70, 1.00) N/A N/A N/A 
Overdose-specific outpatient visits 0.23 (0.04, 0.42) N/A N/A N/A 
Overdose-specific other visits 0.02 (-0.006, 0.04) N/A N/A N/A 
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Incremental cost 
The incremental difference between all cause healthcare cost for non-medical users who suffered from an overdose and those who did not was 
estimated to be $41,102 (P-value <0.05) (Table 46). The cost difference for all-cause ER and all-cause outpatient services were found to be 
significantly different between the two groups. Overdose-specific healthcare costs were estimated to be $11,070. The Stata outputs for 
incremental cost and resource utilization estimation are presented in Appendix B. The effect size of the incremental all-cause healthcare costs 
was estimated to be 0.81. According to Cohen’s interpretation of effect size, an effect size greater than 0.8 represents a large effect size. 
 
Table 46 – Adjusted healthcare costs for non-medical users with and without at least one overdose event in the follow-up period in a matched 
population 
Mean health care cost, US$  
(95% CI) 
Cases 
(N=122) 
Controls 
(N=122) 
Cost difference (95% CI) p-value 
All-cause health care costs  53,626 (26,878, 80,374) 12,524 (6,142, 18,905) 41,102 (15,052, 67,153) 0.002 
All-cause inpatient 23,773 (10,013, 37,533) 6,135 (-4,860, 17,129) 17,638 (1,511, 37,353) 0.032 
All-cause ER  3,741 (2,518, 4,964) 463 (119, 806) 3,279 (2,518, 4,964) <0.0001 
All-cause outpatient  6,191 (3,467, 8,915) 3,192 (1,784, 4,601) 2,999 (77, 5921) 0.044 
All-cause others  14,363 (2,551, 26,174) 2,204 (709, 3,698) 12,159 (718, 23,598) 0.037 
Pharmacy costs  1,687 (641, 2732) 1,886 (1028, 2744) -199 (-1,290, 892) 0.721 
Overdose-specific inpatient  9,963 (1,793, 18,132) N/A N/A N/A 
Overdose-specific ER  923 (596, 1,250) N/A N/A N/A 
Overdose-specific outpatient  163 (-146, 472) N/A N/A N/A 
Overdose-specific others  24 (-11, 60) N/A N/A N/A 
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Table 47 and Table 48 list the five diagnoses with the highest per patient cost for patients who suffered from an overdose and patients who 
did not respectively. When compared to prescription opioid users who suffered from an overdose, the non-medical user overdose group does 
not have any diagnoses that indicate signs of abuse.  
Table 47 – Diagnoses with the highest costs in the follow-up year for non-user who suffered from an overdose 
Diagnosis Description ICD-9 CM Code Cost per patient ($) 
1. Chronic osteomyelitis involving ankle 730.17 170,945 
2. Other diseases of esophagus  530.89 141,815 
3. End stage renal disease 304.00 93,685 
4. Methicillin resistant staphylococcus aureus 041.12 87,732 
5. Other mechanical complication of other internal orthopedic device, 
implant and graft 
996.49 61,625 
 
Table 48 – Diagnoses with the highest costs in the follow-up year for non-medical users who did not suffer from an overdose 
Diagnosis Description ICD-9 CM Code Cost per patient ($) 
1. Edward’s Syndrome 758.2 595,290 
2. Acute and chronic respiratory failure 518.84 75,421 
3. Eating disorder, unspecified 307.50 69,822 
4. Bacteremia 790.7 51,315 
5. Fitting and adjustment of automatic implantable cardiac defibrillator V53.32 50,449 
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Table 49 and Table 50 list the most commonly occurring diagnoses for patients who suffered from an overdose and those who did not 
respectively. In patients who suffered from an overdose, two out of five are codes for depression and one is for pain.  
Table 49 – Most frequent diagnoses in the follow-up year for non-medical users who suffered from an overdose, excluding overdose 
diagnoses 
Diagnosis Description  ICD-9 CM Code Number of patients 
1. Poisoning by unspecified drug or medicinal substances  977.9 45 
2. Major depressive affective disorder, recurrent episode, 
unspecified 
 296.30 30 
3. Depressive disorder, not elsewhere classified  311 29 
4. Alteration of consciousness, other  780.09 24 
5. Abdominal pain, unspecified site  789.00 20 
 
Table 50 – Most frequent diagnoses in the follow-up year for non- medical users who did not suffer from an overdose 
Diagnosis Description  ICD-9 CM Code Number of patients 
1. Need for prophylactic vaccination and inoculation 
against other specified disease 
 V05.8 47 
2. Routine infant or child health check  V20.2 24 
3. Acute upper respiratory infections of  unspecified site  465.9 16 
4. Diabetes mellitus without mention of complication, type 
II or unspecified type, not stated as uncontrolled 
 250.00 14 
5. Major depressive affective disorder, recurrent episode, 
severe, specified as with psychotic behavior 
 296.34 11 
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Sensitivity Analyses 
1. Exclude patients with costs in the follow-up year greater than 1 million  
None of the patients in the non- medical user group had costs in the follow-up period greater than $1 million and therefore, we did not carry 
out this sensitivity analysis for this cohort.  
2. Exclude patients with ESRD 
In the non-medical user group, six patients (all cases) had claims for ESRD in the follow-up period. We assessed for balance after excluding 
the six patients – balance was not achieved for age, sex, CCI score, baseline cost and psychosis. GLM was used to obtain adjusted estimates. 
The results are presented in Table 51.  
Table 51 – Sensitivity Analysis – Adjusted healthcare costs for non-medical users with and without at least one overdose event in the follow-
up period in a matched population after excluding patients with ESRD 
Mean health care cost, US$ 
(95% CI)     
Cases 
(N=116 ) 
Controls 
(N=122 ) 
Cost difference (95% CI) 
 
p-value 
All-cause health care costs 54,077 (23,069, 85,085) 10,866 (5,841, 15,891) 43,211 (12,780, 73,642) 0.005 
All-cause inpatient 20,412 (7,459, 33,365) 4,681 (13,783) 15,732 (-1,398, 32,861) 0.072 
All-cause ER  3,811 (2,523, 5,099) 408 (91, 724) 3,403 (2,085, 4,722) <0.0001 
All-cause outpatient  6,693 (3,494, 9,893) 2,940 (1,658, 4,221) 3,754 (391, 7,117) 0.029 
All-cause others  13,102 (959, 25,246) 1,939 (606, 3,273) 11,163 (-404, 22,729) 0.059 
Pharmacy costs  2,061 (394, 3,728) 1,684 (830, 2,537) 377 (-1,106, 1,861) 0.50 
Overdose-specific inpatient 9,013 (596, 17,431) N/A N/A N/A 
Overdose-specific ER 965 (623, 1308) N/A N/A N/A 
Overdose-specific outpatient  172 (-154, 497) N/A N/A N/A 
Overdose-specific others  26 (-12, 63) N/A N/A N/A 
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3. Adopted 6-month baseline and 6-month follow-up 
We obtained a sample of 150 cases and 219,760 controls after assessing for eligibility and obtained 149 matched pairs after propensity score 
matching. We assessed for balance after excluding the six patients – balance was not achieved for CCI score, baseline cost and depression. 
GLM was used to obtain adjusted estimates. The results of this analysis are presented in Table 52.  
Table 52 – Sensitivity Analysis – Adjusted healthcare costs for non-medical users with and without at least one overdose event in a 6 month 
follow-up period in a matched population 
Mean health care cost, US$  
(95% CI)  
Cases 
(N=149) 
Controls 
(N=149) 
Cost difference (95% CI) 
 
p-value 
All-cause health care costs 33,429 (19,931, 46,568) 8,756 (5,440, 12,073) 24,493 (10,777, 38,210) <0.0001 
All-cause inpatient 14,702 (7,627, 21,777) 3,212 (-580, 7,003) 11,490 (3,444, 19,536) 0.005 
All-cause ER  2,834 (1,971, 3,697) 175 (17, 334) 2,659 (1,780, 3,538) <0.0001 
All-cause outpatient  7,240 (2,105, 12,375) 3,512 (814, 6,209) 3,728 (-2,006, 9,462) 0.203 
All-cause others  4,309 (400, 8,219) 589 (516, 2,827) 2,638 (-1,600, 6,875) 0.222 
Pharmacy costs  514 (265, 764) 579 (342, 817) -65 (-388, 258) 0.693 
Overdose-specific inpatient 8,023 (1,414, 14,631) N/A N/A N/A 
Overdose-specific ER  1,031 (675, 1,387) N/A N/A N/A 
Overdose-specific outpatient  130 (-123, 383) N/A N/A N/A 
Overdose-specific others  23 (-9, 55) N/A N/A N/A 
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Cost Curve 
The costs on the day of the overdose (time point 0) and subsequently after the overdose in prescription opioid users are shown in Figure 19. 
 
 
 
Figure 19 - Costs since overdose event for non-medical users (unadjusted) 
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CHAPTER V: 
 
Discussion 
 
Aim 1  
The sample for our analysis was commercially enrolled beneficiaries in SelectHealth plans who 
were prescribed an opioid, their families and patients who suffered from a prescription opioid 
overdose. The majority of the sample was less than 65 years (94.11%) and female (53%). 
The prevalence of prescription opioid overdoses in the study population was estimated to be 
16.83 in 2011 and 36.9 per 100,000 in 2014, showing an increase of 119.2% over three years. 
We captured overdoses that were presented as Emergency Room (ER) visits, inpatient visits, 
outpatient visits or in other settings. To the best of our knowledge, there have not been any 
studies that have published opioid overdose prevalence rates for the same time period, but 
national rate of opioid overdoses tripled from 2000-2014. 
2
 
Two studies have published national prevalence rates of opioid poisoning close to the time frame 
of our study. Inocencio et al. reported prevalence for ED visits only and Fulton-Kehoe et al. 
reported prevalence for inpatient visits only.  
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Inocencio et al. estimated the prevalence of ER visits for prescription opioid overdoses for 2009 
using DAWN data and reported a prevalence of 130.5 per 100,000.
4
 DAWN was a public health 
surveillance system that monitored drug-related ER visits across the United States. These 
estimates were obtained using surveillance data as compared to administrative data, which could 
explain why this estimate is not comparable to ours.  
Fulton-Kehoe et al. estimated the prevalence of inpatient visits for prescription opioid overdoses 
from 2004-2010 using National Inpatient Sample (NIS) and reported a prevalence of 12.6 per 
100,000 in 2010 and a change in prevalence of 366.70% from 2004-2010. 
69
 The prevalence of 
prescription opioid overdoses in our sample was 16.83 per 100,000 in 2011. This is higher than 
the national sample, but can be attributed to our study capturing overdoses in all settings as 
compared to inpatient visits only.  
We also reported the prevalence of opioid overdoses by group for prescription opioid users, 
family members of prescription opioid users and others (patients who did not have an identifiable 
source of opioid). The prevalence of opioid overdoses in prescription opioid users increased from 
55.6 per 100,000 in 2011 to 102.77 per 100,000 in 2014 (84.83% increase). The prevalence of 
opioid overdoses in family members of prescription opioid users was 5.97 per 100,000 in 2011 
and 8.23 per 100,000 in 2014, showing a 37.86% increase. The prevalence of overdoses in the 
other group increased by 180% from 2011 (8.24 per 100,000) to 2014 (23.07 per 100,000).  
The Drug Abuse and Warning Network (DAWN) reported estimates of the change in the 
prevalence of ER visits attributable to the non-medical use of prescription opioids from 2004-
2011 to be 183%. Non-medical use is defined by DAWN as taking a higher than prescribed or 
recommended dose of one’s own medication, taking a pharmaceutical prescribed for another 
person, malicious poisoning of the patient by another individual, and documented substance 
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abuse involving pharmaceuticals. These estimates include opioid overdoses but may also include 
ER visits due to adverse reactions and hence, might not be comparable to our results. 
112
 While 
we estimated the change in prevalence of all opioid overdoses to be 119%, the non-medical use 
definition used by DAWN might be more appropriate for family members and others since these 
patients may be more likely to exhibit non-medical use behavior as compared to prescription 
users. We found an increase of 38% in overdoses for family members of prescription opioid 
users and 180% increase in the others group from 2011-2014. However, our study estimates are 
more recent, captured the prevalence specifically for overdose and were estimated for all settings 
as compared to only the ER.  
The Centers for Disease Control and Prevention (CDC) published national estimates of age–
adjusted death rates involving opioids (including heroin). They found that the mortality rate for 
opioids increased by 14% from 2013 (7.9 per 100,000) to 2014 (9 per 100,000). 
2
 While we did 
not have mortality data and could not compute death rates, we found that the prevalence of 
opioid overdoses increased by 16.67% from 2013 (31.63 per 100,000) to 2014 (36.9 per 
100,000) in our study population.  
 
Our study results showed hydrocodone and oxycodone were the most frequently prescribed 
opioids before an overdose. This finding is in line with national trends which state that 
hydrocodone and oxycodone are involved in most overdose deaths as compared to any other 
opioid. 
2
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The average Morphine Equivalent Daily Dose (MEDD) in all prescription opioid users was 
81.21 mg/day, while the MEDD in prescription opioid users who suffered from an overdose was 
127.21 mg/day. Literature suggests 100 MEDD is the tipping point for increased risk of 
unintentional opioid overdose. The risk of an overdose increases by 9-fold for patients on doses 
≥100 MEDD.14,31,113 
The number of patients prescribed opioids chronically in our sample has steadily increased from 
2011-2014 (Table 20).  The prevalence of prescription opioid overdoses in acute users was 43.84 
per 100,000 in 2011 and 50.28 per 100,000 in 2014 and that in chronic users was 187.03 per 
100,000 in 2011 and 497.3 per 100,000 in 2014.   
The prevalence of opioid overdoses in acute and chronic opioid users showed very different 
trends over the years (Figure 7). The prevalence in acute users showed a slight decrease in 2012 
and 2013 as compared to 2011 and increased by 30% from 2013-2014. The prevalence of opioid 
overdoses in chronic users showed a sharp increase from 2011-2013 (166% increase) and was 
then steady from 2013 to 2014.  
The increase in overdoses in chronic opioid users might have been due to increased opioid 
prescribing for chronic conditions. The steady rate of overdoses between 2013 and 2014 reflects 
changes that could have been brought about by the increasing awareness of the opioid epidemic. 
Data from 2015 is needed to be able to assess if this change is brought about by interventions 
aimed to reduce opioid overdoses or if it is coincidental. Since the prevalence of overdoses is 
much higher in chronic users as compared to acute users, interventions to reduce overdoses in 
patients who use opioids chronically are essential.  
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In March 2016, the CDC published guidelines for prescribing opioids for chronic pain.  These 
guidelines explicitly state that opioids are not first line therapy for chronic pain. Clinicians are 
advised to use non-pharmacologic therapy and non-opioid pharmacologic therapy for chronic 
pain. If opioids are considered necessary, prescribers are advised evaluate risks for opioid related 
harms, use Prescription Drug Monitoring Programs (PDMPs), prescribe the lowest dose, 
prescribe immediate release opioids, and not prescribe more than 3 days’ supply for acute pain.94  
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Aim 2 
Incremental resource utilization – Prescription opioid-users 
Resource utilization was significantly higher for all places of service in the follow-up year for 
users who suffered from an overdose as compared to those who did not (p<0.05) (Table 31). We 
expected users who have suffered from an overdose to have higher ER and inpatient use as a 
result of the overdose event but users who suffered from an overdose have higher resource 
utilization for outpatient visits and other services as well. Users who had an overdose had 1 more 
all-cause inpatient visit, 2 more all-cause ER visits, 6 more all-cause outpatient visits and 6 more 
all-cause other visits as compared to patients who did not have an overdose event.  
When comparing all-cause inpatient and ER visits to overdose-specific inpatient and ER-visits 
for users who suffered from an overdose, we found that all-cause inpatient and ER visits were 
277% and 294% higher than the overdose-specific inpatient and ER visits. This means that these 
patients had other inpatient and ER visits during the course of the follow-up year that are not 
related to the initial treatment of the overdose. The additional visits could be due to the users 
being more prone to using medical services, to having more than one overdose, or due to long-
term effects of the overdose. However, since we have compared resource utilization between 
matched samples and there are patients who have more than one poisoning in the year, it is more 
likely that the increase in resource utilization is attributable to the long-term effects of opioid 
overdose. Long-term effects of opioid overdoses are discussed later in the discussion.  
It is interesting to note that 13% of patients had a claim for an overdose in the outpatient setting 
and 4% had an overdose claim in other settings. The overdose claims classified as other visits 
were in the patient’s home and ambulance. Other studies which have captured prevalence and 
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costs due to overdose have captured ER visits and/or hospitalizations.
4,64,65,68–71
 In this study, we 
have also been able to capture prevalence and costs of opioid overdoses outside these settings.  
 
Incremental resource utilization – Non-medical users 
Resource utilization was significantly different for all places of service in the follow-up year for 
non-medical users who suffered from an overdose as compared to non-medical users who did not 
(Table 45). These findings are similar to the incremental resource utilization results for the user 
group. Non- medical users who suffered from an overdose had 1 more inpatient visit, 2 more ER 
visits, 6 more outpatient visits and 6 more other visits as compared to non-users who did not 
suffer from an overdose (all p-values <0.05). 
Similar to the prescription opioid user group, we found that average all-cause resource utilization 
was 234% and 277% higher for ER and inpatient visits respectively as compared to overdose-
specific visits in this cohort of patients as well. Approximately 8% and 2% had overdose-specific 
outpatient and other visits respectively. 
 
Incremental costs – Prescription opioid users 
The incremental all-cause health care costs for users who suffered from an overdose were 
$65,277 (p-value<0.05) as compared to users who did not suffer from an overdose (Table 32). 
All-cause inpatient costs account for nearly half of the incremental all-cause costs ($30,411). 
Outpatient costs account for approximately one-fourth of the incremental all-cause costs 
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($15,329). Incremental all-cause ER costs were estimated to be $3,996. All-cause other and 
pharmacy incremental costs were $9,431 and $1,101 respectively (All p-values<0.05). 
 
Incremental costs – Non-medical users 
The incremental all-cause healthcare costs between non-medical users who suffered from an 
overdose and those who did not was estimated to be $41,102 (p<0.05) (Table 46). The 
incremental all-cause hospitalization and all-cause ER costs were estimated to be $17,638 and 
$3,279 respectively. The incremental all-cause other costs accounted for nearly 30% of the total 
all-cause incremental costs ($12,159). The incremental pharmacy costs were higher in non-users 
who did not suffer from an overdose by $199 and incremental all-cause outpatient costs were 
$2,999 (all p-values <0.05). 
 
Overdose-specific costs 
Two studies have estimated the ER and inpatient costs associated with an overdose. Hasegawa et 
al. reported the median ER and inpatient charges per patient for opioid overdoses over a year to 
be $4,521 and $22,460 respectively. 
64
 Yokell et al. estimated the mean ED and inpatient charges 
for all prescription opioid overdoses to be $3,640 and $29,497 respectively. 
65
 Inocencio et al. 
estimated the average cost per overdose to be $4,255 per poisoning event. 
4
 
We estimated the average overdose-specific costs per patient per year to be $12,111 for 
prescription opioid users and $11,070 for non-users. The average overdose-specific ER and 
inpatient costs for prescription opioid users were $1,498 (95%CI, 1,117-1,879) and $10,491 
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(95%CI, 1,450-19,532) respectively. The average overdose specific ER and inpatient costs for 
non-users were $923 (95%CI, 596- 1,250) and $9,963 (95%CI, 1,793-18,132).  
Hasegawa et al. and Yokell et al. report higher estimates because they report charges and not 
costs. Charges between different hospitals can vary widely and are not a true reflection of the 
cost to the payer.
114
 Based on estimates obtained from the Medical Expenditure Panel Survey 
(MEPS) data for ER and inpatient visits, charges were estimated to be nearly three times the 
costs.
115
  Inocencio et al. applied a cost to charge ratio to the ER charge estimates in their study, 
but these ratios were from 2003 and this might have influenced the results. Also, ambulance 
costs were obtained from a 2006 GAO report and drug and device costs were obtained from the 
Red Book and an online emergency medical service company.
84–86
 Therefore, inconsistency of 
data sources and the unavailability of recent data may have biased the results.  
The incremental ER and inpatient costs were estimated to be $3,996 and $30,411 respectively for 
prescription opioid users and $3,279 and $17,638 respectively for non- medical users.  
We examined the most frequent diagnoses in the follow-up year (excluding opioid overdoses) for 
the prescription opioid user cohort and for the non-medical user cohort to identify any lasting 
effects of the overdose. While we could not identify any specific effects looking at the five most 
frequent diagnoses, there are some common diagnosis themes that are seen in patients who 
suffered from an overdose in both groups. Patients in both groups suffered from depression 
which is a risk-factor for overdose and therefore, these patients are also likely to suffer from 
another overdose event. Poisoning by unspecified drugs was also seen in both groups and might 
represent another overdose event or it could also have been the opioid overdose event. There 
were instances when more than one overdose code was used for the same event. Alteration of 
consciousness could have been an additional code with the overdose since patients slip into 
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unconsciousness after an overdose. Both groups had either one or more diagnoses for pain, 
which might have been the reason for taking the opioid medication. The diagnoses for pain were 
much more frequent in prescription opioid users, which is understandable because they were 
prescribed an opioid.  
This analysis has shown that patients who suffered from an overdose, whether prescription 
opioid users on non-medical users, have a higher prevalence of certain risk factors (such as 
depression, non-opioid poisoning and pain) compared to individuals who did not. This suggests 
that these factors may have contributed to the higher per-patient costs of patients who suffered 
from an overdose as compared to the patients who did not. 
While the relationship between opioid overdose and respiratory depression has been confirmed, 
the long-term effects on brain function are still being studied. Depressed respiration can affect 
the amount of oxygen that reaches the brain, a condition called hypoxia. Hypoxia can have short- 
and long-term psychological and neurological effects, including coma and permanent brain 
damage. 
116
 To our knowledge, only one study has looked at the long-term impact of overdose 
and it reported that overdoses can lead to cerebral hypoxia, pulmonary edema, pneumonia and 
cardiac arrhythmia. Overdoses may also lead to muscular impairment and neurological damage 
and the number of overdoses experienced is a significant predictor of poorer cognitive 
performance.
60
 Costs due to these conditions may have been captured in the all-cause 
incremental costs for these patients and may have been the reason that all-cause costs and 
resource utilization were much higher than overdose-specific costs and resource utilization.  
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Strengths and Limitations 
 
The analyses presented here highlight the substantial payer burden associated with patients who 
suffer from an opioid overdose. We are not aware of any other studies that have systematically 
quantified and compared the direct incremental costs of patients who suffered from an opioid 
overdose.  
The availability of prescription and medical claims allowed us to identify a control group i.e., 
patients with an opioid prescription who did not suffer from a poisoning event. This allowed us 
to compare healthcare expenditures between the two groups after adjusting for comorbidities and 
other risk factors. 
While other studies have estimated costs associated with opioid overdoses, they have not been 
able to account for prescription and patient characteristics in their studies due to data limitations.  
Since we had family-level data we were able to estimate the prevalence and costs of opioid 
overdoses in family members of patients with an opioid prescription and patients who did not 
have a known and identifiable source for a prescription opioid. These estimates add to the 
literature on opioid diversion. 
 
Our study has several limitations. Since the data is limited to Utah and Idaho, we did not have a 
nationally representative sample and hence, our estimates of prevalence and cost cannot be 
extrapolated to obtain national estimates. Utah ranked 4th and Idaho ranked 34th for all drug 
poisoning deaths in the United States from 2011-2014. 
117
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Additionally, there are certain geographic differences between the states of Utah and the rest of 
the United States. For example, Utah has the nation’s largest average household size at 3.14 as 
compared to an average household size of 2.63 in the United States.
118
 Larger family sizes means 
that there are more members per household and hence, more people may have access to their 
family member’s prescription opioids in Utah as compared to other states and this might be 
reflected in our estimates. The average household size in Idaho is 2.68, which is very similar to 
the national average.  
We made the assumption that the source of the opioid in prescription opioid users and family 
members of prescription opioid users was the first opioid prescribed opioid to the prescription 
opioid user. We realize that this might not necessarily be accurate and that individuals from both 
these groups could have obtained opioids from other sources, but we do not have the means to 
verify this using claims data.  
While we restricted the sample of recent prescription opioid users to patients for whom the time 
from when they were prescribed an opioid to the overdose was within one year, we did not apply 
the same time restriction to family members of prescription opioid users who suffered from an 
overdose. We made the assumption that the family members could use prescriptions that might 
have been around for longer than a year. In a sensitivity analysis, we tested this assumption by 
only including those family members for whom the time between the most recently prescribed 
opioid to a family member and overdose was one year. We found that 12 family members who 
suffered from an overdose did not meet the one year restriction and were moved to the others 
group. 
We could not limit our study population to beneficiaries who were enrolled continuously over 
five years due to losing a large portion of our population – the sample of 667,718 enrollees 
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reduced to 74,226 enrollees. Not being able to restrict the sample to continuously enrolled 
patients affected various aspects of our study, as discussed below. 
We identified patients as acute and chronic users for each year. We identified patients as chronic 
opioid users if the total days’ supply for all the opioids that a patient was prescribed was greater 
than 120 days in that year. If a patient was prescribed an opioid in the last two months of the 
previous year and the first month of the current year, they were misclassified as an acute user in 
both years even though they were a chronic user across years. We could not use data across years 
to identify acute and chronic users because we did not have enrollment for patients across all 
years.  
Another limitation of the study that stems from not having a large enough sample with 
continuous enrollment is that we had a baseline period of only 3 months.  Not all comorbidities 
may have been documented during this period and this may have affected the performance of the 
propensity score match. We were able to capture comorbidities only if a patient had a medical 
encounter in the 3 months before the overdose. Some of the risk factors that we could have 
potentially captured better if we had a longer baseline period were mental illness (we accounted 
for depression and psychosis in this study), patients with a history of alcohol and substance 
abuse, and patients with a hospitalization 6 months before the overdose event and chronic opioid 
use.
36,37
 If past medical history was available, some of the limitations of a short baseline period 
would have been accounted for.  We carried out a sensitivity analysis and increased baseline 
period to 6 months to see how this affected our cost estimates. We found that the variables were 
better balanced in both the groups. The incremental cost over a six-month follow-up period was 
estimated to be $41,448 in prescription opioid users and $24,493 in non-medical users compared 
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to our original estimates for a twelve-month period of $65,277 in prescription opioid users and 
$41,102 in non-medical users. 
Another limitation that follows from not being able to incorporate continuous enrollment over 
the five-year period is that the prevalence estimates might be underestimates of the true 
prevalence. The patients who have had an overdose may have had an overdose in the past or may 
have one in the future. However, if they were not enrolled in continuously through the study 
period we have not been able to capture it. Since we are not following the same population over 
five years, this might lead to underestimates or overestimates if we are not able to capture the 
true population denominator. 
Other risk factors that we could not account for were demographic factors such as race, income 
and insurance type. While race might not be an important factor in this study since we used data 
from two fairly homogenous states, patients with low income and Medicaid patients are at a 
higher risk of suffering from an opioid overdose. 
34
 Being able to control for income and 
insurance type could have strengthened the propensity score model.  
Even though we have matched cohorts of patients, propensity score methodology only controls 
for unobserved covariates if they are correlated with the observed covariates. One of the reasons 
that the difference in cost estimates between the cases and controls might not truly reflect 
downstream costs of opioid overdoses is that unobserved covariates are not accounted for. 
119
  
In case of misclassification or incorrect coding of opioid overdoses in claims data, cases and 
controls may not have been identified correctly (misclassification bias). While these databases 
are extremely rich sources of healthcare utilization data, they are generated to justify 
reimbursement and not for research purposes. Hence, these are coded to serve the purposes of 
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reimbursement and may not always capture health care costs accurately.
120
 For example, 
Inocencio et al. in their study found a higher prevalence of overdoses using DAWN (public 
health surveillance data) when compared to nationally representative administrative claims data. 
4
  With the implementation of the Affordable Care Act there are certain essential health benefits 
that are mandatory to be covered for all patients. Some of these health benefits that relate to 
opioid overdoses are emergency services, hospitalizations and services for substance abuse 
disorders and mental health. 
121
 This might have led to more accurate coding in recent years.  
Additionally, while we have only included codes that capture prescription opioid overdoses (i.e. 
we did not include overdoses that were a result of heroin or an unidentified opioid). These 
overdoses may have been classified incorrectly and there is no way of knowing that the overdose 
occurred due to use of a specific prescription opioid, thereby biasing these estimates. However, 
this is a limitation that is inherent with claims data and these codes are used extensively in 
studies that examine overdoses using claims data.  
Despite these limitations, this is the first study that used matched case-control methodology to 
estimate incremental resource utilization and costs as well as downstream costs for patients who 
suffer from an overdose due to a prescription opioid. Future studies should explore this area in a 
larger population and address limitations of our study. 
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Conclusion 
In conclusion, our study found that the prevalence of opioid overdoses in chronic opioid users 
are much higher as compared to acute users. While the cost to payers due to overdoses in 
prescription opioid users is substantial, the diversion of prescription opioids has led to additional 
resource utilization and costs. We estimated the incremental cost per patient per year to be 
$65,277 in prescription opioid users who suffered from an overdose as compared to users who 
did not suffer from an overdose and $41,102 in non-medical users who suffered from an 
overdose as compared to non-users who did not. Resource utilization was significantly higher for 
all places of service in the follow-up year for prescription opioid users and non-users who 
suffered from an overdose as compared to their respective controls who did not suffer from an 
overdose. All-cause resource utilization was found to be higher than overdose-specific resource 
utilization for prescription opioid users ($65,277 vs. $12,111) as well as non-medical users 
(41,102 vs. $11,070). Additional research is needed to better understand the long-term impact of 
opioid overdose.  
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Appendix A 
Table A1 – ICD-9 CM Codes for Cancer 
ICD-9-CM code Description 
140 Malignant neoplasm of lip 
141 Malignant neoplasm of tongue 
142 Malignant neoplasm of salivary glands 
143 Malignant neoplasm of gum 
144 Malignant neoplasm of floor of mouth 
145 Malignant neoplasm of other parts of the mouth 
146 Malignant neoplasm of oropharynx 
147 Malignant neoplasm of nasopharynx 
148 Malignant neoplasm of hypopharynx 
149 Malignant neoplasm of other sites in the lip, oral cavity and pharynx 
150 Malignant neoplasm of esophagus 
151 Malignant neoplasm of stomach 
152 Malignant neoplasm of small intestine including duodenum 
153 Malignant neoplasm of colon 
154 Malignant neoplasm of rectum rectosigmoid junction and anus 
155 Malignant neoplasm of liver and intrahepatic bile ducts 
156 Malignant neoplasm of gall bladder and extrahepatic bile ducts 
157 Malignant neoplasm of pancreas 
158 Malignant neoplasm of retroperitoneum and peritoneum 
159 Malignant neoplasm of other sites within the digestive organs and 
peritoneum 
160 Malignant neoplasm of nasal cavities, middle ear and accessory sinus 
161 Malignant neoplasm of larynx 
162 Malignant neoplasm of trachea, bronchus and lung 
163 Malignant neoplasm of pleura 
164 Malignant neoplasm of thymus, heart and mediastinum 
165 Malignant neoplasm of other sites within the respiratory system and 
intrathoracic organs 
170 Malignant neoplasm of bone and articular cartilage 
171 Malignant neoplasm of connective tissue and other soft tissue 
172 Malignant neoplasm of skin 
173 Malignant neoplasm of other sites of the skin 
174 Malignant neoplasm of female breast 
175 Malignant neoplasm of male breast 
176 Kaposi’s sarcoma 
179 Malignant neoplasm of utereus, part unspecified 
180 Malignant neoplasm of cervix, uteri 
181 Malignant neoplasm of placenta 
182 Malignant neoplasm of body of uterus 
183 Malignant neoplasm of ovary and other uterine adnexa 
184 Malignant neoplasm of other and unspecified female genital organs 
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185 Malignant neoplasm of prostate 
186 Malignant neoplasm of testis 
187 Malignant neoplasm of penis and other male genital organs 
188 Malignant neoplasm of bladder 
189 Malignant neoplasm of kidney and other unspecified urinary organs 
190 Malignant neoplasm of eye 
191 Malignant neoplasm of brain 
192 Malignant neoplasm of other and unspecified parts of the nervous system 
193 Malignant neoplasm of thyroid gland 
194 Malignant neoplasm of  other endocrine glands and related structures 
195 Malignant neoplasm of other and ill-defined sites 
196 Secondary and unspecified malignant neoplasm of lymph nodes 
197 Secondary malignant neoplasm of respiratory and digestive systems 
198 Secondary malignant neoplasm of other specified sites 
199 Malignant neoplasm without specification of site 
200 Lymphosarcoma and reticulosarcoma and other specified malignant tumors 
of lymphatic tissue 
201 Hodgkin's disease 
202 Other malignant neoplasms of lymphoid and histiocytic tissue 
203 Multiple myeloma and immunoproliferative neoplasms 
204 Lymphoid leukemia 
205 Myeloid leukemia 
206 Monocytic leukemia 
207 Other specified leukemia 
208 Leukemia of unspecified cell type 
209 Neuroendocrine tumors 
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Appendix B 
Outputs for Incremental Resource Utilization and Incremental Cost Regression Models 
Prescription Opioid Users – Incremental Resource Utilization 
1. ER visits 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -263.22251   
Iteration 1:   log likelihood = -176.10023   
Iteration 2:   log likelihood = -174.94401   
Iteration 3:   log likelihood = -174.93944   
Iteration 4:   log likelihood = -174.93944   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -770.69936   
Iteration 1:   log likelihood = -759.91976   
Iteration 2:   log likelihood = -759.90358   
Iteration 3:   log likelihood = -759.90358   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -934.84302                 Number of obs   =        396 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        396 
                                                  LR chi2(4)      =     176.57 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -174.93944                       Pseudo R2       =     0.3354 
 
Part 2: glm 
------------------------------------------------------------------------------ 
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                                                   Number of obs   =       245 
Deviance         =  842.6044078                    (1/df) Deviance =  3.510852 
Pearson          =  1594.509318                    (1/df) Pearson  =  6.643789 
 
Variance function: V(u) = u                        [Poisson] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  6.244111 
Log likelihood   = -759.9035818                    BIC             = -477.6976 
------------------------------------------------------------------------------ 
      sum_ed |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
probit       | 
    overdose | 
          1  |   1.902227    .162602    11.70   0.000     1.583533    2.220921 
             | 
   age_final | 
          2  |   .3871682   .4004562     0.97   0.334    -.3977116    1.172048 
          3  |   .1534738   .4001484     0.38   0.701    -.6308027    .9377504 
          4  |   .2314768   .4516829     0.51   0.608    -.6538053    1.116759 
             | 
       _cons |  -.7365921   .3833504    -1.92   0.055    -1.487945    .0147608 
-------------+---------------------------------------------------------------- 
glm          | 
    overdose | 
          1  |   .2986575   .0862591     3.46   0.001     .1295928    .4677222 
             | 
   age_final | 
          2  |   .7999304   .3195979     2.50   0.012       .17353    1.426331 
          3  |   .7148737    .321026     2.23   0.026     .0856743    1.344073 
          4  |   .3683642   .3519755     1.05   0.295    -.3214951    1.058223 
             | 
       _cons |   .3021609   .3224269     0.94   0.349    -.3297842    .9341059 
------------------------------------------------------------------------------ 
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Average marginal effects                        Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   2.540564   .1897893    13.39   0.000     2.168584    2.912544 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   3.429131   .1488832    23.03   0.000     3.137325    3.720936 
          2  |   .8885666   .1165933     7.62   0.000     .6600479    1.117085 
------------------------------------------------------------------------------ 
 
.  
end of do-file 
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2. Inpatient visits 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -269.61272   
Iteration 1:   log likelihood = -208.17735   
Iteration 2:   log likelihood = -207.74554   
Iteration 3:   log likelihood = -207.74307   
Iteration 4:   log likelihood = -207.74307   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -339.97556   
Iteration 1:   log likelihood = -337.51863   
Iteration 2:   log likelihood = -337.51057   
Iteration 3:   log likelihood = -337.51057   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -545.25364                 Number of obs   =        396 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        396 
                                                  LR chi2(4)      =     123.74 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -207.74307                       Pseudo R2       =     0.2295 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       167 
Deviance         =  263.5472348                    (1/df) Deviance =  1.626835 
Pearson          =  506.3669634                    (1/df) Pearson  =  3.125722 
 
Variance function: V(u) = u                        [Poisson] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  4.101923 
Log likelihood   = -337.5105727                    BIC             = -565.5678 
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------------------------------------------------------------------------------ 
sum_inpati~t |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
probit       | 
    overdose | 
          1  |   1.502703   .1460241    10.29   0.000     1.216501    1.788905 
             | 
   age_final | 
          2  |   .7408724   .5025287     1.47   0.140    -.2440657    1.725811 
          3  |   .8786724    .504048     1.74   0.081    -.1092436    1.866588 
          4  |   1.251627    .547635     2.29   0.022     .1782822    2.324972 
             | 
       _cons |  -1.834893   .4998827    -3.67   0.000    -2.814645    -.855141 
-------------+---------------------------------------------------------------- 
glm          | 
    overdose | 
          1  |   .3739636   .1492062     2.51   0.012     .0815248    .6664024 
             | 
   age_final | 
          2  |   .0919023    .506289     0.18   0.856    -.9004058    1.084211 
          3  |   .1916932   .5067236     0.38   0.705    -.8014668    1.184853 
          4  |   .4198935   .5245535     0.80   0.423    -.6082126       1.448 
             | 
       _cons |   .3191836   .5217878     0.61   0.541    -.7035017    1.341869 
------------------------------------------------------------------------------ 
 
Average marginal effects                        Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   1.355833   .1322435    10.25   0.000      1.09664    1.615025 
------------------------------------------------------------------------------ 
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Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   1.620543   .1197501    13.53   0.000     1.385837    1.855249 
          2  |   .2647099   .0557083     4.75   0.000     .1555237    .3738961 
------------------------------------------------------------------------------ 
 
.  
end of do-file 
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3. Outpatient visits 
 
Iteration 0:   log likelihood = -3303.6224   
Iteration 1:   log likelihood = -3267.3872   
Iteration 2:   log likelihood = -3267.2892   
Iteration 3:   log likelihood = -3267.2892   
 
Generalized linear models                         No. of obs      =        396 
Optimization     : ML                             Residual df     =        391 
                                                  Scale parameter =          1 
Deviance         =  4899.673625                   (1/df) Deviance =   12.53113 
Pearson          =  6351.898458                   (1/df) Pearson  =   16.24526 
 
Variance function: V(u) = u                       [Poisson] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  AIC             =   16.52671 
Log likelihood   = -3267.289247                   BIC             =   2560.941 
 
-------------------------------------------------------------------------------- 
               |                 OIM 
sum_outpatient |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
---------------+---------------------------------------------------------------- 
    1.overdose |   .4121217   .0256854    16.04   0.000     .3617792    .4624642 
               | 
     age_final | 
            2  |   .3442714   .0855326     4.03   0.000     .1766306    .5119122 
            3  |   .4954678   .0853132     5.81   0.000     .3282571    .6626785 
            4  |   .6252919   .0920336     6.79   0.000     .4449094    .8056744 
               | 
         _cons |   2.141166   .0835431    25.63   0.000     1.977425    2.304907 
-------------------------------------------------------------------------------- 
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Average marginal effects                        Number of obs     =        396 
Model VCE    : OIM 
 
Expression   : Predicted mean sum_outpatient, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   6.642965   .4118413    16.13   0.000     5.835771    7.450159 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
.  
. margins overdose, 
 
Predictive margins                              Number of obs     =        396 
Model VCE    : OIM 
 
Expression   : Predicted mean sum_outpatient, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   19.66792    .318623    61.73   0.000     19.04343    20.29241 
          2  |   13.02496   .2569925    50.68   0.000     12.52126    13.52865 
------------------------------------------------------------------------------ 
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4. Other visits  
 
twopm sum_others ib2.overdose ib1.age_final, firstpart (probit) secondpart(glm, family(poisson) link (log)) 
 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -215.84723   
Iteration 1:   log likelihood = -188.27759   
Iteration 2:   log likelihood =  -188.0518   
Iteration 3:   log likelihood = -188.05176   
Iteration 4:   log likelihood = -188.05176   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -2630.4167   
Iteration 1:   log likelihood =  -2522.581   
Iteration 2:   log likelihood = -2522.5343   
Iteration 3:   log likelihood = -2522.5343   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood =  -2710.586                 Number of obs   =        396 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        396 
                                                  LR chi2(4)      =      55.59 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -188.05176                       Pseudo R2       =     0.1288 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       303 
Deviance         =  4057.558434                    (1/df) Deviance =  13.61597 
Pearson          =  8381.825642                    (1/df) Pearson  =  28.12693 
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Variance function: V(u) = u                        [Poisson] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  16.68339 
Log likelihood   = -2522.534259                    BIC             =  2354.866 
------------------------------------------------------------------------------ 
  sum_others |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
probit       | 
    overdose | 
          1  |   .9405659   .1560945     6.03   0.000     .6346263    1.246505 
             | 
   age_final | 
          2  |   .9258904   .3687404     2.51   0.012     .2031724    1.648608 
          3  |   1.201343   .3715334     3.23   0.001     .4731509    1.929535 
          4  |     1.6535   .4547588     3.64   0.000     .7621892    2.544811 
             | 
       _cons |  -.7160624   .3556843    -2.01   0.044    -1.413191    -.018934 
-------------+---------------------------------------------------------------- 
glm          | 
    overdose | 
          1  |    .689651   .0436712    15.79   0.000      .604057    .7752449 
             | 
   age_final | 
          2  |  -.0771242   .1892333    -0.41   0.684    -.4480147    .2937663 
          3  |   .5957498   .1876744     3.17   0.002     .2279148    .9635849 
          4  |   1.188143   .1913609     6.21   0.000     .8130822    1.563203 
             | 
       _cons |   1.290475   .1885568     6.84   0.000     .9209107     1.66004 
------------------------------------------------------------------------------ 
 
.  
. margins, dydx(overdose) 
Warning: cannot perform check for estimable functions. 
 
Average marginal effects                        Number of obs     =        396 
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Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |    6.22668   .3822002    16.29   0.000     5.477581    6.975778 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
.  
. margins overdose, 
Warning: cannot perform check for estimable functions. 
 
Predictive margins                              Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   9.892069   .3141548    31.49   0.000     9.276337     10.5078 
          2  |   3.665389   .2241005    16.36   0.000      3.22616    4.104618 
------------------------------------------------------------------------------ 
 
end of do-file 
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Prescription Opioid Users – Incremental Costs 
1. All-cause costs 
 
Iteration 0:   log likelihood = -4614.9511   
Iteration 1:   log likelihood = -4529.3023   
Iteration 2:   log likelihood = -4527.3992   
Iteration 3:   log likelihood = -4527.3852   
Iteration 4:   log likelihood = -4527.3852   
 
Generalized linear models                         No. of obs      =        396 
Optimization     : ML                             Residual df     =        391 
                                                  Scale parameter =   4.541037 
Deviance         =  807.8319408                   (1/df) Deviance =   2.066066 
Pearson          =  1775.545341                   (1/df) Pearson  =   4.541037 
 
Variance function: V(u) = u^2                     [Gamma] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  AIC             =   22.89083 
Log likelihood   = -4527.385175                   BIC             =  -1530.901 
 
------------------------------------------------------------------------------ 
             |                 OIM 
    sum_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   1.638966   .2198071     7.46   0.000     1.208152     2.06978 
             | 
   age_final | 
          2  |   1.573318    .572826     2.75   0.006        .4506    2.696037 
          3  |    1.62512   .5771368     2.82   0.005     .4939526    2.756287 
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          4  |   2.215431   .6680046     3.32   0.001     .9061659    3.524696 
             | 
       _cons |    8.02287    .570287    14.07   0.000     6.905128    9.140612 
------------------------------------------------------------------------------ 
Average marginal effects                        Number of obs     =        396 
Model VCE    : OIM 
 
Expression   : Predicted mean sum_cost, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   65277.12   13182.48     4.95   0.000     39439.94     91114.3 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
  
Predictive margins                              Number of obs     =        396 
Model VCE    : OIM 
 
Expression   : Predicted mean sum_cost, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   81007.14   12994.27     6.23   0.000     55538.85    106475.4 
          2  |   15730.03    2397.38     6.56   0.000     11031.25     20428.8 
------------------------------------------------------------------------------ 
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2. ER costs 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood =  -264.6264   
Iteration 1:   log likelihood = -180.42481   
Iteration 2:   log likelihood = -179.59547   
Iteration 3:   log likelihood = -179.59371   
Iteration 4:   log likelihood = -179.59371   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -2368.9882   
Iteration 1:   log likelihood = -2346.7054   
Iteration 2:   log likelihood = -2345.4705   
Iteration 3:   log likelihood = -2345.4627   
Iteration 4:   log likelihood = -2345.4627   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -2525.0564                 Number of obs   =        396 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        396 
                                                  LR chi2(4)      =     170.07 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -179.59371                       Pseudo R2       =     0.3213 
 
Part 2: glm 
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------------------------------------------------------------------------------ 
                                                   Number of obs   =       242 
Deviance         =  337.4110422                    (1/df) Deviance =  1.423675 
Pearson          =  470.9666919                    (1/df) Pearson  =  1.987201 
 
Variance function: V(u) = u^2                      [Gamma] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  19.42531 
Log likelihood   =  -2345.46267                    BIC             = -963.4672 
------------------------------------------------------------------------------ 
     er_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
probit       | 
    overdose | 
          1  |   1.850771   .1586993    11.66   0.000     1.539726    2.161816 
             | 
   age_final | 
          2  |   .3196991   .3981413     0.80   0.422    -.4606435    1.100042 
          3  |   .1614674   .3980126     0.41   0.685     -.618623    .9415578 
          4  |   .2344065   .4495105     0.52   0.602    -.6466179    1.115431 
             | 
       _cons |  -.7267969   .3813834    -1.91   0.057    -1.474295    .0207009 
-------------+---------------------------------------------------------------- 
glm          | 
    overdose | 
          1  |   .1324462   .2099557     0.63   0.528    -.2790594    .5439517 
             | 
   age_final | 
          2  |   2.231618   .5897765     3.78   0.000     1.075677    3.387558 
          3  |   2.181602    .593429     3.68   0.000     1.018502    3.344701 
          4  |   2.045879   .6645902     3.08   0.002     .7433065    3.348452 
             | 
       _cons |   6.450095   .5934368    10.87   0.000      5.28698     7.61321 
------------------------------------------------------------------------------ 
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Average marginal effects                        Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   3995.506   718.7325     5.56   0.000     2586.816    5404.195 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
 
Predictive margins                              Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   5726.213    618.225     9.26   0.000     4514.514    6937.911 
          2  |   1730.707   366.7221     4.72   0.000     1011.945    2449.469 
------------------------------------------------------------------------------ 
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3. Inpatient costs  
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -269.29181   
Iteration 1:   log likelihood = -208.81404   
Iteration 2:   log likelihood = -208.38525   
Iteration 3:   log likelihood = -208.38291   
Iteration 4:   log likelihood = -208.38291   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -1972.8971   
Iteration 1:   log likelihood = -1936.0155   
Iteration 2:   log likelihood = -1935.9527   
Iteration 3:   log likelihood = -1935.9526   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -2144.3356                 Number of obs   =        396 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        396 
                                                  LR chi2(4)      =     121.82 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -208.38291                       Pseudo R2       =     0.2262 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       166 
Deviance         =   365.031372                    (1/df) Deviance =  2.267276 
Pearson          =  957.6491663                    (1/df) Pearson  =  5.948131 
 
Variance function: V(u) = u^2                      [Gamma] 
Link function    : g(u) = ln(u)                    [Log] 
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                                                   AIC             =  23.38497 
Log likelihood   = -1935.952646                    BIC             = -457.9987 
------------------------------------------------------------------------------ 
inpatient_~t |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
probit       | 
    overdose | 
          1  |   1.490906   .1459619    10.21   0.000     1.204826    1.776986 
             | 
   age_final | 
          2  |   .7243258   .5015667     1.44   0.149    -.2587269    1.707378 
          3  |   .8777545   .5030691     1.74   0.081    -.1082428    1.863752 
          4  |     1.2481   .5466271     2.28   0.022     .1767306     2.31947 
             | 
       _cons |  -1.827711   .4988567    -3.66   0.000    -2.805452   -.8499701 
-------------+---------------------------------------------------------------- 
glm          | 
    overdose | 
          1  |   .7474327   .5064159     1.48   0.140    -.2451243     1.73999 
             | 
   age_final | 
          2  |   .6517187   1.748092     0.37   0.709    -2.774478    4.077916 
          3  |   1.041935   1.752476     0.59   0.552    -2.392855    4.476725 
          4  |   1.064627   1.851243     0.58   0.565    -2.563742    4.692996 
             | 
       _cons |   9.210802   1.797896     5.12   0.000     5.686991    12.73461 
------------------------------------------------------------------------------ 
 
 
Average marginal effects                        Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
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------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   30411.01   8075.895     3.77   0.000     14582.55    46239.47 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   34335.89   7822.879     4.39   0.000     19003.33    49668.45 
          2  |   3924.882   1825.448     2.15   0.032       347.07    7502.694 
------------------------------------------------------------------------------ 
 
.  
end of do-file 
  
  
 
172 
4. Outpatient costs 
Iteration 0:   log likelihood = -4382.7346   
Iteration 1:   log likelihood = -4097.9163   
Iteration 2:   log likelihood = -4097.5232   
Iteration 3:   log likelihood = -4097.5219   
Iteration 4:   log likelihood = -4097.5219   
 
Generalized linear models                         No. of obs      =        396 
Optimization     : ML                             Residual df     =        391 
                                                  Scale parameter =   10.51825 
Deviance         =  1099.108483                   (1/df) Deviance =   2.811019 
Pearson          =  4112.635131                   (1/df) Pearson  =   10.51825 
 
Variance function: V(u) = u^2                     [Gamma] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  AIC             =   20.71981 
Log likelihood   = -4097.521852                   BIC             =  -1239.624 
 
--------------------------------------------------------------------------------- 
                |                 OIM 
outpatient_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
----------------+---------------------------------------------------------------- 
     1.overdose |   1.169392    .354604     3.30   0.001     .4743811    1.864403 
                | 
      age_final | 
             2  |   1.502715   .8713529     1.72   0.085    -.2051057    3.210535 
             3  |   .7615865   .8866044     0.86   0.390    -.9761262    2.499299 
             4  |   1.283735    1.02237     1.26   0.209    -.7200728    3.287543 
                | 
          _cons |   7.644392   .8771214     8.72   0.000     5.925266    9.363519 
--------------------------------------------------------------------------------- 
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Average marginal effects                        Number of obs     =        396 
Model VCE    : OIM 
 
Expression   : Predicted mean outpatient_cost, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   15329.32   5575.264     2.75   0.006     4402.007    26256.64 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
.  
. margins overdose, 
 
Predictive margins                              Number of obs     =        396 
Model VCE    : OIM 
 
Expression   : Predicted mean outpatient_cost, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   22234.31   5244.431     4.24   0.000     11955.42    32513.21 
          2  |   6904.991   1798.902     3.84   0.000     3379.207    10430.77 
------------------------------------------------------------------------------ 
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5. Other costs 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -221.57936   
Iteration 1:   log likelihood = -197.56251   
Iteration 2:   log likelihood = -197.41542   
Iteration 3:   log likelihood = -197.41541   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -3004.5281   
Iteration 1:   log likelihood = -2865.0035   
Iteration 2:   log likelihood = -2862.6974   
Iteration 3:   log likelihood = -2862.6811   
Iteration 4:   log likelihood = -2862.6811   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -3060.0965                 Number of obs   =        396 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        396 
                                                  LR chi2(4)      =      48.33 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -197.41541                       Pseudo R2       =     0.1091 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       298 
Deviance         =  1055.539384                    (1/df) Deviance =  3.602523 
Pearson          =  3798.453619                    (1/df) Pearson  =  12.96401 
 
Variance function: V(u) = u^2                      [Gamma] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  19.24618 
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Log likelihood   = -2862.681071                    BIC             =  -613.709 
------------------------------------------------------------------------------ 
 others_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
probit       | 
    overdose | 
          1  |   .8470326   .1511792     5.60   0.000     .5507268    1.143338 
             | 
   age_final | 
          2  |   .8815926   .3662105     2.41   0.016     .1638332    1.599352 
          3  |   1.174112   .3688836     3.18   0.001     .4511132     1.89711 
          4  |   1.507522   .4430626     3.40   0.001      .639135    2.375908 
             | 
       _cons |  -.6877088   .3533679    -1.95   0.052    -1.380297    .0048796 
-------------+---------------------------------------------------------------- 
glm          | 
    overdose | 
          1  |    1.58492   .4329985     3.66   0.000     .7362582    2.433581 
             | 
   age_final | 
          2  |   .1407963   1.647191     0.09   0.932     -3.08764    3.369232 
          3  |   .5452201   1.648981     0.33   0.741    -2.686724    3.777164 
          4  |   1.991364   1.768294     1.13   0.260    -1.474429    5.457158 
             | 
       _cons |   7.191259   1.664037     4.32   0.000     3.929805    10.45271 
------------------------------------------------------------------------------ 
 
 
Average marginal effects                        Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   9430.524   3795.388     2.48   0.013       1991.7    16869.35 
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------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
 
Predictive margins                              Number of obs     =        396 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   11166.38   3916.298     2.85   0.004     3490.581    18842.19 
          2  |   1735.859    630.225     2.75   0.006      500.641    2971.078 
------------------------------------------------------------------------------ 
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6. Pharmacy costs 
Iteration 0:   log likelihood =  -3575.973   
Iteration 1:   log likelihood = -3533.5122   
Iteration 2:   log likelihood = -3533.1633   
Iteration 3:   log likelihood = -3533.1631   
 
Generalized linear models                         No. of obs      =        396 
Optimization     : ML                             Residual df     =        391 
                                                  Scale parameter =   2.523649 
Deviance         =  683.3335821                   (1/df) Deviance =   1.747656 
Pearson          =   986.746564                   (1/df) Pearson  =   2.523649 
 
Variance function: V(u) = u^2                     [Gamma] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  AIC             =   17.86951 
Log likelihood   =  -3533.16309                   BIC             =  -1655.399 
 
------------------------------------------------------------------------------ 
             |                 OIM 
   phar_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   .3785697   .1600025     2.37   0.018     .0649705    .6921689 
             | 
   age_final | 
          2  |   .8867081    .427394     2.07   0.038     .0490313    1.724385 
          3  |   1.404489   .4291205     3.27   0.001      .563428     2.24555 
          4  |   1.045968   .4934182     2.12   0.034     .0788861     2.01305 
             | 
       _cons |   6.650307   .4209417    15.80   0.000     5.825277    7.475338 
------------------------------------------------------------------------------ 
 
 
Average marginal effects                        Number of obs     =        396 
Model VCE    : OIM 
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Expression   : Predicted mean phar_cost, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   1101.021   480.2126     2.29   0.022     159.8213     2042.22 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        396 
Model VCE    : OIM 
 
Expression   : Predicted mean phar_cost, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   3493.532   404.1305     8.64   0.000      2701.45    4285.613 
          2  |   2392.511   275.1801     8.69   0.000     1853.168    2931.854 
------------------------------------------------------------------------------ 
 
 
  
  
 
179 
Non-users – Incremental resource utilization 
1. ER visits 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -168.46337   
Iteration 1:   log likelihood = -97.524476   
Iteration 2:   log likelihood = -96.366217   
Iteration 3:   log likelihood = -96.365146   
Iteration 4:   log likelihood = -96.365146   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -365.24234   
Iteration 1:   log likelihood = -354.37719   
Iteration 2:   log likelihood = -354.34622   
Iteration 3:   log likelihood = -354.34622   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -450.71136                 Number of obs   =        244 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        244 
                                                  LR chi2(10)     =     144.20 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -96.365146                       Pseudo R2       =     0.4280 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       131 
Deviance         =  356.3116239                    (1/df) Deviance =  2.969264 
Pearson          =  439.5344177                    (1/df) Pearson  =  3.662787 
 
Variance function: V(u) = u                        [Poisson] 
Link function    : g(u) = ln(u)                    [Log] 
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                                                   AIC             =  5.577805 
Log likelihood   = -354.3462164                    BIC             = -228.7121 
----------------------------------------------------------------------------------- 
           sum_ed |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
probit            | 
         overdose | 
               1  |   2.269462   .2279632     9.96   0.000     1.822662    2.716261 
                  | 
        age_final | 
               2  |  -.7049595    .308816    -2.28   0.022    -1.310228   -.0996913 
               3  |  -.5936604   .3262024    -1.82   0.069    -1.233005    .0456845 
               4  |   .0230673   .4726306     0.05   0.961    -.9032716    .9494063 
                  | 
           gender | 
               2  |    .357899   .2222605     1.61   0.107    -.0777236    .7935216 
                  | 
        cci_score |   -.046686    .129763    -0.36   0.719    -.3010169    .2076449 
                  | 
       elx_grp_28 | 
               1  |   .8398603   .5007042     1.68   0.093     -.141502    1.821222 
                  | 
       elx_grp_30 | 
               1  |   1.058552   .6357613     1.67   0.096    -.1875168    2.304622 
                  | 
       elx_grp_31 | 
               1  |  -.4585234   .2998457    -1.53   0.126     -1.04621    .1291634 
                  | 
log_baseline_cost |    .003187   .0290198     0.11   0.913    -.0536909    .0600649 
            _cons |  -.6803018   .3035904    -2.24   0.025    -1.275328   -.0852755 
------------------+---------------------------------------------------------------- 
glm               | 
         overdose | 
               1  |   .1815591   .1516583     1.20   0.231    -.1156858    .4788039 
                  | 
        age_final | 
               2  |   .1688993    .151763     1.11   0.266    -.1285507    .4663494 
               3  |   .4613513   .1624143     2.84   0.005     .1430252    .7796774 
               4  |   .0779566   .2163505     0.36   0.719    -.3460826    .5019958 
                  | 
           gender | 
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               2  |  -.5529449   .1057043    -5.23   0.000    -.7601215   -.3457683 
                  | 
        cci_score |  -.1546712   .0763988    -2.02   0.043    -.3044101   -.0049324 
                  | 
       elx_grp_28 | 
               1  |    .537184   .2423762     2.22   0.027     .0621354    1.012233 
                  | 
       elx_grp_30 | 
               1  |  -.0991649   .2703705    -0.37   0.714    -.6290814    .4307517 
                  | 
       elx_grp_31 | 
               1  |   .8016525   .1235299     6.49   0.000     .5595384    1.043767 
                  | 
log_baseline_cost |   .0843133   .0174543     4.83   0.000     .0501036     .118523 
            _cons |   .4631874   .2049811     2.26   0.024     .0614319     .864943 
----------------------------------------------------------------------------------- 
 
Average marginal effects                        Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   2.678185    .253755    10.55   0.000     2.180834    3.175536 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
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------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   3.196999   .2269984    14.08   0.000      2.75209    3.641908 
          2  |   .5188136   .1180824     4.39   0.000     .2873765    .7502508 
------------------------------------------------------------------------------ 
 
end of do-file 
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2. Inpatient visits 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -161.67466   
Iteration 1:   log likelihood = -113.14335   
Iteration 2:   log likelihood = -112.01492   
Iteration 3:   log likelihood = -112.01365   
Iteration 4:   log likelihood = -112.01365   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood =  -226.7823   
Iteration 1:   log likelihood = -220.63213   
Iteration 2:   log likelihood = -220.61283   
Iteration 3:   log likelihood = -220.61283   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -332.62648                 Number of obs   =        244 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        244 
                                                  LR chi2(10)     =      99.32 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -112.01365                       Pseudo R2       =     0.3072 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =        92 
Deviance         =  215.8543019                    (1/df) Deviance =  2.664868 
Pearson          =  337.1172029                    (1/df) Pearson  =  4.161941 
 
Variance function: V(u) = u                        [Poisson] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  5.035061 
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Log likelihood   = -220.6128263                    BIC             = -150.4106 
----------------------------------------------------------------------------------- 
    sum_inpatient |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
probit            | 
         overdose | 
               1  |   1.701103   .2150142     7.91   0.000     1.279683    2.122523 
                  | 
        age_final | 
               2  |   .4907994   .2780572     1.77   0.078    -.0541827    1.035782 
               3  |   .5479936   .2924207     1.87   0.061    -.0251404    1.121128 
               4  |   .5186591   .3932459     1.32   0.187    -.2520888    1.289407 
                  | 
           gender | 
               2  |   .0416975   .2052586     0.20   0.839     -.360602     .443997 
                  | 
        cci_score |   .1233415   .1579979     0.78   0.435    -.1863288    .4330117 
                  | 
       elx_grp_28 | 
               1  |    .465346   .5140937     0.91   0.365    -.5422592    1.472951 
                  | 
       elx_grp_30 | 
               1  |  -.2561456   .7010828    -0.37   0.715    -1.630243    1.117951 
                  | 
       elx_grp_31 | 
               1  |   .0911531   .2766749     0.33   0.742    -.4511198    .6334259 
                  | 
log_baseline_cost |    .088938   .0281786     3.16   0.002     .0337089     .144167 
            _cons |  -2.308551   .3343774    -6.90   0.000    -2.963919   -1.653184 
------------------+---------------------------------------------------------------- 
glm               | 
         overdose | 
               1  |  -.1645824   .2236116    -0.74   0.462    -.6028531    .2736883 
                  | 
        age_final | 
               2  |   .1963831   .2718678     0.72   0.470    -.3364679    .7292342 
               3  |   .4108142   .2839624     1.45   0.148    -.1457419    .9673703 
               4  |   .2448995   .2970152     0.82   0.410    -.3372396    .8270387 
                  | 
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           gender | 
               2  |  -.5096374   .1407855    -3.62   0.000    -.7855719   -.2337028 
                  | 
        cci_score |   .0603846   .0644891     0.94   0.349    -.0660118     .186781 
                  | 
       elx_grp_28 | 
               1  |   -.750825   .5658585    -1.33   0.185    -1.859887    .3582373 
                  | 
       elx_grp_30 | 
               1  |   .0949317   .5039202     0.19   0.851    -.8927338    1.082597 
                  | 
       elx_grp_31 | 
               1  |   .3675877   .1708189     2.15   0.031     .0327888    .7023866 
                  | 
log_baseline_cost |   .0763567   .0236478     3.23   0.001      .030008    .1227055 
            _cons |   .4240338   .3073953     1.38   0.168    -.1784499    1.026517 
----------------------------------------------------------------------------------- 
 
Average marginal effects                        Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   1.187284   .2030539     5.85   0.000     .7893053    1.585262 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
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------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   1.569207   .1580336     9.93   0.000     1.259467    1.878947 
          2  |   .3819233   .1213076     3.15   0.002     .1441649    .6196818 
------------------------------------------------------------------------------ 
 
end of do-file 
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3. Outpatient visits 
Iteration 0:   log likelihood =  -1941.436   
Iteration 1:   log likelihood =  -1893.789   
Iteration 2:   log likelihood = -1893.7576   
Iteration 3:   log likelihood = -1893.7576   
 
Generalized linear models                         No. of obs      =        244 
Optimization     : ML                             Residual df     =        233 
                                                  Scale parameter =          1 
Deviance         =  2927.152423                   (1/df) Deviance =   12.56289 
Pearson          =  4317.717983                   (1/df) Pearson  =   18.53098 
 
Variance function: V(u) = u                       [Poisson] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  AIC             =   15.61277 
Log likelihood   = -1893.757572                   BIC             =   1646.312 
 
----------------------------------------------------------------------------------- 
                  |                 OIM 
   sum_outpatient |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
       1.overdose |   .5375132   .0402109    13.37   0.000     .4587014    .6163251 
                  | 
        age_final | 
               2  |   .1369592   .0573686     2.39   0.017     .0245189    .2493995 
               3  |   .3265451   .0581533     5.62   0.000     .2125668    .4405235 
               4  |  -.0006791    .082524    -0.01   0.993    -.1624232    .1610651 
                  | 
         2.gender |   .0748006     .03978     1.88   0.060    -.0031669     .152768 
        cci_score |    .030507   .0211669     1.44   0.150    -.0109793    .0719933 
     1.elx_grp_28 |  -.7493537    .139098    -5.39   0.000    -1.021981   -.4767266 
     1.elx_grp_30 |   .4214614   .1028947     4.10   0.000     .2197914    .6231313 
     1.elx_grp_31 |   .0192083   .0510049     0.38   0.706    -.0807594     .119176 
log_baseline_cost |    .082145   .0056316    14.59   0.000     .0711072    .0931828 
            _cons |   1.456523   .0647182    22.51   0.000     1.329678    1.583369 
----------------------------------------------------------------------------------- 
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Average marginal effects                        Number of obs     =        244 
Model VCE    : OIM 
 
Expression   : Predicted mean sum_outpatient, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   6.282776   .4650145    13.51   0.000     5.371364    7.194188 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        244 
Model VCE    : OIM 
 
Expression   : Predicted mean sum_outpatient, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   15.11006   .3619223    41.75   0.000     14.40071    15.81942 
          2  |   8.827287    .275168    32.08   0.000     8.287967    9.366606 
------------------------------------------------------------------------------ 
end of do-file 
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4. Other visits 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -159.52587   
Iteration 1:   log likelihood = -134.23175   
Iteration 2:   log likelihood = -133.89223   
Iteration 3:   log likelihood = -133.89117   
Iteration 4:   log likelihood = -133.89117   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -1383.0872   
Iteration 1:   log likelihood = -1199.9319   
Iteration 2:   log likelihood =   -1198.69   
Iteration 3:   log likelihood = -1198.6893   
Iteration 4:   log likelihood = -1198.6893   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -1332.5805                 Number of obs   =        244 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        244 
                                                  LR chi2(10)     =      51.27 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -133.89117                       Pseudo R2       =     0.1607 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       156 
Deviance         =  1909.628994                    (1/df) Deviance =  13.16986 
Pearson          =  2749.959625                    (1/df) Pearson  =  18.96524 
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Variance function: V(u) = u                        [Poisson] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  15.50884 
Log likelihood   = -1198.689291                    BIC             =    1177.4 
----------------------------------------------------------------------------------- 
       sum_others |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
probit            | 
         overdose | 
               1  |   .6784057   .1897298     3.58   0.000     .3065422    1.050269 
                  | 
        age_final | 
               2  |   .7965336   .2474413     3.22   0.001     .3115576     1.28151 
               3  |   .5968794   .2625654     2.27   0.023     .0822607    1.111498 
               4  |   .9150297   .4127336     2.22   0.027     .1060867    1.723973 
                  | 
           gender | 
               2  |   .4542447   .1895301     2.40   0.017     .0827725    .8257169 
                  | 
        cci_score |   .2647693   .1966063     1.35   0.178    -.1205719    .6501106 
                  | 
       elx_grp_28 | 
               1  |    .936025   .6380629     1.47   0.142    -.3145553    2.186605 
                  | 
       elx_grp_30 | 
               1  |  -.1069828   .5678184    -0.19   0.851    -1.219886    1.005921 
                  | 
       elx_grp_31 | 
               1  |  -.2095275   .2534474    -0.83   0.408    -.7062753    .2872203 
                  | 
log_baseline_cost |    .062733    .025224     2.49   0.013     .0132949    .1121711 
            _cons |  -1.162396   .2693916    -4.31   0.000    -1.690394   -.6343985 
------------------+---------------------------------------------------------------- 
glm               | 
         overdose | 
               1  |   .5562921    .070421     7.90   0.000     .4182695    .6943147 
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                  | 
        age_final | 
               2  |  -1.650641   .0896206   -18.42   0.000    -1.826294   -1.474988 
               3  |  -.8932945   .0771312   -11.58   0.000    -1.044469   -.7421202 
               4  |   -1.37713   .1105135   -12.46   0.000    -1.593732   -1.160527 
                  | 
           gender | 
               2  |  -.0066167    .054279    -0.12   0.903    -.1130015    .0997681 
                  | 
        cci_score |   .1867462   .0214131     8.72   0.000     .1447774    .2287151 
                  | 
       elx_grp_28 | 
               1  |  -1.068284   .2462421    -4.34   0.000     -1.55091   -.5856588 
                  | 
       elx_grp_30 | 
               1  |   .1632291   .2387883     0.68   0.494    -.3047873    .6312456 
                  | 
       elx_grp_31 | 
               1  |  -.3281661   .0946451    -3.47   0.001     -.513667   -.1426652 
                  | 
log_baseline_cost |   .2301726   .0108194    21.27   0.000     .2089671    .2513782 
            _cons |   1.015503   .1251469     8.11   0.000     .7702191    1.260786 
----------------------------------------------------------------------------------- 
 
Average marginal effects                        Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   5.946818   .8438828     7.05   0.000     4.292838    7.600797 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
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Predictive margins                              Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   10.05121   .8442013    11.91   0.000      8.39661    11.70582 
          2  |   4.104396   .4701557     8.73   0.000     3.182908    5.025885 
------------------------------------------------------------------------------ 
 
.  
end of do-file 
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Non-users – Incremental cost estimation 
1. All-cause costs 
 
Iteration 0:   log likelihood = -2659.7031   
Iteration 1:   log likelihood = -2588.6215   
Iteration 2:   log likelihood = -2575.6264   
Iteration 3:   log likelihood = -2575.5877   
Iteration 4:   log likelihood = -2575.5877   
 
Generalized linear models                         No. of obs      =        244 
Optimization     : ML                             Residual df     =        233 
                                                  Scale parameter =    4.83807 
Deviance         =  474.9786983                   (1/df) Deviance =   2.038535 
Pearson          =  1127.270289                   (1/df) Pearson  =    4.83807 
 
Variance function: V(u) = u^2                     [Gamma] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  AIC             =   21.20154 
Log likelihood   = -2575.587727                   BIC             =  -805.8615 
 
----------------------------------------------------------------------------------- 
                  |                 OIM 
         sum_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
       1.overdose |   1.454419   .3198381     4.55   0.000     .8275482     2.08129 
                  | 
        age_final | 
               2  |   .1866414   .5082002     0.37   0.713    -.8094127    1.182696 
               3  |    .750468   .5193165     1.45   0.148    -.2673736     1.76831 
               4  |  -.0927814   .6397097    -0.15   0.885    -1.346589    1.161027 
                  | 
         2.gender |  -.1475685   .3158639    -0.47   0.640    -.7666502    .4715133 
        cci_score |  -.0463075   .2586336    -0.18   0.858      -.55322    .4606051 
     1.elx_grp_28 |   -1.39919   .8119126    -1.72   0.085    -2.990509    .1921298 
     1.elx_grp_30 |  -.2050553   .9159732    -0.22   0.823     -2.00033    1.590219 
     1.elx_grp_31 |  -.8364814   .4150795    -2.02   0.044    -1.650022   -.0229407 
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log_baseline_cost |   .2709387   .0404346     6.70   0.000     .1916883    .3501891 
            _cons |   7.306485   .5000464    14.61   0.000     6.326412    8.286558 
----------------------------------------------------------------------------------- 
 
Average marginal effects                        Number of obs     =        244 
Model VCE    : OIM 
 
Expression   : Predicted mean sum_cost, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   41102.28   13291.25     3.09   0.002      15051.9    67152.65 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        244 
Model VCE    : OIM 
 
Expression   : Predicted mean sum_cost, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   53625.84    13647.1     3.93   0.000     26878.01    80373.66 
          2  |   12523.56   3255.912     3.85   0.000     6142.091    18905.03 
------------------------------------------------------------------------------ 
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2. ER costs 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -168.60295   
Iteration 1:   log likelihood = -95.657801   
Iteration 2:   log likelihood = -94.544993   
Iteration 3:   log likelihood = -94.544025   
Iteration 4:   log likelihood = -94.544025   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -1197.0403   
Iteration 1:   log likelihood =  -1179.027   
Iteration 2:   log likelihood = -1178.7198   
Iteration 3:   log likelihood = -1178.7186   
Iteration 4:   log likelihood = -1178.7186   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -1273.2626                 Number of obs   =        244 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        244 
                                                  LR chi2(10)     =     148.12 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -94.544025                       Pseudo R2       =     0.4393 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       130 
Deviance         =  161.9366414                    (1/df) Deviance =  1.360812 
Pearson          =  212.4156339                    (1/df) Pearson  =  1.785005 
 
Variance function: V(u) = u^2                      [Gamma] 
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Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  18.30336 
Log likelihood   = -1178.718581                    BIC             =    -417.3 
----------------------------------------------------------------------------------- 
          er_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
probit            | 
         overdose | 
               1  |   2.318329   .2307339    10.05   0.000     1.866098    2.770559 
                  | 
        age_final | 
               2  |  -.7411354   .3109235    -2.38   0.017    -1.350534   -.1317365 
               3  |  -.5995424    .327574    -1.83   0.067    -1.241576     .042491 
               4  |   .0360439   .4752967     0.08   0.940    -.8955206    .9676083 
                  | 
           gender | 
               2  |   .3202644   .2237752     1.43   0.152    -.1183268    .7588557 
                  | 
        cci_score |  -.0455226   .1303803    -0.35   0.727    -.3010634    .2100182 
                  | 
       elx_grp_28 | 
               1  |   .8908504   .5025357     1.77   0.076    -.0941015    1.875802 
                  | 
       elx_grp_30 | 
               1  |   1.080977   .6382927     1.69   0.090    -.1700534    2.332008 
                  | 
       elx_grp_31 | 
               1  |  -.4437491   .3017793    -1.47   0.141    -1.035226    .1477274 
                  | 
log_baseline_cost |   .0080193   .0292487     0.27   0.784    -.0493071    .0653456 
            _cons |  -.7204174    .306217    -2.35   0.019    -1.320592   -.1202431 
------------------+---------------------------------------------------------------- 
glm               | 
         overdose | 
               1  |   .3085878   .3788721     0.81   0.415    -.4339879    1.051164 
                  | 
        age_final | 
               2  |   .6598823   .3605457     1.83   0.067    -.0467742    1.366539 
  
 
197 
               3  |    .475668    .396337     1.20   0.230    -.3011381    1.252474 
               4  |   .0303546   .4924477     0.06   0.951    -.9348252    .9955345 
                  | 
           gender | 
               2  |  -.5194774   .2657891    -1.95   0.051    -1.040414    .0014597 
                  | 
        cci_score |  -.3722108   .1631738    -2.28   0.023    -.6920256   -.0523961 
                  | 
       elx_grp_28 | 
               1  |   .0440796   .7237874     0.06   0.951    -1.374518    1.462677 
                  | 
       elx_grp_30 | 
               1  |  -.1082225   .7302242    -0.15   0.882    -1.539436    1.322991 
                  | 
       elx_grp_31 | 
               1  |   .8343444    .425985     1.96   0.050    -.0005709     1.66926 
                  | 
log_baseline_cost |   .0914062   .0365476     2.50   0.012     .0197742    .1630383 
            _cons |   7.163403    .470287    15.23   0.000     6.241657    8.085148 
----------------------------------------------------------------------------------- 
Average marginal effects                        Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   3278.557   635.3301     5.16   0.000     2033.333    4523.781 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
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Predictive margins                              Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   3741.048   624.0603     5.99   0.000     2517.913    4964.184 
          2  |   462.4913   175.0305     2.64   0.008     119.4379    805.5447 
------------------------------------------------------------------------------ 
 
.  
end of do-file 
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3. Inpatient costs 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -160.63548   
Iteration 1:   log likelihood = -107.90992   
Iteration 2:   log likelihood = -106.32958   
Iteration 3:   log likelihood = -106.32784   
Iteration 4:   log likelihood = -106.32784   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -1028.7183   
Iteration 1:   log likelihood = -1012.8525   
Iteration 2:   log likelihood = -1012.3168   
Iteration 3:   log likelihood = -1012.3111   
Iteration 4:   log likelihood = -1012.3111   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -1118.6389                 Number of obs   =        244 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        244 
                                                  LR chi2(10)     =     108.62 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -106.32784                       Pseudo R2       =     0.3381 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =        90 
Deviance         =  154.4116604                    (1/df) Deviance =  1.954578 
Pearson          =  238.1585207                    (1/df) Pearson  =  3.014665 
 
Variance function: V(u) = u^2                      [Gamma] 
Link function    : g(u) = ln(u)                    [Log] 
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                                                   AIC             =  22.74025 
Log likelihood   = -1012.311079                    BIC             = -201.0733 
----------------------------------------------------------------------------------- 
   inpatient_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
probit            | 
         overdose | 
               1  |   1.860982   .2312691     8.05   0.000     1.407703    2.314261 
                  | 
        age_final | 
               2  |   .4004631   .2831235     1.41   0.157    -.1544488     .955375 
               3  |   .5456884   .2957294     1.85   0.065    -.0339306    1.125307 
               4  |   .5216619   .3976127     1.31   0.190    -.2576446    1.300968 
                  | 
           gender | 
               2  |   .0373065    .210404     0.18   0.859    -.3750777    .4496907 
                  | 
        cci_score |   .1427534   .1648231     0.87   0.386     -.180294    .4658008 
                  | 
       elx_grp_28 | 
               1  |   .5560502   .5230124     1.06   0.288    -.4690352    1.581136 
                  | 
       elx_grp_30 | 
               1  |  -.1719662   .7288591    -0.24   0.813    -1.600504    1.256571 
                  | 
       elx_grp_31 | 
               1  |   .0148247   .2859197     0.05   0.959    -.5455677    .5752171 
                  | 
log_baseline_cost |   .0992009   .0293133     3.38   0.001     .0417479     .156654 
            _cons |  -2.471176   .3511603    -7.04   0.000    -3.159438   -1.782914 
------------------+---------------------------------------------------------------- 
glm               | 
         overdose | 
               1  |  -.3389021   .8647399    -0.39   0.695    -2.033761    1.355957 
                  | 
        age_final | 
               2  |   1.028488   .9636936     1.07   0.286    -.8603167    2.917293 
               3  |   1.594489   1.000876     1.59   0.111    -.3671921    3.556169 
               4  |   .7234581   1.012998     0.71   0.475    -1.261982    2.708899 
                  | 
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           gender | 
               2  |  -.5251408   .4228238    -1.24   0.214     -1.35386    .3035786 
                  | 
        cci_score |  -.2706861   .1987667    -1.36   0.173    -.6602616    .1188895 
                  | 
       elx_grp_28 | 
               1  |  -2.940899   1.592993    -1.85   0.065    -6.063107    .1813089 
                  | 
       elx_grp_30 | 
               1  |   .4983783   1.889857     0.26   0.792    -3.205672    4.202429 
                  | 
       elx_grp_31 | 
               1  |  -1.112942   .5790143    -1.92   0.055     -2.24779    .0219048 
                  | 
log_baseline_cost |   .1897206   .0620138     3.06   0.002     .0681758    .3112654 
            _cons |   8.850585   .8271154    10.70   0.000     7.229468     10.4717 
----------------------------------------------------------------------------------- 
 
Average marginal effects                        Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   17637.84   8227.948     2.14   0.032     1511.354    33764.32 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
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------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   23772.66   7020.495     3.39   0.001     10012.75    37532.58 
          2  |   6134.829   5609.403     1.09   0.274      -4859.4    17129.06 
------------------------------------------------------------------------------ 
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4. Outpatient costs 
Iteration 0:   log likelihood = -2274.2017   
Iteration 1:   log likelihood = -2208.6055   
Iteration 2:   log likelihood = -2207.1545   
Iteration 3:   log likelihood = -2207.1535   
Iteration 4:   log likelihood = -2207.1535   
 
Generalized linear models                         No. of obs      =        244 
Optimization     : ML                             Residual df     =        233 
                                                  Scale parameter =   4.235795 
Deviance         =   469.236054                   (1/df) Deviance =   2.013889 
Pearson          =  986.9401244                   (1/df) Pearson  =   4.235795 
 
Variance function: V(u) = u^2                     [Gamma] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  AIC             =   18.18159 
Log likelihood   = -2207.153467                   BIC             =  -811.6041 
 
----------------------------------------------------------------------------------- 
                  |                 OIM 
  outpatient_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
       1.overdose |    .662436   .2994764     2.21   0.027      .075473    1.249399 
                  | 
        age_final | 
               2  |   .4588781   .4284095     1.07   0.284     -.380789    1.298545 
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               3  |   .7825226    .425233     1.84   0.066    -.0509188    1.615964 
               4  |  -.3093444   .6199111    -0.50   0.618    -1.524348     .905659 
                  | 
         2.gender |   .4957808   .2829621     1.75   0.080    -.0588147    1.050376 
        cci_score |  -.1444597   .2317326    -0.62   0.533    -.5986472    .3097279 
     1.elx_grp_28 |  -1.685375   .7473566    -2.26   0.024    -3.150167   -.2205834 
     1.elx_grp_30 |   .0399886   .8509749     0.05   0.963    -1.627892    1.707869 
     1.elx_grp_31 |  -.7484504    .413254    -1.81   0.070    -1.558413    .0615125 
log_baseline_cost |   .1959248    .035509     5.52   0.000     .1263285    .2655211 
            _cons |   6.183886   .4258054    14.52   0.000     5.349323    7.018449 
----------------------------------------------------------------------------------- 
 
.  
. margins, dydx(overdose) 
 
Average marginal effects                        Number of obs     =        244 
Model VCE    : OIM 
 
Expression   : Predicted mean outpatient_cost, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   2998.982   1491.018     2.01   0.044     76.63937    5921.324 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
.  
. margins overdose, 
 
  
 
205 
Predictive margins                              Number of obs     =        244 
Model VCE    : OIM 
 
Expression   : Predicted mean outpatient_cost, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   6191.048   1390.002     4.45   0.000     3466.694    8915.402 
          2  |   3192.066   718.6265     4.44   0.000     1783.584    4600.548 
------------------------------------------------------------------------------ 
 
.  
end of do-file 
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5. Other costs 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood = -164.76579   
Iteration 1:   log likelihood = -144.46125   
Iteration 2:   log likelihood = -144.18529   
Iteration 3:   log likelihood = -144.18477   
Iteration 4:   log likelihood = -144.18477   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood =  -1425.462   
Iteration 1:   log likelihood = -1351.6752   
Iteration 2:   log likelihood = -1319.2629   
Iteration 3:   log likelihood =  -1318.256   
Iteration 4:   log likelihood = -1318.2541   
Iteration 5:   log likelihood = -1318.2541   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -1462.4389                 Number of obs   =        244 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        244 
                                                  LR chi2(10)     =      41.16 
                                                  Prob > chi2     =     0.0000 
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Log likelihood = -144.18477                       Pseudo R2       =     0.1249 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       145 
Deviance         =  422.8296335                    (1/df) Deviance =  3.155445 
Pearson          =  525.5194005                    (1/df) Pearson  =  3.921787 
 
Variance function: V(u) = u^2                      [Gamma] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  18.33454 
Log likelihood   = -1318.254135                    BIC             = -244.0527 
----------------------------------------------------------------------------------- 
      others_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
probit            | 
         overdose | 
               1  |   .5764128   .1837839     3.14   0.002      .216203    .9366225 
                  | 
        age_final | 
               2  |   .6788988   .2437303     2.79   0.005     .2011962    1.156601 
               3  |   .4326588   .2587344     1.67   0.094    -.0744512    .9397688 
               4  |   .5513308   .3791721     1.45   0.146    -.1918329    1.294494 
                  | 
           gender | 
               2  |   .4251966   .1852329     2.30   0.022     .0621467    .7882465 
                  | 
        cci_score |    .308736   .1884878     1.64   0.101    -.0606933    .6781652 
                  | 
       elx_grp_28 | 
               1  |   .5154494   .5246035     0.98   0.326    -.5127544    1.543653 
                  | 
       elx_grp_30 | 
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               1  |   .0112757   .5538965     0.02   0.984    -1.074342    1.096893 
                  | 
       elx_grp_31 | 
               1  |   -.284345   .2471364    -1.15   0.250    -.7687235    .2000334 
                  | 
log_baseline_cost |   .0612936   .0244634     2.51   0.012     .0133462     .109241 
            _cons |  -1.106196   .2640727    -4.19   0.000    -1.623769   -.5886228 
------------------+---------------------------------------------------------------- 
glm               | 
         overdose | 
               1  |   1.551324   .4337998     3.58   0.000     .7010919    2.401556 
                  | 
        age_final | 
               2  |  -1.443855   .7560193    -1.91   0.056    -2.925625     .037916 
               3  |  -1.093934   .7539406    -1.45   0.147     -2.57163    .3837625 
               4  |  -1.932791   .8423624    -2.29   0.022    -3.583791   -.2817915 
                  | 
           gender | 
               2  |  -.6734859   .4021854    -1.67   0.094    -1.461755    .1147831 
                  | 
        cci_score |   .2540371   .2376598     1.07   0.285    -.2117675    .7198418 
                  | 
       elx_grp_28 | 
               1  |  -.9316728   .8627686    -1.08   0.280    -2.622668    .7593225 
                  | 
       elx_grp_30 | 
               1  |   .9356786   1.124225     0.83   0.405    -1.267763     3.13912 
                  | 
       elx_grp_31 | 
               1  |  -.7913392   .5635196    -1.40   0.160    -1.895817     .313139 
                  | 
log_baseline_cost |   .2806016   .0564755     4.97   0.000     .1699117    .3912915 
            _cons |   7.057489   .7917773     8.91   0.000     5.505635    8.609344 
----------------------------------------------------------------------------------- 
 
 
Average marginal effects                        Number of obs     =        244 
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Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |   12159.03   5836.473     2.08   0.037     719.7569    23598.31 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |   14362.62   6026.288     2.38   0.017     2551.312    26173.93 
          2  |   2203.586   762.6601     2.89   0.004     708.8001    3698.373 
------------------------------------------------------------------------------ 
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6. Pharmacy costs 
Fitting probit regression for first part: 
 
Iteration 0:   log likelihood =  -149.7225   
Iteration 1:   log likelihood = -136.06494   
Iteration 2:   log likelihood = -135.89186   
Iteration 3:   log likelihood =  -135.8917   
Iteration 4:   log likelihood =  -135.8917   
 
Fitting glm regression for second part: 
 
Iteration 0:   log likelihood = -1456.7049   
Iteration 1:   log likelihood = -1395.4911   
Iteration 2:   log likelihood =  -1385.301   
Iteration 3:   log likelihood = -1385.2009   
Iteration 4:   log likelihood = -1385.2008   
 
Two-part model 
------------------------------------------------------------------------------ 
Log pseudolikelihood = -1521.0925                 Number of obs   =        244 
 
Part 1: probit 
------------------------------------------------------------------------------ 
                                                  Number of obs   =        244 
                                                  LR chi2(10)     =      27.66 
                                                  Prob > chi2     =     0.0020 
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Log likelihood =  -135.8917                       Pseudo R2       =     0.0924 
 
Part 2: glm 
------------------------------------------------------------------------------ 
                                                   Number of obs   =       170 
Deviance         =  427.8099446                    (1/df) Deviance =  2.690629 
Pearson          =  495.1278272                    (1/df) Pearson  =  3.114011 
 
Variance function: V(u) = u^2                      [Gamma] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =  16.42589 
Log likelihood   =  -1385.20079                    BIC             =  -388.782 
----------------------------------------------------------------------------------- 
        phar_cost |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
probit            | 
         overdose | 
               1  |  -.4445152   .1883963    -2.36   0.018    -.8137652   -.0752652 
                  | 
        age_final | 
               2  |  -.3735017   .2652341    -1.41   0.159    -.8933511    .1463477 
               3  |  -.5122345   .2952557    -1.73   0.083    -1.090925    .0664561 
               4  |  -1.104836   .3932684    -2.81   0.005    -1.875628   -.3340439 
                  | 
           gender | 
               2  |   .1269393   .1892901     0.67   0.502    -.2440624     .497941 
                  | 
        cci_score |  -.1512138    .123552    -1.22   0.221    -.3933713    .0909437 
                  | 
       elx_grp_28 | 
               1  |   .1661636   .6036901     0.28   0.783    -1.017047    1.349374 
                  | 
       elx_grp_30 | 
               1  |    .015216   .6256157     0.02   0.981    -1.210968      1.2414 
                  | 
       elx_grp_31 | 
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               1  |  -.0631984   .2564134    -0.25   0.805    -.5657594    .4393626 
                  | 
log_baseline_cost |   .0965615   .0265668     3.63   0.000     .0444915    .1486315 
            _cons |   .6393116   .2609617     2.45   0.014     .1278362    1.150787 
------------------+---------------------------------------------------------------- 
glm               | 
         overdose | 
               1  |   .0781905   .3110686     0.25   0.802    -.5314928    .6878739 
                  | 
        age_final | 
               2  |   1.069872   .3800385     2.82   0.005     .3250104    1.814734 
               3  |   1.885358   .3999978     4.71   0.000     1.101376    2.669339 
               4  |   1.887878    .683738     2.76   0.006     .5477762     3.22798 
                  | 
           gender | 
               2  |  -.9815496   .3215047    -3.05   0.002    -1.611687    -.351412 
                  | 
        cci_score |   .1338833    .324344     0.41   0.680    -.5018191    .7695858 
                  | 
       elx_grp_28 | 
               1  |  -1.144062   .6982181    -1.64   0.101    -2.512544    .2244205 
                  | 
       elx_grp_30 | 
               1  |  -.1114865   .8150442    -0.14   0.891    -1.708944    1.485971 
                  | 
       elx_grp_31 | 
               1  |  -.8401248    .402763    -2.09   0.037    -1.629526   -.0507238 
                  | 
log_baseline_cost |    .204456   .0407566     5.02   0.000     .1245745    .2843375 
            _cons |   5.429232   .4088537    13.28   0.000     4.627893     6.23057 
----------------------------------------------------------------------------------- 
 
 
Average marginal effects                        Number of obs     =        244 
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Expression   : twopm combined expected values, predict() 
dy/dx w.r.t. : 1.overdose 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  1.overdose |  -199.0433   556.4555    -0.36   0.721    -1289.676    891.5895 
------------------------------------------------------------------------------ 
Note: dy/dx for factor levels is the discrete change from the base level. 
 
Predictive margins                              Number of obs     =        244 
 
Expression   : twopm combined expected values, predict() 
 
------------------------------------------------------------------------------ 
             |            Delta-method 
             |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    overdose | 
          1  |    1686.81    533.349     3.16   0.002     641.4651    2732.155 
          2  |   1885.853   437.9278     4.31   0.000      1027.53    2744.176 
------------------------------------------------------------------------------ 
 
.  
end of do-file 
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